Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2R,3R,4S,5R)-9-(3,4-dihydroxy-5-trityloxymethyl-tetrahydrofuran-2-yl)-1,9-dihydropurin-6-one
KIN59
(3-benzyl-2,4,5-trioxoimidazolidin-1-yl)acetic acid
-
(4xi)-2',3'-O-[(1R)-2-carboxyethylidene]-5-methylcytidine
-
(4xi)-5-methyl-2',3'-O-[(1R)-2-phosphonoethylidene]cytidine
-
(E)-1-((2-fluorophenyl)(hydroxyimino)methyl)-5-iodopyrimidine-2,4(1H,3H)-dione
-
(E)-1-((4-chlorophenyl)(hydroxyimino)methyl)-5-iodopyrimidine-2,4(1H,3H)-dione
-
(E)-1-((4-ethylphenyl)(hydroxyimino)methyl)-5-iodopyrimidine-2,4(1H,3H)-dione
-
(E)-1-((4-fluorophenyl)(hydroxyimino)methyl)-5-iodopyrimidine-2,4(1H,3H)-dione
-
(E)-1-((hydroxyimino)(3-methoxyphenyl)methyl)-5-iodopyrimidine-2,4(1H,3H)-dione
-
(E)-1-((hydroxyimino)(4-methoxyphenyl)methyl)-5-iodopyrimidine-2,4(1H,3H)-dione
-
(E)-1-((hydroxyimino)(p-tolyl)methyl)-5-iodopyrimidine-2,4(1H,3H)-dione
-
(E)-1-((hydroxyimino)(phenyl)methyl)-5-iodopyrimidine-2,4(1H,3H)-dione
-
(R)-(1-fluoro-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propan-2-yloxy)methylphosphonic phosphoric anhydride
-
strong inhibitory effect
(R)-1-[3-fluoro-2-(phosphonomethoxy)-propyl]thymine
-
at 0.01 mM, 82% inhibition of V79 cell-expressed thymidine phosphorylase, 56% inhibition of thymidine phosphorylase from placenta
(R)-1-[3-fluoro-2-(phosphonomethoxy)propyl]thymine
-
efficient inhibitor
(R)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]thymine
-
at 0.01 mM, 84% inhibition of V79 cell-expressed thymidine phosphorylase, 84% inhibition of thymidine phosphorylase from placenta
(S)-(1-fluoro-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propan-2-yloxy)methylphosphonic phosphoric anhydride
-
strong inhibitory effect
(S)-1-[3-fluoro-2-(phosphonomethoxy)propyl]thymine
-
efficient inhibitor
(Z)-1-((2-fluorophenyl)(hydroxyimino)methyl)-6-methylpyrimidine-2,4(1H,3H)-dione
-
(Z)-1-((3,4-dichlorophenyl)(hydroxyimino)methyl)-6-methylpyrimidine-2,4(1H,3H)-dione
-
(Z)-1-((3-fluorophenyl)(hydroxyimino)methyl)-6-methylpyrimidine-2,4(1H,3H)-dione
-
(Z)-1-((4-bromophenyl)(hydroxyimino)methyl)-6-methylpyrimidine-2,4(1H,3H)-dione
-
(Z)-1-((4-chlorophenyl)(hydroxyimino)methyl)-6-methylpyrimidine-2,4(1H,3H)-dione
-
(Z)-1-((4-ethylphenyl)(hydroxyimino)methyl)-6-methylpyrimidine-2,4(1H,3H)-dione
-
(Z)-1-((4-fluorophenyl)(hydroxyimino)methyl)-6-methylpyrimidine-2,4(1H,3H)-dione
-
(Z)-1-((hydroxyimino)(3-methoxyphenyl)methyl)-6-methylpyrimidine-2,4(1H,3H)-dione
-
(Z)-1-((hydroxyimino)(4-methoxyphenyl)methyl)-6-methylpyrimidine-2,4(1H,3H)-dione
-
(Z)-1-((hydroxyimino)(m-tolyl)methyl)-6-methylpyrimidine-2,4(1H,3H)-dione
-
(Z)-1-((hydroxyimino)(p-tolyl)methyl)-6-methylpyrimidine-2,4(1H,3H)-dione
-
(Z)-1-((hydroxyimino)(phenyl)methyl)-6-methylpyrimidine-2,4(1H,3H)-dione
-
(Z)-1-((hydroxyimino)(thiophen-2-yl)methyl)-6-methylpyrimidine-2,4(1H,3H)-dione
-
(Z)-N'-((4-chloro-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)methylene)-2-oxo-1,2,4a,8a-tetrahydroquinoline-6-carbohydrazide
-
([(1R)-2-fluoro-1-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]ethoxy]methyl)phosphonic acid
-
-
([(1R)-2-fluoro-1-[(5-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl]ethoxy]methyl)phosphonic acid
-
at 0.01 mM, complete inhibition of V79 cell-expressed thymidine phosphorylase
([(1R)-2-fluoro-1-[(5-methyl-2,6-dioxotetrahydropyrimidin-1(2H)-yl)methyl]ethoxy]methyl)phosphonic acid
-
low inhibitory effect
([(1R)-2-hydroxy-1-[(5-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl]ethoxy]methyl)phosphonic acid
-
at 0.01 mM, 91% inhibition of V79 cell-expressed thymidine phosphorylase, 79% inhibition of thymidine phosphorylase from placenta
([(1S)-2-fluoro-1-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]ethoxy]methyl)phosphonic acid
-
-
([(1S)-2-fluoro-1-[(5-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl]ethoxy]methyl)phosphonic acid
-
at 0.01 mM, complete inhibition of V79 cell-expressed thymidine phosphorylase
([(1S)-2-fluoro-1-[(5-methyl-2,6-dioxotetrahydropyrimidin-1(2H)-yl)methyl]ethoxy]methyl)phosphonic acid
-
low inhibitory effect
([(1S)-2-hydroxy-1-[(5-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl]ethoxy]methyl)phosphonic acid
-
at 0.01 mM, complete of V79 cell-expressed thymidine phosphorylase, 95% inhibition of thymidine phosphorylase from placenta
([2,2,2-trifluoro-1-[(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]ethoxy]methyl)phosphonic acid
-
-
([[(2R,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]oxy]methyl)phosphonic acid
-
-
1-((methoxyimino)(phenyl)methyl)-6-methylpyrimidine-2,4(1H,3H)-dione
-
1-(2-phenylethyl)imidazolidine-2,4,5-trione
-
1-(8-phosphonooctyl)-6-amino-5-bromouracil
-
competitive
1-(8-phosphonooctyl)-7-deazaxanthine
-
competitive
1-benzoyl-6-methylpyrimidine-2,4(1H,3H)-dione
-
1-benzylimidazolidine-2,4,5-trione
-
1-[(2-methylphenyl)methyl]imidazolidine-2,4,5-trione
-
1-[(R)-3-fluoro-2-(phosphonomethoxy)propyl]thymine
-
-
1-[2-(phosphonomethoxy)ethyl]thymine
-
at 0.01 mM, complete inhibition of V79 cell-expressed thymidine phosphorylase, 85% inhibition of thymidine phosphorylase from placenta
1H-pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione
-
2,7-bis(methylsulfanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5(4H)-one
-
-
2-(3,4-dichlorophenyl)-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
2-(3,4-dihydroxyphenyl)quinazolin-4(3H)-one
-
2-(3-bromophenyl)-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
-
2-(3-methylphenyl)-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
-
2-(4-bromo-3-methylphenyl)-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
-
2-(4-bromophenyl)-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
-
2-(4-methylphenyl)-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
-
2-(benzylsulfanyl)-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
-
2-(diphenylmethyl)-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
2-(furan-2-yl)-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
-
2-(methylsulfanyl)-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
-
2-(methylsulfanyl)-7-sulfanylidene-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5(4H)-one
-
-
2-(methylsulfanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7(4H,6H)-dione
-
-
2-(pyridin-2-yl)-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
-
2-benzyl-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
2-deoxy-alpha-D-ribose 1-phosphate
dRib-1-P , a non-competitive product inhibitor of the forward reaction, in the reverse reaction, dRib-1-P enhanced the binding of thymine
2-mercapto-7H-pyrrolo[2,3-d]pyrimidin-4(3H)-one
-
2-phenyl-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
2-phenyl-7-sulfanylidene-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5(4H)-one
2-phenylquinazolin-4(3H)-one
-
2-phenyl[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7(4H,6H)-dione
2-[(2-phenylethyl)sulfanyl]-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
-
2-[(3,4-dichlorophenyl)methyl]-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
2-[(3-phenylpropyl)sulfanyl]-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
-
2-[[(5-chloro-2-methylidene-6-oxo-1,2,3,6-tetrahydropyrimidin-4-yl)methyl]sulfanyl]-7-phenyl-2,3-dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-one
-
3,3'-(1,3,4-oxadiazole-2,5-diyl)dipyridine
-
3-(((4-chlorophenyl)amino)(phenyl)methyl)-5-(2,6-dimethylphenyl)1,3,4-oxadiazole-2(3H)-thione
-
3-(((4-chlorophenyl)amino)methyl)-5-(2-iodophenyl)-1,3,4-oxadiazole-2(3H)-thione
-
3-((4-benzylpiperazin-1-yl)methyl)-5-(4-chlorophenyl)-1,3,4-oxadiazole-2(3H)-thione
-
3-((5-(4-chlorophenyl)-2-thioxo-1,3,4-oxadiazol-3(2H)-yl)methyl)thiazolidine-2,4-dione
-
3-((benzylamino)methyl)-5-(4-chlorophenyl)-1,3,4-oxadiazole-2(3H)-thione
-
3-(3-(quinoxalin-2-yl)thiazolo[2,3-c][1,2,4]triazol-5-yl)benzene-1,2-diol
-
3-(3-benzyl-2,4,5-trioxoimidazolidin-1-yl)propanamide
-
3-benzoyl-5-chloropyrimidine-2,4(1H,3H)-dione
-
-
3-benzyl-1H-2-benzopyran-1-one
-
3-[(2-methoxy-6-nitroanilino)methyl]-5-(4-methylphenyl)-1,3,4-oxadiazole-2(3H)-thione
-
3-[(2-methylphenyl)methyl]-1H-2-benzopyran-1-one
-
3-[(3,4-dimethylanilino)methyl]-5-phenyl-1,3,4-oxadiazole-2(3H)-thione
-
3-[(E)-[(2,4-dichlorophenyl)imino]methyl]-4H-1-benzopyran-4-one
-
3-[(E)-[(3-methoxy-4-methylphenyl)imino]methyl]-4H-1-benzopyran-4-one
-
3-[2,4,5-trioxo-3-(2-phenylethyl)imidazolidin-1-yl]propanamide
-
3-[3-[(2-methylphenyl)methyl]-2,4,5-trioxoimidazolidin-1-yl]propanamide
-
4,6-dihydroxy-5-nitropyrimidine
-
0.1 mM, competitive
4-(2,5-difluorobenzyl)-N-(4-(trifluoromethyl)phenyl)piperazine-1-carbothioamide
-
4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)-N'-(1-(4-nitrophenyl)ethylidene)benzohydrazide
-
4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)-N'-(2,3,4-trihydroxybenzylidene)benzohydrazide
-
4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)-N'-(2,3,4-trimethoxybenzylidene)benzohydrazide
-
4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)-N'-(2-nitrobenzylidene)benzohydrazide
-
4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)-N'-(3,4,5-trimethoxybenzylidene)benzohydrazide
-
4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)-N'-(4-(phenoxymethyl)benzylidene)benzohydrazide
-
4-oxo-4H-1-benzopyran-3-carbaldehyde
-
4-[(Z)-[(3-hydroxynaphthalen-2-yl)methylidene]amino]-1,5-dimethyl-2-phenylpyrazolidin-3-one
-
5-(2-chlorophenyl)-3-(((4-chlorophenyl)amino)(phenyl)methyl)-1,3,4-oxadiazole-2(3H)-thione
-
5-(2-chlorophenyl)-3-((thiazol-2-ylamino)methyl)-1,3,4-oxadiazole-2(3H)-thione
-
5-(4-chlorophenyl)-3-(((2-nitrophenyl)amino)methyl)-1,3,4-oxadiazole-2(3H)-thione
-
5-(4-chlorophenyl)-3-(((3,3-diphenylpropyl)amino)methyl)-1,3,4-oxadiazole-2(3H)-thione
-
5-(4-chlorophenyl)-3-(((4-fluorophenyl)amino)methyl)-1,3,4-oxadiazole-2(3H)-thione
-
5-(4-chlorophenyl)-3-(((4-hydroxyphenyl)amino)methyl)-1,3,4-oxadiazole-2(3H)-thione
-
5-(4-chlorophenyl)-3-((2-methyl-1H-imidazol-1-yl)methyl)-1,3,4-oxadiazole-2(3H)-thione
-
5-(4-chlorophenyl)-3-((4-(2-methoxyphenyl)piperazin-1-yl)methyl)-1,3,4-oxadiazole-2(3H)-thione
-
5-(4-chlorophenyl)-3-((4-cyclohexylpiperazin-1-yl)methyl)-1,3,4-oxadiazole-2(3H)-thione
-
5-(4-chlorophenyl)-3-((cyclohexylamino)methyl)-1,3,4-oxadiazole-2(3H)-thione
-
5-(4-chlorophenyl)-3-((dicyclohexylamino)methyl)-1,3,4-oxadiazole-2(3H)-thione
-
5-(4-chlorophenyl)-3-((naphthalen-1-ylamino)methyl)-1,3,4-oxadiazole-2(3H)-thione
-
5-(4-chlorophenyl)-3-((phenylamino)methyl)-1,3,4-oxadiazole-2(3H)-thione
-
5-(4-chlorophenyl)-3-((thiazol-2-ylamino)methyl)-1,3,4-oxadiazole-2(3H)-thione
-
5-(4-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione
-
5-(benzylsulfanyl)-2-phenyl-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
5-(methylsulfanyl)-2-phenyl-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
5-amino-6-chlorouracil
-
-
5-benzyl-6-chloropyrimidine-2,4(1H,3H)-dione
-
-
5-benzylacyclouridine
-
-
5-bromo-6-(3'-methylimidazol-1-yl)uracil
IC50: 0.038 mM
5-bromo-6-amino-uracil
-
enzyme inhibition results in a significant increase in basal and oxidative stress-induced apoptosis, the effect is abrogated by supplementation with 2-deoxy-D-ribose-1-phosphate
5-bromo-6-aminouracil
-
-
5-bromo-6-[(2'-nitroimidazol-1'-yl)methyl]uracil
IC50: 0.16 mM
5-bromo-6-[(3-methylimidazol-1-yl)methyl]uracil
IC50: 0.017 mM
5-bromo-6-[(4'-nitroimidazol-1'-yl)methyl]uracil
IC50: 0.181 mM
5-bromo-6-[[(1,3-dihydroxypropan-2-yl)amino]methyl]pyrimidine-2,4(1H,3H)-dione
-
5-bromo-6-[[(2,3-dihydroxypropyl)amino]methyl]pyrimidine-2,4(1H,3H)-dione
-
5-bromo-6-[[(2-hydroxyethyl)amino]methyl]pyrimidine-2,4(1H,3H)-dione
-
5-Bromouracil
-
0.1 mM, competitive
5-butyl-6-chloropyrimidine-2,4(1H,3H)-dione
-
-
5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride
-
-
5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4-(1H,3H)-pyrimidine
-
-
5-chloro-6-(3'-methylimidazol-1-yl)uracil
IC50: 0.035 mM
5-chloro-6-[(2'-nitroimidazol-1'-yl)methyl]uracil
IC50: 0.115 mM
5-chloro-6-[(3-methylimidazol-1-yl)methyl]uracil
IC50: 0.018 mM
5-chloro-6-[(4'-nitroimidazol-1'-yl)methyl]uracil
IC50: 0.2 mM
5-chloro-6-[([4-oxo-8-[4-(pentafluoro-lambda6-sulfanyl)phenyl]-1,2,3,4-tetrahydropyrazolo[1,5-a][1,3,5]triazin-2-yl]sulfanyl)methyl]pyrimidine-2,4(1H,3H)-dione
-
5-chloro-6-[1-(2-iminopyrrolidinyl) methyl] uracil hydrochloride
-
5-chloro-6-[1-(2-iminopyrrolidinyl)methyl] uracil hydrochloride
5-chloro-6-[1-(2-iminopyrrolidinyl)methyl]uracil
-
-
5-chloro-6-[1-(2-iminopyrrolidinyl)methyl]uracil hydrochloride
-
-
5-chloro-6-[1-(2-iminopyrrolidinyl)methyl]uracilhydrochloride
-
5-chloro-6-[1-(imminopyrrolidinyl)methyl]uracil hydrochloride
5-chloro-6-[[(1,3-dihydroxypropan-2-yl)amino]methyl]pyrimidine-2,4(1H,3H)-dione
-
5-chloro-6-[[(2-hydroxyethyl)amino]methyl]pyrimidine-2,4(1H,3H)-dione
-
5-ethyl-1-[(R)-3-fluoro-2-(phosphonomethoxy)propyl]uracil
-
-
5-ethyl-1-[(R)-3-hydroxy-2-(phosphonomethoxy)propyl]uracil
-
-
5-ethyl-1-[(S)-3-fluoro-2-(phosphonomethoxy)propyl]uracil
-
-
5-fluoro-6-[(2-aminoimidazol-1-yl)methyl]uracil
i.e. AIFU, synthesis, overview, uncompetitive with respect to phosphate, acts as transition state analogs, mimicking the anionic thymine leaving group anchored by their protonated side chains to the enzyme-bound phosphate by electrostatic and H-bonding interactions, modeling of ligand binding at the active site, overview
5-iodo-6-[[(piperidin-1-yl)amino]methyl]pyrimidine-2,4(1H,3H)-dione
-
5-Iodouracil
His116 directly interacts with the inhibitor via its NE2 group, enzyme binding structure, overview
5-Nitrouracil
-
0.1 mM, competitive
5-phenyl-1,3,4-oxadiazole-2(3H)-thione
-
5-phenyl-6-pyrrolidin-1-ylpyrimidine-2,4(1H,3H)-dione
-
-
5-sulfanylidene-2-(thiophen-2-yl)-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
-
5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
-
5-[(1E)-but-1-en-1-yl]-6-chloropyrimidine-2,4(1H,3H)-dione
-
-
5-[(E)-[2-(quinoxalin-2-yl)hydrazinylidene]methyl]benzene-1,2,4-triol
-
6-(((1,3-dihydroxypropan-2-yl)amino)methyl)-5-iodopyrimidine-2,4(1H,3H)-dione
the inhibitor shows a noncompetitive inhibition mode with both thymidine and inorganic phosphate substrates. Effect of 8g on cell viabilities of different cancer cell lines, overview
6-(2-aminoethyl)amine-5-chlorouracil
-
AEAC
6-(3-methylimidazol-1-yl)uracil
IC50: 0.110 mM
6-(4-phenlybutylamino)uracil
-
PBAU, 50% inhibition at 0.03 mM
6-amino-5-bromopyrimidine-2,4(1H,3H)-dione
-
6-aminouracil
-
0.1 mM, competitive
6-benzyl-2-thiouracil
-
0.1 mM, mixed inhibition
6-bromo-5-phenylpyrimidine-2,4(1H,3H)-dione
-
-
6-chloro-5-(1-methylethenyl)pyrimidine-2,4(1H,3H)-dione
-
-
6-chloro-5-(2-naphthyl)pyrimidine-2,4(1H,3H)-dione
-
-
6-chloro-5-(2-thienyl)pyrimidine-2,4(1H,3H)-dione
-
-
6-chloro-5-(3,5-dimethylphenyl)pyrimidine-2,4(1H,3H)-dione
-
-
6-chloro-5-(4-fluorophenyl)pyrimidine-2,4(1H,3H)-dione
-
-
6-chloro-5-cyclohex-1-en-1-ylpyrimidine-2,4(1H,3H)-dione
-
-
6-chloro-5-cyclopent-1-en-1-yluracil
-
-
6-chloro-5-ethylpyrimidine-2,4(1H,3H)-dione
-
-
6-chloro-5-heptylpyrimidine-2,4(1H,3H)-dione
-
-
6-chloro-5-hexylpyrimidine-2,4(1H,3H)-dione
-
-
6-chloro-5-pentylpyrimidine-2,4(1H,3H)-dione
-
-
6-chloro-5-phenylpyrimidine-2,4(1H,3H)-dione
-
-
6-chloro-5-propylpyrimidine-2,4(1H,3H)-dione
-
-
6-chloro-5-pyridin-3-ylpyrimidine-2,4(1H,3H)-dione hydrochloride
-
-
6-chloro-5-[(1E)-1-ethylprop-1-en-1-yl]pyrimidine-2,4(1H,3H)-dione
-
-
6-chloro-5-[(1E)-pent-1-en-1-yl]pyrimidine-2,4(1H,3H)-dione
-
-
6-chloro-5-[(1E)-prop-1-en-1-yl]pyrimidine-2,4(1H,3H)-dione
-
-
6-fluoro-5-phenylpyrimidine-2,4(1H,3H)-dione
-
-
6-methyl-5-phenylpyrimidine-2,4(1H,3H)-dione
-
-
6-[(2'-aminoimidazol-1'-yl)methyl]-5-bromouracil
IC50: 0.000019 mM
6-[(2'-aminoimidazol-1'-yl)methyl]-5-chlorouracil
IC50: below 0.000049 mM
6-[(2'-aminoimidazol-1'-yl)methyl]uracil
IC50: 0.0001 mM
6-[(2'-nitroimidazol-1'-yl)methyl]uracil
IC50: 0.2577 mM
6-[(2-aminoethyl)amino]-5-phenylpyrimidine-2,4(1H,3H)-dione
-
-
6-[(3-methylimidazol-1-yl)methyl]thymine
IC50: 0.06 mM
6-[(3-methylimidazol-1-yl)methyl]uracil
IC50: 0.042 mM
6-[(4'-aminoimidazol-1'-yl)methyl]-5-bromouracil
IC50: 0.041 mM
6-[(4'-aminoimidazol-1'-yl)methyl]-5-chlorouracil
IC50: 0.026 mM
6-[(4'-aminoimidazol-1'-yl)methyl]uracil
IC50: 0.143 mM
6-[(4'-nitroimidazol-1'-yl)methyl]uracil
IC50: 0.5 mM
6-[(dimethylamino)methyl]-5-iodopyrimidine-2,4(1H,3H)-dione
-
6-[(dipentylamino)methyl]-5-iodopyrimidine-2,4(1H,3H)-dione
-
6-[(dipropylamino)methyl]-5-iodopyrimidine-2,4(1H,3H)-dione
-
6-[[(2,3-dihydroxypropyl)(methyl)amino]methyl]-5-iodopyrimidine-2,4(1H,3H)-dione
-
6-[[(2-hydroxyethyl)amino]methyl]-5-iodopyrimidine-2,4(1H,3H)-dione
-
6-[[bis(2-ethoxyethyl)amino]methyl]-5-iodopyrimidine-2,4(1H,3H)-dione
-
7-(4-tert-butylphenyl)-2-sulfanylidene-2,3-dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-one
-
7-(4-tert-butylphenyl)-2-[[(5-chloro-2-methylidene-6-oxo-1,2,3,6-tetrahydropyrimidin-4-yl)methyl]sulfanyl]-2,3-dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-one
-
7-(methylsulfanyl)-2-phenyl-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5(4H)-one
-
7-(methylsulfanyl)-2-phenyl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5(4H)-one
-
-
7-phenyl-2-sulfanylidene-2,3-dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-one
-
7-phenylpyrazolo[1,5-a][1,3,5]triazine-2,4(1H,3H)-dione
-
8-phenyl-2-sulfanylidene-2,3-dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-one
-
8-[4-(pentafluoro-lambda6-sulfanyl)phenyl]-2-sulfanylidene-2,3-dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-one
-
9-[8-phosphonooctyl]-7-deazaxanthine
-
allyloxymethylthymine
-
0.1 mM, uncompetitive
aurothioglucose
-
the expression of tyhmidine phosphorylase mRNA is significantly decreased by stimulation with aurothioglucose
dexamethasone
-
the expression of tyhmidine phosphorylase mRNA is significantly decreased by stimulation with dexamethasone
diethyl ((2-[(3,4-dihydro-5-methyl-2,4-dioxopyrimidin-1(2H)-yl)methyl]cyclopent-1-en-1-yl)(difluoro)methyl)phosphonate
-
-
diethyl ((2-[(3,4-dihydro-5-methyl-2,4-dioxopyrimidin-1(2H)-yl)methyl]cyclopent-1-en-1-yl)methyl)phosphonate
-
-
diethyl ((2-[(5-chloro-3,4-dihydro-2,4-dioxopyrimidin-1(2H)-yl)methyl]cyclopent-1-en-1-yl)methyl)phosphonate
-
-
diethyl (2-[(5-chloro-3,4-dihydro-2,4-dioxopyrimidin-1(2H)-yl)methyl]benzyl)phosphonate
-
-
diethyl ([2-(hydroxymethyl)cyclopent-1-en-1-yl]methyl)phosphonate
-
-
diethyl [(Z)-4-(5-chloro-3,4-dihydro-2,4-dioxopyrimidin-1(2H)-yl)but-2-en-1-yl]phosphonate
-
-
diethyl [(Z)-4-hydroxybut-2-en-1-yl]phosphonate
-
-
diethyl [2-(hydroxymethyl)benzyl]phosphonate
-
-
disodium ((2-[(3,4-dihydro-5-methyl-2,4-dioxopyrimidin-1(2H)-yl)methyl]cyclopent-1-en-1-yl)(difluoro)methyl)phosphonate
-
-
disodium ((2-[(3,4-dihydro-5-methyl-2,4-dioxopyrimidin-1(2H)-yl)methyl]cyclopent-1-en-1-yl)methyl)phosphonate
-
-
disodium ((2-[(5-chloro-3,4-dihydro-2,4-dioxopyrimidin-1(2H)-yl)methyl]cyclopent-1-en-1-yl)methyl)phosphonate
-
-
disodium (2-[(5-chloro-3,4-dihydro-2,4-dioxopyrimidin-1(2H)-yl)methyl]benzyl)phosphonate
-
-
disodium [(Z)-4-(5-chloro-3,4-dihydro-2,4-dioxopyrimidin-1(2H)-yl)but-2-en-1-yl]phosphonate
-
-
ethyl (3-benzyl-2,4,5-trioxoimidazolidin-1-yl)acetate
-
ethyl [2,4,5-trioxo-3-(2-phenylethyl)imidazolidin-1-yl]acetate
-
ethyl [3-[(2-methylphenyl)methyl]-2,4,5-trioxoimidazolidin-1-yl]acetate
-
hydrogen [[(1R,2S,4S)-2-(hydroxymethyl)-4-(5-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)pyrrolidinium-1-yl]methyl]phosphonate
-
-
KIN59
i.e. 5'-O-tritylinosine, noncompetitive inhibition
N'-(2,4-dichlorobenzylidene)-4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)benzohydrazide
-
N'-(2-cyanobenzylidene)-4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)benzohydrazide
-
N'-(2-hydroxy-3-methoxybenzylidene)-4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)benzohydrazide
-
N'-(3,5-dichloro-2-hydroxybenzylidene)-4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)benzohydrazide
-
N'-(3-aminobenzylidene)-4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)benzohydrazide
-
N'-(3-cyanobenzylidene)-4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)benzohydrazide
-
N'-(3-hydroxy-4-methoxybenzylidene)-4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)benzohydrazide
-
N'-(4-(dimethylamino)benzylidene)-4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)benzohydrazide
-
N'-(4-chlorobenzylidene)-4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)benzohydrazide
-
N'-(4-cyanobenzylidene)-4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)benzohydrazide
-
N'-(4-hydroxy-3,5-dimethoxybenzylidene)-4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)benzohydrazide
-
N'-(4-hydroxy-3-methoxybenzylidene)-4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)benzohydrazide
-
N'-(5-bromo-2-methoxybenzylidene)-4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)benzohydrazide
-
N'-(anthracen-9-ylmethylene)-4-(5-(isoquinolin-3-yl)-1,3,4-oxadiazol-2-yl)benzohydrazide
-
N-((5-(4-chlorophenyl)-2-thioxo-1,3,4-oxadiazole-3(2H)-yl)methyl)3(trifluoromethyl) benzamide
-
N-(4-oxo-2-sulfanylidene-8-[[4-(trifluoromethyl)phenyl]methyl]-1,2,3,4-tetrahydropyrazolo[1,5-a][1,3,5]triazin-7-yl)thiourea
-
N-(8-benzyl-4-oxo-2-sulfanylidene-1,2,3,4-tetrahydropyrazolo[1,5-a][1,3,5]triazin-7-yl)thiourea
-
NSC 65043
-
IC50: 0.077 mM
p-chloromercuribenzoate
-
above 0.01 mM
TAS-102
is a combination of trifluridine (FTD, a fluorinated thymidine analogue) and tipiracil hydrochloride (TPI, a TP inhibitor) at a 1:0.5 molar ratio. The FTD monophosphate metabolite trifluoromethyl deoxyuridine 5'-monophosphate inhibits TS by binding to its active site, but the inhibition is rapidly reversible. Phosphorylation of trifluoromethyl deoxyuridine 5'-monophosphate results in the formation of trifluoromethyl deoxyuridine 5'-triphosphate that is misincorporated into DNA. Importantly, the concentration of FTD incorporated into DNA is approximately 300fold higher than that of 5FU. FTD is rapidly degraded by TP to its inactive metabolite (5-trifluoromethyl-2,4(1H,3H)-pyrimidinedione). Thus, the main mechanism of action of TAS-102 is its misincorporation into DNA. Tipiracil inhibits the main catabolic pathway of the drug, thus enhancing its half-life and cytotoxicity
thymidine phosphorylase inhibitor
-
-
-
tipiracil hydrochloride
TPI
trifluridine
FTD, is rapidly degraded by TP to its inactive metabolite, 5-trifluoromethyl-2,4(1H,3H)-pyrimidinedione
Uracil
-
inhibits activity in turmor tissue, but not in normal tissue
Urea
-
inhibition at high concentration, 4 M, stimulation at low concentration
[(2S,3aR,4R,6R,6aR)-4-(5-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-6-(hydroxymethyl)tetrahydrofuro[3,4-d][1,3]dioxol-2-yl]phosphonic acid
-
-
[(2S,4R,5S)-5-(2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxy-1,3-oxazolidin-2-yl]phosphonic acid
-
-
[(3aR,4R,6R,6aR)-4-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-6-(hydroxymethyl)tetrahydrofuro[3,4-d][1,3]dioxol-2-yl]phosphonic acid
-
-
[(3aR,4R,6R,6aR)-4-(hydroxymethyl)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuro[3,4-d][1,3]dioxol-2-yl]phosphonic acid
-
-
[2,4,5-trioxo-3-(2-phenylethyl)imidazolidin-1-yl]acetic acid
-
[3-[(2-methylphenyl)methyl]-2,4,5-trioxoimidazolidin-1-yl]acetic acid
-
[8-(2,4-dioxo-2,3,4,6-tetrahydro-1H-pyrrolo[3,4-d]pyrimidin-1-yl)octyl]phosphonic acid
-
no antitumor activity found with CCRF-CEM T-lymphoblastoid cells, human promyelocytic leukemia HL-60 cells, human cervix carcinoma HeLa S3 cells
[8-(2,4-dioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidin-1-yl)octyl]phosphonic acid
-
no antitumor activity found with CCRF-CEM T-lymphoblastoid cells, human promyelocytic leukemia HL-60 cells, human cervix carcinoma HeLa S3 cells
[[(1R)-2-(5-ethyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-1-(fluoromethyl)ethoxy]methyl]phosphonic acid
-
-
[[(2R,3aR,6aR)-6-(4-amino-5-methyl-2-oxopyrimidin-1(2H)-yl)-4-(hydroxymethyl)hexahydrofuro[3,4-b]furan-2-yl]methyl]phosphonic acid
-
[[(2S,3aR,6aR)-6-(4-amino-5-methyl-2-oxopyrimidin-1(2H)-yl)-4-(hydroxymethyl)hexahydrofuro[3,4-b]furan-2-yl]methyl]phosphonic acid
-
[[(2S,3aR,6aS)-4-(4-amino-5-methyl-2-oxopyrimidin-1(2H)-yl)-6-(hydroxymethyl)hexahydrofuro[3,4-b]furan-2-yl]methyl]phosphonic acid
-
[[(3S,4R)-3-hydroxy-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)pyrrolidin-1-yl]carbonyl]phosphonic acid
-
-
[[2-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy]methyl]phosphonic acid
-
-
[[2-(5-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)ethoxy]methyl]phosphonic acid
-
at 0.01 mM, complete inhibition of V79 cell-expressed thymidine phosphorylase, 82% inhibition of thymidine phosphorylase from placenta
2-benzyl-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
-
2-benzyl-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
2-phenyl-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
-
2-phenyl-5-sulfanylidene-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one
-
2-phenyl-7-sulfanylidene-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5(4H)-one
-
-
2-phenyl-7-sulfanylidene-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5(4H)-one
-
2-phenyl[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7(4H,6H)-dione
-
-
2-phenyl[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7(4H,6H)-dione
-
5'-O-trityl-inosine
-
i.e. KIN59, IC50: 0.067 mM, noncompetitively inhibits, when thymidine or phosphate is the variable substrate. Suppresses thymidine phosphorylase-triggered angiogenesis via a noncompetitive mechanism of action
5'-O-trityl-inosine
IC50: 0.067 mM, reversible, noncmpetitive
5'-O-tritylinosine
-
-
5'-O-tritylinosine
i.e. KIN59, noncompetitive. Inhibitor docking and conformational changes, molecular modeling using the crystal structure of the enzyme, molecular dynamics simulations, binding site and mode, overview
5'-O-tritylinosine
-
i.e. KIN59, a small-molecule inhibitor. KIN59 not only prevents the formation of new blood vessels but also promotes the degradation of small pre-existing immature blood vessels, not due to unspecific cell toxicity
5-chloro-6-[1-(2-iminopyrrolidinyl)methyl] uracil hydrochloride
-
-
5-chloro-6-[1-(2-iminopyrrolidinyl)methyl] uracil hydrochloride
-
5-chloro-6-[1-(imminopyrrolidinyl)methyl]uracil hydrochloride
-
i.e. TPI, competitive
5-chloro-6-[1-(imminopyrrolidinyl)methyl]uracil hydrochloride
-
-
5-fluorouracil
-
0.1 mM, competitive
5-fluorouracil
5-FU, is an anticancer drug, which inhibits human thymidine phosphorylase (hTP) and plays a key role in maintaining the process of DNA replication and repair. It is involved in regulating pyrimidine nucleotide production, by which it inhibits the mechanism of cell proliferation and cancerous tumor growth. In the cell, 80% of 5-FU is metabolized by dihydropyrimidine dehydrogenase (DPD)
5-fluorouracil
5FU, 5-fluorouracil pharmacodynamics, overview. 5FU catabolism is driven by the activity of dihydropyrimidine dehydrogenase (DPD). The expression of the enzymes orotate phosphoribosyl transferase (OPRT), TK, TP, TS and DPD has been demonstrated to influence 5FU activity both in in vitro and in vivo models. 5-Fluoro-2'-deoxyuridine (FUdR), an active antiblastic drug as it can be converted to FdUMP by thymidine kinase (TK), resulting in thymidylate synthase (TS) blockade. FUdR can be hydrolyzed by TP completing the three-step process from capecitabine to 5FU
6-amino-5-bromouracil
-
-
6-amino-5-bromouracil
-
-
6-amino-5-chlorouracil
-
inhibits angiogenic activity, competitive
6-amino-5-chlorouracil
-
-
6-aminothymine
-
-
7-deazaxanthine
-
competitive, 50% inhibition at 0.04 mM
thymidine
substrate inhibition
thymidine
yields a non-competitive inhibition pattern in agreement with a random mechanism
thymine
the substrate is a non-competitive inhibitor of the enzyme
thymine
thymine is a product activator, but becomes a substrate inhibitor at concentrations eight times higher than its Km. Thymine is an effector rather than a product inhibitor
additional information
-
a specific thymidine phosphorylase inhibitor TPI completely inhibits
-
additional information
-
iodination reduces activity, 63% inactivation after 5 min and complete inactivation after 20 min
-
additional information
-
5- and 6-substituted uracil analogs
-
additional information
-
no inhibition by 5'-deoxy-5-fluorouridine
-
additional information
-
thymidine phosphorylase and its degradation product 2-deoxy-D-ribose suppress hypoxia-induced apoptosis, the upregulation of hypoxia-inducible factor 1alpha and the proapoptotic factor, BNIP3, and caspase 3 activation induced by hypoxia
-
additional information
-
thymidine phosphorylase promoter methylation is a mechanism for down-regulation of enzyme expression in cancer cells
-
additional information
-
not inhibited by 1-[(4S,5R)-4-hydroxyisoxazolidin-5-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
-
additional information
-
capecitabine does not affect enzyme activity and expression
-
additional information
-
synthesis of 5-alkyl, 5-aryl, or 5-fluoro derivatives of 1-[2-(phosphonomethoxy)-ethyl]thymine inhibitors that mimic the interatomic distance between the incoming phosphate and leaving pyrimidine groups at the transition state for the putative SN2 mechanism of thymidine phosphorylase, structures, the inhibitors are not effective compared to (phosphonomethoxy)-alkyl-pyrimidine inhibitors, overview. Switching the N1-linked side chains found in 1-[2-(phosphonomethoxy)-ethyl]thymine, 1-[(R)-3-hydroxy-2-(phosphonomethoxy)propyl]thymine and 1-[(R)-3-fluoro-2-(phosphonomethoxy)propyl]thymine to the N3-position of the nucleobases resulted in significant loss of activity. Replacement of the iminopyrrolidine ring found in 5-ethyl-1-[(R)-3-hydroxy-2-(phosphonomethoxy)propyl]uracil with a 3-methylimidazol-3-ium ring leads to a series of less active 5-halo-6-[(3-methylimidazol-3-ium-1-yl)methyl]-uracil chlorides. On the other hand, replacement with a 2-aminoimidazole ring, leads to a number of 6-[(2-aminoimidazol-1-yl)methyl]-5-chloro-(and 5-bromo)uracil hydrochlorides with similar inhibitory strength compared to 5-ethyl-1-[(R)-3-hydroxy-2-(phosphonomethoxy)propyl]uracil, computer-modeling simulations, overview
-
additional information
-
enzyme inhibitors can abrogate the tumorigenic and metastatic properties of the enzyme, e.g. 2-deoxy-L-ribose, which does not inhibit the enzyme but affects its biological functions
-
additional information
comparison of binding structures of 5-FU and its derivatives to human thymidine phosphorylase and dihydropyrimidine dehydrogenase (DPD), analysis of strategies to reduce drug binding to DPD to decrease the required dose of 5-FU. hTP can still undergo open-closed conformations in the absence of the ligand, but the presence of a positively charged ligand better stabilizes the closed conformation and rigidifies the core region of the protein more than unliganded or neutral liganded system. Molecular dynamics simulations, overview. One of the three hinge segments linking the two major alpha and alpha/beta domains of the hTP is an important contributing factor to the enzyme's open-close conformational twist during its inactivation-activation process. In addition, the angle between the alpha/beta-domain and the alpha-domain has shown to undergo wide rotations over the course of MD simulation in the absence of a phosphate, suggesting that it contributes to the stabilization of the closed conformation of the hTP
-
additional information
-
comparison of binding structures of 5-FU and its derivatives to human thymidine phosphorylase and dihydropyrimidine dehydrogenase (DPD), analysis of strategies to reduce drug binding to DPD to decrease the required dose of 5-FU. hTP can still undergo open-closed conformations in the absence of the ligand, but the presence of a positively charged ligand better stabilizes the closed conformation and rigidifies the core region of the protein more than unliganded or neutral liganded system. Molecular dynamics simulations, overview. One of the three hinge segments linking the two major alpha and alpha/beta domains of the hTP is an important contributing factor to the enzyme's open-close conformational twist during its inactivation-activation process. In addition, the angle between the alpha/beta-domain and the alpha-domain has shown to undergo wide rotations over the course of MD simulation in the absence of a phosphate, suggesting that it contributes to the stabilization of the closed conformation of the hTP
-
additional information
synthesis, thymidine phosphorylase inhibitory and computational study of 1,3,4-oxadiazole-2-thione derivatives as potential anticancer agents. Determination of growth inhibition of MCF-7 cells, and analysis of toxicity and pharmacokinetics in the human body. Docking study using the ligand-bound TP structure (PDB ID 1UOU). Structure-function analysis. Electron withdrawing groups at R1 position of phenyl ring and less bulky amines group at R2 position have better anticancer activity. Amine groups at R2 position play an important role in binding to the active site residues of enzyme TP
-
additional information
an array of structurally diverse non-nucleobase derivatives has been designed, synthesized, and established as promising TP inhibitors, structure-function analysis, docking studies, overview. Analysis of oxadiazole and imidazolidine derivatives, pyrazolone and pyrazolo [1,5-a] [1,3,5]triazine analogues, 1,2,4-triazolo [1,5-a] [1,3,5]triazine analogues, quinazoline and quinoxaline derivatives, chromone and isocoumarin derivatives, and plant glycosides
-
additional information
synthesis and biological evaluation of 1-(aryl-aldehyde-oxime)uracil derivatives as a class of thymidine phosphorylase inhibitors, molecular docking and binding energies, overview. The crystal structure of thymidine phosphorylase (PDB ID 1UOU) is used as protein receptor in molecular docking
-
additional information
designed as transition-state analogues by mimicking the oxacarbenium ion, the pyrimidine-2,4-diones are synthesized and evaluated as inhibitors of hTP activity, kinetic mechanisms for the most potent molecule and evaluation of the interaction mode using molecular docking, overview
-
additional information
-
designed as transition-state analogues by mimicking the oxacarbenium ion, the pyrimidine-2,4-diones are synthesized and evaluated as inhibitors of hTP activity, kinetic mechanisms for the most potent molecule and evaluation of the interaction mode using molecular docking, overview
-
additional information
synthesis of isoquinoline-base-oxadiazole derivatives as potent inhibitors of thymidine phosphorylase and molecular docking study, overview. Twenty derivatives of isoquinoline bearing oxadiazole are characterized through different spectroscopic techniques such as HREI-MS, 1H-NMR and 13C-NMR and evaluated for thymidine phosphorylase inhibition, structure-activity relationships study
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in endometrial cancer.
Adenocarcinoma
Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer.
Adenocarcinoma
Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma.
Adenocarcinoma
Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases.
Adenocarcinoma
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Adenocarcinoma
Different angiogenic pathways in human cervical cancers.
Adenocarcinoma
Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines.
Adenocarcinoma
Effects of sex steroids and growth factors on invasive activity and 5'-deoxy-5-fluorouridine sensitivity in ovarian adenocarcinoma OMC-3 cells.
Adenocarcinoma
Expression of platelet-derived endothelial cell growth factor in prostatic adenocarcinoma.
Adenocarcinoma
Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas.
Adenocarcinoma
Gene Regulation and Clinical Roles for Interferons in Neoplastic Diseases.
Adenocarcinoma
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Adenocarcinoma
Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo.
Adenocarcinoma
Papers to appear in forthcoming issues
Adenocarcinoma
Platelet-derived endothelial cell growth factor as a prognostic factor for radiotherapy outcome in patients with adenocarcinoma of the uterine cervix.
Adenocarcinoma
Platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer.
Adenocarcinoma
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Adenocarcinoma
Prognostic role of angiogenesis and its correlations with thymidine phosphorylase and p53 expression in ductal adenocarcinoma of the pancreas.
Adenocarcinoma
STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [18F]FLT PET imaging.
Adenocarcinoma
The expression of thymidine phosphorylase and its correlation with angiogenesis in gastric adenocarcinoma.
Adenocarcinoma
The influence of 5-fluorouracil on activity of thymidine phosphorylase in gastric adenocarcinoma and normal adjacent tissue.
Adenocarcinoma
The role of vascular endothelial growth factor-A (VEGF-A) and platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in Paget's disease of the vulva and breast.
Adenocarcinoma
The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers.
Adenocarcinoma
Thymidine phosphorylase expression in gallbladder adenocarcinomas.
Adenocarcinoma
Thymidine phosphorylase expression is predominantly observed in stroma of well-differentiated adenocarcinoma of endometrium and correlates with a frequency of vascular involvement.
Adenocarcinoma
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
Adenocarcinoma
[Lactate dehydrogenase, adenosine deaminase and thymidine phosphorylase activity of blood and tissues in breast tumor patients]
Adenocarcinoma of Lung
Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma.
Adenocarcinoma of Lung
Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma.
Adenocarcinoma, Papillary
Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum.
Adenocarcinoma, Scirrhous
[The alteration of PyNPase activity in breast cancers due to preoperative oral administration of 5'-DFUR]
Adenofibroma
[Lactate dehydrogenase, adenosine deaminase and thymidine phosphorylase activity of blood and tissues in breast tumor patients]
Adenoma
Concurrent expression of angiogenic growth factors and neovascularization during tumourigenesis in colorectal carcinoma patients.
Adenoma
Differential expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) in nonpolypoid and polypoid lesions of the colon.
Adenoma
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human gallbladder lesions.
Adenoma
Neoplastic stroma and epithelium show up-regulation of platelet-derived endothelial cell growth factor/thymidine phosphorylase in colorectal carcinomas but not adenomas.
Adenoma
The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion.
Adenoma
The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinomas.
Adenoma
Thymidine phosphorylase expression in human colorectal mucosa, adenoma and carcinoma: role of p53 expression.
Adenoma
Tissue concentration of platelet-derived endothelial cell growth factor in colorectal cancer.
Adenoma
Variations in the expression of platelet-derived endothelial cell growth factor in human colorectal polyps.
Adenoma
[Determination of thymidine phosphorylase in adenoma and cancer of the human prostate]
Ameloblastoma
Immunohistochemical detection of platelet-derived endothelial cell growth factor/thymidine phosphorylase and angiopoietins in ameloblastic tumors.
Angiofibroma
Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis.
Arthritis
The angiogenic pathway "vascular endothelial growth factor/flk-1(KDR)-receptor" in rheumatoid arthritis and osteoarthritis.
Arthritis, Rheumatoid
2-Arylquinazolin-4(3H)-ones: A novel class of thymidine phosphorylase inhibitors.
Arthritis, Rheumatoid
Expression of the angiogenic factor thymidine phosphorylase in THP-1 monocytes: induction by autocrine tumor necrosis factor-alpha and inhibition by aspirin.
Arthritis, Rheumatoid
Serum gliostatin levels in patients with rheumatoid factor-negative and -positive rheumatoid arthritis and changes of these levels after surgical treatments.
Arthritis, Rheumatoid
Synthesis, molecular docking study and thymidine phosphorylase inhibitory activity of 3-formylcoumarin derivatives.
Arthritis, Rheumatoid
The Janus kinase inhibitor tofacitinib inhibits TNF-?-induced gliostatin expression in rheumatoid fibroblast-like synoviocytes.
Arthritis, Rheumatoid
Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3.
Arthritis, Rheumatoid
Thymidine phosphorylase regulates the expression of CXCL10 in rheumatoid arthritis fibroblast-like synoviocytes.
Astrocytoma
Neurotrophic action of gliostatin on cortical neurons. Identity of gliostatin and platelet-derived endothelial cell growth factor.
Astrocytoma
Stromal angiogenesis in human glioma: a role of platelet-derived endothelial cell growth factor.
Ataxia Telangiectasia
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.
Atherosclerosis
Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis.
Atherosclerosis
Highly accumulated platelet vascular endothelial growth factor in coagulant thrombotic region.
Atherosclerosis
Thymidine phosphorylase participates in platelet signaling and promotes thrombosis.
Bile Duct Neoplasms
Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer.
Biliary Tract Neoplasms
Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer.
Biliary Tract Neoplasms
Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy.
Bone Diseases
Pinpointing a Factor in Myeloma Bone Disease.
Bone Resorption
Pinpointing a Factor in Myeloma Bone Disease.
Bone Resorption
Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma.
Brain Diseases
Anesthetic Considerations for Liver Transplantation in a Patient with Mitochondrial Neurogastrointestinal Encephalopathy Syndrome.
Brain Diseases
Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B.
Brain Diseases
MNGIE Syndrome: Liver Cirrhosis Should Be Ruled Out Prior to Bone Marrow Transplantation.
Brain Diseases
Non-myeloablative bone marrow transplant and platelet infusion can transiently improve the clinical outcome of mitochondrial neurogastrointestinal encephalopathy: A case report.
Brain Diseases
Novel sequence variations in the thymidine phosphorylase gene causing mitochondrial neurogastrointestinal encephalopathy.
Brain Diseases
Primary muscle diseases in Thammasat University Hospital: muscle biopsy study of 12 cases.
Brain Neoplasms
In vitro study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors.
Brain Neoplasms
Intracavitary chemotherapy with 5-fluoro-2'-deoxyuridine (FdUrd) in malignant brain tumors.
Brain Neoplasms
Intrathecal 5-fluoro-2'-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: an in vivo study.
Brain Neoplasms
Stromal angiogenesis in human glioma: a role of platelet-derived endothelial cell growth factor.
Brain Neoplasms
Transduction of thymidine phosphorylase cDNA facilitates efficacy of cytosine deaminase/5-FC gene therapy for malignant brain tumor.
Brain Neoplasms
[5'-Deoxy-5-fluorouridine and 5-fluorouracil concentrations and thymidine phosphorylase activity in brain tumors following intravenous administration of 5'-deoxy-5-fluorouridine]
Brain Neoplasms
[Activities of pyrimidine nucleoside phosphorylase in brain tumors and antitumor effect of 5'-DFUR]
Brain Neoplasms
[Pyrimidine nucleoside phosphorylase in brain tumors and anti-tumor effect of 5'-DFUR]
Breast Diseases
[Prognostic effect of PyNPase (pyrimidine nucleoside phosphorylase) activity in breast cancer]
Breast Neoplasms
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
Breast Neoplasms
A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action.
Breast Neoplasms
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Breast Neoplasms
Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling.
Breast Neoplasms
Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells.
Breast Neoplasms
Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma.
Breast Neoplasms
Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting.
Breast Neoplasms
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Breast Neoplasms
Clinical significance of determination of surrogate markers of angiogenesis in breast cancer.
Breast Neoplasms
Clinical usefulness of oral combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR) and cyclophosphamide for metastatic breast cancer.
Breast Neoplasms
Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications.
Breast Neoplasms
Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
Breast Neoplasms
Comparison of ELISA level and immunohistochemical status for thymidine phosphorylase (TP) in invasive breast carcinoma.
Breast Neoplasms
Correlation between elevated intratumoral thymidine phosphorylase and prognosis of node-positive breast carcinoma undergoing adjuvant doxifluridine treatment.
Breast Neoplasms
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Breast Neoplasms
Effects of introduction of dThdPase cDNA on sensitivity to 5'-deoxy-5-fluorouridine and tumor angiogenesis.
Breast Neoplasms
Effects of orally administered 5-fluorouracil and its derivative 5'-deoxy-5-fluorouridine on 7,12-dimethylbenz[a]anthracene-induced breast carcinomas in rats.
Breast Neoplasms
Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients.
Breast Neoplasms
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Breast Neoplasms
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer.
Breast Neoplasms
Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
Breast Neoplasms
Expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in human breast carcinoma cells and tissues.
Breast Neoplasms
Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel.
Breast Neoplasms
Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: implication for method to detect expression of these molecules in clinic.
Breast Neoplasms
Expression of uridine and thymidine phosphorylase genes in human breast carcinoma.
Breast Neoplasms
HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer.
Breast Neoplasms
Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines.
Breast Neoplasms
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.
Breast Neoplasms
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Breast Neoplasms
Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer.
Breast Neoplasms
Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.
Breast Neoplasms
Localization of thymidine phosphorylase in breast cancer tissue.
Breast Neoplasms
Mitomycin C and capecitabine combination (MiXe) in heavily pretreated metastatic breast cancer patients. A dose-finding study.
Breast Neoplasms
Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer.
Breast Neoplasms
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.
Breast Neoplasms
Papers to Appear in Forthcoming Issues
Breast Neoplasms
Papers to appear in forthcoming issues
Breast Neoplasms
Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis.
Breast Neoplasms
Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer.
Breast Neoplasms
Prediction of the effect of 5'-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients.
Breast Neoplasms
Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients.
Breast Neoplasms
Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data.
Breast Neoplasms
Prognostic value of thymidine phosphorylase expression in breast carcinoma.
Breast Neoplasms
Pyrimidine nucleoside phosphorylase-activity and biological characteristics of breast-cancer.
Breast Neoplasms
Regulation of endothelial growth factor expressions in breast cancer.
Breast Neoplasms
Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer.
Breast Neoplasms
Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF.
Breast Neoplasms
Reproducible immunohistochemical criteria based on multiple raters' judgments for expression of thymidine phosphorylase in breast cancer tissue.
Breast Neoplasms
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.
Breast Neoplasms
Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer.
Breast Neoplasms
Synthesis, thymidine phosphorylase inhibitory and computational study of novel 1,3,4-oxadiazole-2-thione derivatives as potential anticancer agents.
Breast Neoplasms
The activity of thymidine phosphorylase correlates with tumor size and lymph nodes status in breast carcinoma.
Breast Neoplasms
The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium.
Breast Neoplasms
The influence of elevated levels of platelet-derived endothelial cell growth factor/thymidine phosphorylase on tumourigenicity, tumour growth, and oxygenation.
Breast Neoplasms
The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo.
Breast Neoplasms
The influence of pyrimidine nucleoside phosphorylase activity on metastasis of breast cancer.
Breast Neoplasms
The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas.
Breast Neoplasms
Thymidine phoshorylase expression in breast cancer: the prognostic significance and its association with other angiogenesis related proteins and extracellular matrix components.
Breast Neoplasms
Thymidine phosphorylase and breast carcinoma.
Breast Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results.
Breast Neoplasms
Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer.
Breast Neoplasms
Thymidine Phosphorylase Expression and Microvascular Density Correlation Analysis in Canine Mammary Tumor: Possible Prognostic Factor in Breast Cancer.
Breast Neoplasms
Thymidine phosphorylase expression correlates with tumor differentiation and Bcl-2 in invasive breast cancer.
Breast Neoplasms
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Breast Neoplasms
Thymidine phosphorylase is regulated by tamoxifen in T47D breast cancer cell line.
Breast Neoplasms
Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Breast Neoplasms
Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast.
Breast Neoplasms
Up-regulated pyrimidine nucleoside phosphorylase in breast carcinoma correlates with lymph node metastasis.
Breast Neoplasms
Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast.
Breast Neoplasms
Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.
Breast Neoplasms
Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer.
Breast Neoplasms
[Activity of the enzymes of DNA metabolism in the blood of patients with breast cancer]
Breast Neoplasms
[Clinical significance of pyrimidine nucleoside phosphorylase (PyNPase) in breast cancer]
Breast Neoplasms
[Demonstration of pyrimidine nucleoside phosphorylases in breast cancer]
Breast Neoplasms
[Distributions of pyrimidine nucleoside phosphorylase (PyNPase) in tissues of benign and malignant mammary diseases--immunohistochemical observations]
Breast Neoplasms
[Estimation of level of enzyme induction of thymidine phosphorylase, dihydropyrimidine dehydrogenase, and thymidylate synthase in primary and recurrent breast cancer]
Breast Neoplasms
[Expressions of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase in breast cancer and their correlations with prognosis.]
Breast Neoplasms
[Influences of 5'-deoxy-5-fluorouridine (5'-DFUR) on cell cycle in patients with breast cancer]
Breast Neoplasms
[Lactate dehydrogenase, adenosine deaminase and thymidine phosphorylase activity of blood and tissues in breast tumor patients]
Breast Neoplasms
[Measurement of PyNPase and analysis on correlation between breast cancer tissue and lymph node]
Breast Neoplasms
[Prognostic effect of PyNPase (pyrimidine nucleoside phosphorylase) activity in breast cancer]
Breast Neoplasms
[PyNPase and DPD expression potentially predict response to 5'-DFUR treatment for node-positive breast cancer patients]
Breast Neoplasms
[Relationships among the expression of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase and the prognosis of breast cancer]
Breast Neoplasms
[Significance of pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase levels to predict postoperative recurrence in primary breast cancer]
Breast Neoplasms
[Significance of tissue PyNPase, TS, and DPD activities in breast cancer]
Breast Neoplasms
[The correlation between thymidine phosphorylase levels detected by new assay methods (ELISA) and enzyme activity assay (HPLC) in breast cancer]
Breast Neoplasms
[The study of 5-FU levels and pyrimidine nucleoside phosphorylase (PyNPase) activity in human breast cancer tissue after administration of 5'-deoxy-5-fluorouridine (5'-DFUR)]
Breast Neoplasms
[Use of enzyme test in chemotherapy of patients with cancer of the breast]
Carcinogenesis
Anti-tumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse and rat bladder carcinogenesis.
Carcinogenesis
Expression of granulocyte colony-stimulating factor receptor and platelet-derived endothelial cell growth factor in oral and oropharyngeal precancerous lesions.
Carcinogenesis
Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor.
Carcinogenesis
Immunohistochemical detection of platelet-derived endothelial cell growth factor/thymidine phosphorylase and angiopoietins in ameloblastic tumors.
Carcinogenesis
Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma.
Carcinogenesis
Relative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue.
Carcinogenesis
Variations in the expression of platelet-derived endothelial cell growth factor in human colorectal polyps.
Carcinoma
5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression.
Carcinoma
A case report of papilla Vater carcinoma showing positive expression of thymidine phosphorylase.
Carcinoma
Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma.
Carcinoma
Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast.
Carcinoma
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in cervical cancer.
Carcinoma
Angiogenesis in ovarian clear cell carcinoma and its relation to endometriosis.
Carcinoma
Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival.
Carcinoma
Angiogenic growth factors in preinvasive breast disease.
Carcinoma
Angiogenic switch occurs during the precancerous stage of human esophageal squamous cell carcinoma.
Carcinoma
Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.
Carcinoma
Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase.
Carcinoma
Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts.
Carcinoma
Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas.
Carcinoma
Clinical value of thymidine kinase in patients with cervical carcinoma.
Carcinoma
Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma.
Carcinoma
Clinicopathological and prognostic significance of thymidine phosphorylase expression in gastric carcinoma.
Carcinoma
Coexpression of cyclooxygenase-2 and thymidine phosphorylase as a prognostic indicator in patients with FIGO stage IIB squamous cell carcinoma of uterine cervix treated with radiotherapy and concurrent chemotherapy.
Carcinoma
Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Carcinoma
Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma.
Carcinoma
Comparative antitumor activity and intestinal toxicity of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine.
Carcinoma
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Carcinoma
Concurrent expression of angiogenic growth factors and neovascularization during tumourigenesis in colorectal carcinoma patients.
Carcinoma
Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma.
Carcinoma
Correlation between expression levels of thymidine phosphorylase (dThdPase) and clinical features in human gastric carcinoma.
Carcinoma
Correlation between expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) and microvessel density in early-stage human colon carcinomas.
Carcinoma
Correlation between thymidine phosphorylase expression and invasion phenotype in cervical carcinoma cells.
Carcinoma
Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma.
Carcinoma
Correlation between tumor angiogenesis and expression of thymidine phosphorylase, and patient outcome in uterine cervical carcinoma.
Carcinoma
Differences and relationships of thymidine phosphorylase expression in tumor-associated macrophages and cancer cells in squamous cell carcinoma of the esophagus.
Carcinoma
Different angiogenic pathways in human cervical cancers.
Carcinoma
Differential expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) in nonpolypoid and polypoid lesions of the colon.
Carcinoma
Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines.
Carcinoma
Distribution of thymidine phosphorylase activity in gastric carcinoma and adjacent normal gastric tissue.
Carcinoma
Effect of intratumoral OK-432 administration of thymidine phosphorylase expression in human gastric carcinoma.
Carcinoma
Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Carcinoma
Effects of smoking and alcohol consumption on 5-fluorouracil-related metabolic enzymes in oral squamous cell carcinoma.
Carcinoma
Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
Carcinoma
Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors.
Carcinoma
Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma.
Carcinoma
Expression of basic fibroblast growth factor is associated with a good outcome in patients with squamous cell carcinoma of the esophagus.
Carcinoma
Expression of granulocyte colony-stimulating factor receptor and platelet-derived endothelial cell growth factor in oral and oropharyngeal precancerous lesions.
Carcinoma
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers.
Carcinoma
Expression of platelet-derived endothelial cell growth factor in bladder carcinoma.
Carcinoma
Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: relationship to various biological factors.
Carcinoma
Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma.
Carcinoma
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in cervical intraepithelial neoplasia.
Carcinoma
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human gallbladder lesions.
Carcinoma
Expression of pyrimidine nucleoside phosphorylase mRNA plays an important role in the prognosis of patients with oesophageal cancer.
Carcinoma
Expression of thymidine phosphorylase and angiogenesis in human ovarian tumor.
Carcinoma
Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics.
Carcinoma
Expression of thymidine phosphorylase and VEGF in esophageal squamous cell carcinoma.
Carcinoma
Expression of thymidine phosphorylase as an effect prediction factor for uterine cervical squamous cell carcinoma after radiotherapy: an immunohistochemical study.
Carcinoma
Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder.
Carcinoma
Expression of thymidine phosphorylase in human gastric carcinoma.
Carcinoma
Expression of thymidine phosphorylase in primary human renal cell carcinoma by ELISA method.
Carcinoma
Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: implication for method to detect expression of these molecules in clinic.
Carcinoma
Expressions of thymidine phosphorylase (dThdPase) and vascular endothelial growth factor on angiogenesis in intestinal-type gastric carcinoma.
Carcinoma
Frequent expression of thymidine phosphorylase in Epstein-Barr virus-associated gastric carcinoma of diffuse type.
Carcinoma
Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma.
Carcinoma
Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for oral squamous cell carcinoma.
Carcinoma
High level concentration of pyrimidine nucleoside phosphorylase in esophageal squamous cell carcinoma but no correlation with clinicopathological parameters.
Carcinoma
High levels of thymidine phosphorylase as an independent prognostic factor in renal cell carcinoma.
Carcinoma
Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: the influence of neoadjuvant treatment.
Carcinoma
IL-10 expression is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma.
Carcinoma
Immunohistochemical expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in squamous cell carcinoma of the esophagus.
Carcinoma
Immunohistochemical localization of thymidine phosphorylase in gastric cancer: is there a role of the differential expression in tumor cells and associated stromal cells?
Carcinoma
Impact of thymidine phosphorylase-expressing macrophages for surgical margin in partial nephrectomy.
Carcinoma
Increased expression of platelet-derived endothelial cell growth factor in human hepatocellular carcinomas correlated with high Edmondson grades and portal vein tumor thrombosis.
Carcinoma
Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha.
Carcinoma
Induction of thymidine phosphorylase expression and enhancement of Furtulon sensitivity by Taxol in a human ovarian carcinoma cell line.
Carcinoma
Induction of thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line.
Carcinoma
Influence of platelet-derived endothelial cell growth factor/thymidine phosphorylase on the cell cycle in head and neck squamous cell carcinoma in vitro.
Carcinoma
Localization of thymidine phosphorylase expression in colorectal carcinoma tissues by in situ RT-PCR assay.
Carcinoma
Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas.
Carcinoma
Neoangiogenesis in patients with gastric carcinoma in relation to the expression of vascular endothelial growth factor and thymidine phosphorylase.
Carcinoma
No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix.
Carcinoma
Over expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in patients with interstitial cystitis and bladder carcinoma.
Carcinoma
Papers to Appear in Forthcoming Issues
Carcinoma
Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy.
Carcinoma
PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis.
Carcinoma
Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.
Carcinoma
Platelet-derived endothelial cell growth factor (PD-ECGF) is up-regulated in human hepatocellular carcinoma (HCC) and the corresponding hepatitis liver.
Carcinoma
Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix.
Carcinoma
Platelet-derived endothelial cell growth factor in keratinizing-type squamous cell uterine cervical cancer.
Carcinoma
Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer.
Carcinoma
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Carcinoma
Poor Prognosis Associated with High Levels of Thymidine Phosphorylase and Thrombocytosis in Patients with Renal Cell Carcinoma.
Carcinoma
Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase.
Carcinoma
Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor.
Carcinoma
Predictive value of thymidine phosphorylase in gastric carcinoma.
Carcinoma
Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma.
Carcinoma
Production of platelet-derived endothelial cell growth factor by normal and transformed human cells in culture.
Carcinoma
Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma.
Carcinoma
Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma.
Carcinoma
Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma.
Carcinoma
Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma.
Carcinoma
Prognostic Significance of Thymidine Phosphorylase in Superficial Bladder Carcinoma.
Carcinoma
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Carcinoma
Pyrimidine nucleoside phosphorylase-activity and biological characteristics of breast-cancer.
Carcinoma
Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma.
Carcinoma
Regulation and novel action of thymidine phosphorylase in non-small cell lung cancer: crosstalk with Nrf2 and HO-1.
Carcinoma
Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells.
Carcinoma
Reliability of platelet-derived endothelial cell growth factor as a prognostic factor for oral and oropharyngeal carcinomas.
Carcinoma
Role of tumor angiogenesis in gallbladder carcinoma: with special reference to thymidine phosphorylase.
Carcinoma
Selective inhibition of spontaneous pulmonary metastasis of Lewis lung carcinoma by 5'-deoxy-5-fluorouridine.
Carcinoma
Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites.
Carcinoma
Significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor in carcinoma of the papilla of Vater.
Carcinoma
TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma.
Carcinoma
The activity and expression of thymidine phosphorylase in human solid tumours.
Carcinoma
The effect of neoadjuvant therapy on the 5-fluorouracil metabolic and relative enzymes of oral squamous cell carcinoma.
Carcinoma
The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma.
Carcinoma
The expression of thymidine phosphorylase suppresses spontaneous apoptosis of cancer cells in esophageal squamous cell carcinoma.
Carcinoma
The expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor is correlated to angiogenesis in breast cancer.
Carcinoma
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Carcinoma
The predictive value of p53, Ki-67 and angiogenetic factors in primary hypopharyngeal carcinoma.
Carcinoma
The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus.
Carcinoma
The role of thymidine phosphorylase expression in the invasiveness of gastric carcinoma.
Carcinoma
The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells.
Carcinoma
The role of vascular endothelial growth factor-A (VEGF-A) and platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in Paget's disease of the vulva and breast.
Carcinoma
The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells.
Carcinoma
The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers.
Carcinoma
Thymidine Kinase 1 and Thymidine Phosphorylase Expression in Non-small Cell Lung Carcinoma in Relation to Angiogenesis and Proliferation.
Carcinoma
Thymidine phosphorylase activity in nonsmall cell lung carcinoma tissues.
Carcinoma
Thymidine phosphorylase activity in renal cell carcinoma: relationship between histological parameters and chemosensitivity to fluorouracil-related drugs.
Carcinoma
Thymidine phosphorylase and angiogenesis in early stage esophageal squamous cell carcinoma.
Carcinoma
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer.
Carcinoma
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil.
Carcinoma
Thymidine phosphorylase as a prognostic factor in renal cell carcinoma.
Carcinoma
Thymidine phosphorylase expression causes both the increase of intratumoral microvessels and decrease of apoptosis in human esophageal carcinomas.
Carcinoma
Thymidine phosphorylase expression in gastric carcinoma as a marker for metastasis.
Carcinoma
Thymidine phosphorylase expression in human colorectal mucosa, adenoma and carcinoma: role of p53 expression.
Carcinoma
Thymidine phosphorylase expression in invasive carcinoma: correlations with clinicopathologic variables and in vitro chemosensitivity to 5-fluorouracil.
Carcinoma
Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis.
Carcinoma
Thymidine phosphorylase expression in oral squamous cell carcinoma.
Carcinoma
Thymidine phosphorylase expression in progression of cervical cancer: correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis.
Carcinoma
Thymidine phosphorylase expression in tumor stroma of uterine cervical carcinomas: histological features and microvessel density.
Carcinoma
Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas.
Carcinoma
Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma.
Carcinoma
Thymidine phosphorylase expression results in a decrease in apoptosis and increase in intratumoral microvessel density in human gastric carcinomas.
Carcinoma
Thymidine phosphorylase in human esophageal squamous cell carcinoma.
Carcinoma
Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors.
Carcinoma
Thymidine phosphorylase levels as a prognostic factor in renal cell carcinoma.
Carcinoma
Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil.
Carcinoma
Thymidine phosphorylase/platelet-derived endothelial cell growth factor (PD-ECGF) associated with prognosis in renal cell carcinoma.
Carcinoma
Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma.
Carcinoma
Thymidine phosphorylase/platelet-derived endothelial cell growth factor is upregulated in advanced solid types of gastric cancer.
Carcinoma
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Carcinoma
Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma.
Carcinoma
Transcriptional expression of the genes implicated in angiogenesis and tumor invasion in cervical carcinomas.
Carcinoma
Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma.
Carcinoma
Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum.
Carcinoma
Tumor angiogenesis as an independent prognostic factor after extended radical esophagectomy for invasive squamous cell carcinoma of the esophagus.
Carcinoma
Variations in the expression of platelet-derived endothelial cell growth factor in human colorectal polyps.
Carcinoma
Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas.
Carcinoma
[Activities of pyrimidine nucleoside phosphorylase in brain tumors and antitumor effect of 5'-DFUR]
Carcinoma
[Effect of thymidine phosphorylase cDNA transfection on the inhibition of human colon carcinoma cell line by 5'-deoxy-5-fluorouridine].
Carcinoma
[Improved sensitivity of gastric carcinoma cells to fluorouracil-related drugs by transfection of thymidine phosphorylase gene].
Carcinoma
[Influence of interferon-?2a on thymidine phosphorylase expression and anticancer activity of 5'-deoxy-fluorouridine in human colon carcinoma cell lines LOVO and SW480].
Carcinoma
[Long-term outcome of preoperative chemotherapy with 5'-deoxy-5-fluorouridine (5'-DFUR) for gastric cancer]
Carcinoma
[Prognostic effect of PyNPase (pyrimidine nucleoside phosphorylase) activity in breast cancer]
Carcinoma
[Study of PyNPase activity in patients with gastric cancer--the association with preoperative IAP values]
Carcinoma
[The alteration of PyNPase activity in breast cancers due to preoperative oral administration of 5'-DFUR]
Carcinoma
[The expressions of TP, MK and CD105 in laryngeal squamous cell carcinoma and their clinical significance]
Carcinoma
[The mRNA expression of platelet-derived endothelial cell growth factor of bladder transitional cell carcinoma and its relation to invasiveness]
Carcinoma
[Use of the study of DNA metabolism enzyme activities as a test system in the treatment of breast cancer]
Carcinoma in Situ
Angiogenic growth factors in preinvasive breast disease.
Carcinoma in Situ
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in cervical intraepithelial neoplasia.
Carcinoma in Situ
Thymidine phosphorylase expression in progression of cervical cancer: correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis.
Carcinoma, Adenosquamous
Different angiogenic pathways in human cervical cancers.
Carcinoma, Ductal
Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast.
Carcinoma, Ductal
HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer.
Carcinoma, Ductal
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives.
Carcinoma, Ductal
The role of vascular endothelial growth factor-A (VEGF-A) and platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in Paget's disease of the vulva and breast.
Carcinoma, Ductal
Thymidine phosphorylase expression and stromal vascularity in ductal carcinoma in situ of the breast.
Carcinoma, Ductal
Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast.
Carcinoma, Endometrioid
Angiogenesis and endometrial cancer.
Carcinoma, Endometrioid
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in ovarian cancers.
Carcinoma, Hepatocellular
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
Carcinoma, Hepatocellular
Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients.
Carcinoma, Hepatocellular
Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment.
Carcinoma, Hepatocellular
Effects of 5'-DFUR and lentinan on cytokines and PyNPase against AH66 ascites hepatoma in rats.
Carcinoma, Hepatocellular
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Carcinoma, Hepatocellular
Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.
Carcinoma, Hepatocellular
High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection.
Carcinoma, Hepatocellular
Increased expression of platelet-derived endothelial cell growth factor in human hepatocellular carcinomas correlated with high Edmondson grades and portal vein tumor thrombosis.
Carcinoma, Hepatocellular
Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice.
Carcinoma, Hepatocellular
Platelet-derived endothelial cell growth factor (PD-ECGF) is up-regulated in human hepatocellular carcinoma (HCC) and the corresponding hepatitis liver.
Carcinoma, Hepatocellular
Prognostic value of thymidine phosphorylase activity in liver tissue adjacent to hepatocellular carcinoma.
Carcinoma, Hepatocellular
The significance of thymidine phosphorylase activity in hepatocellular carcinoma and chronic diseased livers: a special reference to liver fibrosis and multicentric tumor occurrence.
Carcinoma, Hepatocellular
Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Thymidine phosphorylase activity in liver tissue and its correlation with multifocal occurrence of hepatocellular carcinomas.
Carcinoma, Hepatocellular
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in hepatocellular carcinoma and metastatic liver cancer.
Carcinoma, Hepatocellular
Thymidine phosphorylase promotes malignant progression in hepatocellular carcinoma through pentose Warburg effect.
Carcinoma, Hepatocellular
Thymidine phosphorylase promotes metastasis and serves as a marker of poor prognosis in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Transfection of thymidine phosphorylase cDNA to human hepatocellular carcinoma cells enhances sensitivity to fluoropyrimidine but augments endothelial cell migration.
Carcinoma, Hepatocellular
[Activities of pyrimidine nucleoside phosphorylase in brain tumors and antitumor effect of 5'-DFUR]
Carcinoma, Hepatocellular
[Expression rates of three angiogenic factors in hepatocellular carcinoma and their relation with microvessel density and portal vein tumor thrombosis]
Carcinoma, Hepatocellular
[Interferon alpha enhances the sensitivity of SMMC-7721 hepatocellular carcinoma cells to 5'-deoxy-5-fluorouridine related to up-regulation of thymidine phosphorylase]
Carcinoma, Hepatocellular
[Interferon-alpha upregulates thymidine phosphorylase expression via JAK-STAT transcriptional activation and mRNA stabilization in human hepatocellular carcinoma SMMC-7721 cells]
Carcinoma, Hepatocellular
[Up-regulation of thymidine phosphorylase and anti-angiogenesis by interferon alpha in human hepatocellular carcinoma cell line and xenograft]
Carcinoma, Intraductal, Noninfiltrating
Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast.
Carcinoma, Intraductal, Noninfiltrating
Does thymidine phosphorylase correlate with angiogenesis in intraductal carcinoma of the breast?
Carcinoma, Intraductal, Noninfiltrating
The role of vascular endothelial growth factor-A (VEGF-A) and platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in Paget's disease of the vulva and breast.
Carcinoma, Intraductal, Noninfiltrating
Thymidine phosphorylase expression and stromal vascularity in ductal carcinoma in situ of the breast.
Carcinoma, Large Cell
Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines.
Carcinoma, Lewis Lung
Comparative antitumor activity and intestinal toxicity of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine.
Carcinoma, Lewis Lung
Selective inhibition of spontaneous pulmonary metastasis of Lewis lung carcinoma by 5'-deoxy-5-fluorouridine.
Carcinoma, Non-Small-Cell Lung
Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways.
Carcinoma, Non-Small-Cell Lung
Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neo-angiogenesis in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Metformin Induces Cytotoxicity by Down-Regulating Thymidine Phosphorylase and Excision Repair Cross-Complementation 1 Expression in Non-Small Cell Lung Cancer Cells.
Carcinoma, Non-Small-Cell Lung
Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer.
Carcinoma, Non-Small-Cell Lung
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
Regulation and novel action of thymidine phosphorylase in non-small cell lung cancer: crosstalk with Nrf2 and HO-1.
Carcinoma, Non-Small-Cell Lung
Thymidine Kinase 1 and Thymidine Phosphorylase Expression in Non-small Cell Lung Carcinoma in Relation to Angiogenesis and Proliferation.
Carcinoma, Non-Small-Cell Lung
Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues.
Carcinoma, Non-Small-Cell Lung
Up-regulation of ERK1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small cell lung cancer cells.
Carcinoma, Ovarian Epithelial
Expression of the thymidine phosphorylase gene in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor.
Carcinoma, Ovarian Epithelial
Expression of thymidine phosphorylase in epithelial ovarian cancer: correlation with angiogenesis, apoptosis, and ultrasound-derived peak systolic velocity.
Carcinoma, Ovarian Epithelial
Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Papers to Appear in Forthcoming Issues
Carcinoma, Ovarian Epithelial
Papers to appear in forthcoming issues
Carcinoma, Ovarian Epithelial
Platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Relationship between the expression of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase and survival in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Role of lymphangiogenesis in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Thymidylate synthase expression in epithelial ovarian cancer: relationship with thymidine phosphorylase expression and prognosis.
Carcinoma, Pancreatic Ductal
Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival.
Carcinoma, Pancreatic Ductal
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives.
Carcinoma, Papillary
Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum.
Carcinoma, Renal Cell
Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase.
Carcinoma, Renal Cell
Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Carcinoma, Renal Cell
Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma.
Carcinoma, Renal Cell
Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
Carcinoma, Renal Cell
Expression of thymidine phosphorylase in primary human renal cell carcinoma by ELISA method.
Carcinoma, Renal Cell
High levels of thymidine phosphorylase as an independent prognostic factor in renal cell carcinoma.
Carcinoma, Renal Cell
Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: the influence of neoadjuvant treatment.
Carcinoma, Renal Cell
Impact of thymidine phosphorylase-expressing macrophages for surgical margin in partial nephrectomy.
Carcinoma, Renal Cell
Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix.
Carcinoma, Renal Cell
Poor Prognosis Associated with High Levels of Thymidine Phosphorylase and Thrombocytosis in Patients with Renal Cell Carcinoma.
Carcinoma, Renal Cell
Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma.
Carcinoma, Renal Cell
Thymidine phosphorylase activity in renal cell carcinoma: relationship between histological parameters and chemosensitivity to fluorouracil-related drugs.
Carcinoma, Renal Cell
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil.
Carcinoma, Renal Cell
Thymidine phosphorylase as a prognostic factor in renal cell carcinoma.
Carcinoma, Renal Cell
Thymidine phosphorylase levels as a prognostic factor in renal cell carcinoma.
Carcinoma, Renal Cell
Thymidine phosphorylase/platelet-derived endothelial cell growth factor (PD-ECGF) associated with prognosis in renal cell carcinoma.
Carcinoma, Small Cell
Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines.
Carcinoma, Squamous Cell
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in cervical cancer.
Carcinoma, Squamous Cell
Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas.
Carcinoma, Squamous Cell
Coexpression of cyclooxygenase-2 and thymidine phosphorylase as a prognostic indicator in patients with FIGO stage IIB squamous cell carcinoma of uterine cervix treated with radiotherapy and concurrent chemotherapy.
Carcinoma, Squamous Cell
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Carcinoma, Squamous Cell
Differences and relationships of thymidine phosphorylase expression in tumor-associated macrophages and cancer cells in squamous cell carcinoma of the esophagus.
Carcinoma, Squamous Cell
Different angiogenic pathways in human cervical cancers.
Carcinoma, Squamous Cell
Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines.
Carcinoma, Squamous Cell
Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors.
Carcinoma, Squamous Cell
Expression of basic fibroblast growth factor is associated with a good outcome in patients with squamous cell carcinoma of the esophagus.
Carcinoma, Squamous Cell
Expression of granulocyte colony-stimulating factor receptor and platelet-derived endothelial cell growth factor in oral and oropharyngeal precancerous lesions.
Carcinoma, Squamous Cell
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers.
Carcinoma, Squamous Cell
Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics.
Carcinoma, Squamous Cell
Expression of thymidine phosphorylase as an effect prediction factor for uterine cervical squamous cell carcinoma after radiotherapy: an immunohistochemical study.
Carcinoma, Squamous Cell
Influence of platelet-derived endothelial cell growth factor/thymidine phosphorylase on the cell cycle in head and neck squamous cell carcinoma in vitro.
Carcinoma, Squamous Cell
Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma.
Carcinoma, Squamous Cell
Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy.
Carcinoma, Squamous Cell
Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.
Carcinoma, Squamous Cell
Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix.
Carcinoma, Squamous Cell
Platelet-derived endothelial cell growth factor in keratinizing-type squamous cell uterine cervical cancer.
Carcinoma, Squamous Cell
Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer.
Carcinoma, Squamous Cell
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Carcinoma, Squamous Cell
Production of platelet-derived endothelial cell growth factor by normal and transformed human cells in culture.
Carcinoma, Squamous Cell
Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma.
Carcinoma, Squamous Cell
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Carcinoma, Squamous Cell
Reliability of platelet-derived endothelial cell growth factor as a prognostic factor for oral and oropharyngeal carcinomas.
Carcinoma, Squamous Cell
Structural properties of 3.0 kb and 3.2 kb transcripts encoding platelet-derived endothelial cell growth factor/thymidine phosphorylase in A431 cells.
Carcinoma, Squamous Cell
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Carcinoma, Squamous Cell
The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus.
Carcinoma, Squamous Cell
The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers.
Carcinoma, Squamous Cell
Thymidine phosphorylase expression causes both the increase of intratumoral microvessels and decrease of apoptosis in human esophageal carcinomas.
Carcinoma, Squamous Cell
Thymidine phosphorylase expression in progression of cervical cancer: correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis.
Carcinoma, Squamous Cell
Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma.
Carcinoma, Squamous Cell
Thymidine phosphorylase in human esophageal squamous cell carcinoma.
Carcinoma, Transitional Cell
Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma.
Carcinoma, Transitional Cell
Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder.
Carcinoma, Transitional Cell
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer.
Carcinoma, Transitional Cell
[The mRNA expression of platelet-derived endothelial cell growth factor of bladder transitional cell carcinoma and its relation to invasiveness]
Cardiovascular Diseases
Thymidine phosphorylase: A potential new target for treating cardiovascular disease.
Cervical Intraepithelial Neoplasia
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in cervical intraepithelial neoplasia.
Cervical Intraepithelial Neoplasia
Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix.
Cervical Intraepithelial Neoplasia
[Immunohistochemical study of thymidine phosphorylase in uterine cervical intraepithelial neoplasia]
Cervical Intraepithelial Neoplasia
[Ki-67 expression, thymidine phosphorylase and PTEN in intraepithelial cervical carcinoma].
Cholangiocarcinoma
Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combination chemotherapy in cholangiocarcinoma?: case series.
Cholangiocarcinoma
Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma.
Cholangiocarcinoma
Interrelationship of platelet-derived endothelial cell growth factor, liver macrophages, and tumor microvessel density in patients with cholangiocellular carcinoma.
Cholangiocarcinoma
The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
Thymidine phosphorylase promotes angiogenesis and tumour growth in intrahepatic cholangiocarcinoma.
Choroidal Neovascularization
Subconjunctival doxifluridine administration suppresses rat choroidal neovascularization through activated thymidine phosphorylase.
Coinfection
Mycoplasma pneumoniae thymidine phosphorylase.
Colitis, Ulcerative
Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease.
Colitis, Ulcerative
Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease.
Colonic Neoplasms
Anticancer effectiveness of polymeric drug nanocarriers on colorectal cancer cells.
Colonic Neoplasms
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
Colonic Neoplasms
Changes over time in thymidine phosphorylase and dihydropyrimidine dehydrogenase when colon cancer samples are left at room temperature.
Colonic Neoplasms
Correlation between expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) and microvessel density in early-stage human colon carcinomas.
Colonic Neoplasms
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Colonic Neoplasms
Differential expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) in nonpolypoid and polypoid lesions of the colon.
Colonic Neoplasms
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Colonic Neoplasms
Enhancement of the anti-tumor effect of 5'-deoxy-5-fluorouridine by transfection of thymidine phosphorylase gene into human colon cancer cells.
Colonic Neoplasms
Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease.
Colonic Neoplasms
Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.
Colonic Neoplasms
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Colonic Neoplasms
Logistic regression model of the clinical response to 5-fluorouracil based chemotherapy for metastatic colorectal cancer patients.
Colonic Neoplasms
Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells.
Colonic Neoplasms
Platelet-derived endothelial cell growth factor mediates Rho-associated coiled-coil domain kinase messenger RNA expression and promotes cell motility.
Colonic Neoplasms
Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues.
Colonic Neoplasms
Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers.
Colonic Neoplasms
PyNPase expression in human colon cancer.
Colonic Neoplasms
Pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase indicate chemosensitivity of human colon cancer specimens to doxifluridine and 5-fluorouracil, respectively.
Colonic Neoplasms
Radiosensitization by thymidine phosphorylase inhibitor in thymidine phosphorylase negative and overexpressing bladder cancer cell lines.
Colonic Neoplasms
Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells.
Colonic Neoplasms
Significance of expression of pyrimidine metabolizing genes in colon cancer.
Colonic Neoplasms
Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer.
Colonic Neoplasms
The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion.
Colonic Neoplasms
The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase.
Colonic Neoplasms
Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.
Colonic Neoplasms
[Analysis of the salvage synthesis within biosynthesis of nucleic acid route in colon cancer]
Colonic Neoplasms
[Effects of expression of thymidine phosphorylase induced by gamma-interferon on regulation of antineoplastic activity of fluorouracil on colonic cancer]
Colonic Neoplasms
[Enhanced anticancer effects of 5'-DFUR on colorectal cancer cell lines SW480 and LOVO by transfection with thymidine phosphorylase cDNA].
Colonic Neoplasms
[Significance of 5'-deoxy-5-fluorouridine (5'-DFUR) administration before surgery for advanced gastric and colonic cancers--activity of pyrimidine nucleoside phosphorylase (PyNPase) and serum immunosuppressive acidic protein (IAP)]
Colonic Neoplasms
[Thymidine phosphorylase is correlated with DPD in colon cancer]
Colorectal Neoplasms
5-Fluorouracil-related gene expression in hepatic artery infusion-treated patients with hepatic metastases from colorectal carcinomas.
Colorectal Neoplasms
5-Fluorouracil-related gene expression in primary sites and hepatic metastases of colorectal carcinomas.
Colorectal Neoplasms
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
Colorectal Neoplasms
Association between p53 expression and Bcl-2, P-glycoprotein, topoisomerase II alpha, thymidylate synthase and thymidine phosphorylase as potential therapeutic targets in colorectal cancer patients.
Colorectal Neoplasms
Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
Colorectal Neoplasms
Clinical relevance of the concentrations of both pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer.
Colorectal Neoplasms
Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
Colorectal Neoplasms
Clinical significance of pyrimidine nucleoside phosphorylase in colorectal carcinoma.
Colorectal Neoplasms
Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma.
Colorectal Neoplasms
Clinicopathological significance of vascular endothelial growth factor, thymidine phosphorylase and microvessel density in colorectal cancer.
Colorectal Neoplasms
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Colorectal Neoplasms
Comparative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in gastric and colorectal cancers.
Colorectal Neoplasms
Comparative analysis of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in colorectal cancer and surrounding normal tissue.
Colorectal Neoplasms
Correlation between malignancy grade and p53 gene in relation to thymidine phosphorylase activity in colorectal cancer patients.
Colorectal Neoplasms
Correlation of thymidine phosphorylase staining and the Ki-67 labeling index to clinicopathologic factors and hepatic metastasis in patients with colorectal cancer.
Colorectal Neoplasms
Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.
Colorectal Neoplasms
Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines.
Colorectal Neoplasms
Development and characterization of 1C6-203, a new monoclonal antibody specific to human thymidine phosphorylase.
Colorectal Neoplasms
Effects of Platelet-Derived Endothelial Cell Growth Factor and Doppler Perfusion Index in Patients with Colorectal Hepatic Metastases.
Colorectal Neoplasms
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Colorectal Neoplasms
Endogenous gamma-interferon activates thymidine phosphorylase in colorectal cancer tissue.
Colorectal Neoplasms
Enhancement of the anti-tumor effect of 5'-deoxy-5-fluorouridine by transfection of thymidine phosphorylase gene into human colon cancer cells.
Colorectal Neoplasms
Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer.
Colorectal Neoplasms
Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
Colorectal Neoplasms
Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer.
Colorectal Neoplasms
Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma.
Colorectal Neoplasms
Expression of pyrimidine nucleoside phosphorylase (PyNPase) in colorectal cancer.
Colorectal Neoplasms
Expression of thymidine phosphorylase by macrophages in colorectal cancer tissues.
Colorectal Neoplasms
Fatty liver suppressed the angiogenesis in liver metastatic lesions.
Colorectal Neoplasms
Fluorescence and computational studies of thymidine phosphorylase affinity toward lipidated 5-FU derivatives.
Colorectal Neoplasms
Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis.
Colorectal Neoplasms
High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil.
Colorectal Neoplasms
Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma.
Colorectal Neoplasms
Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase.
Colorectal Neoplasms
Integrated safety summary for trifluridine/tipiracil (TAS-102).
Colorectal Neoplasms
Interferon alpha and 5'-deoxy-5-fluorouridine in colon cancer: effects as single agents and in combination on growth of xenograft tumours.
Colorectal Neoplasms
Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer.
Colorectal Neoplasms
Localization of thymidine phosphorylase expression in colorectal carcinoma tissues by in situ RT-PCR assay.
Colorectal Neoplasms
Localization of thymidine phosphorylase in advanced gastric and colorectal cancer.
Colorectal Neoplasms
Localization of thymidine phosphorylase in breast cancer tissue.
Colorectal Neoplasms
Methylenetetrahydrofolate reductase C677T is not associated with expression of pyrimidine metabolic enzyme genes in colorectal cancer.
Colorectal Neoplasms
Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
Colorectal Neoplasms
Neoplastic stroma and epithelium show up-regulation of platelet-derived endothelial cell growth factor/thymidine phosphorylase in colorectal carcinomas but not adenomas.
Colorectal Neoplasms
Occurrence of hematogenous metastasis and serum levels of thymidine phosphorylase in colorectal cancer.
Colorectal Neoplasms
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Colorectal Neoplasms
Platelet-derived endothelial cell growth factor expression is an independent prognostic factor in colorectal cancer patients after curative surgery.
Colorectal Neoplasms
Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer.
Colorectal Neoplasms
Platelet-derived endothelial cell growth factor/thymidine phosphorylase inhibitor augments radiotherapeutic efficacy in experimental colorectal cancer.
Colorectal Neoplasms
Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
Colorectal Neoplasms
Prediction of 5'-deoxy-5-fluorouridine sensitivity in colorectal cancer cases by thymidine phosphorylase activity and preliminary identification of susceptibility related genes.
Colorectal Neoplasms
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Colorectal Neoplasms
Predictive role of thymidine phosphorylase expression in patients with colorectal cancer and its association with angiogenesis-related proteins and extracellular matrix components.
Colorectal Neoplasms
Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Colorectal Neoplasms
Progesterone receptor positive colorectal tumors have lower thymidine phosphorylase expression: an immunohistochemical study.
Colorectal Neoplasms
Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.
Colorectal Neoplasms
Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
Colorectal Neoplasms
Prognostic significance of the serum thymidine phosphorylase levels in venous blood drainage specimens in patients with colorectal cancer.
Colorectal Neoplasms
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Colorectal Neoplasms
PyNPase expression in human colon cancer.
Colorectal Neoplasms
Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer.
Colorectal Neoplasms
Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil.
Colorectal Neoplasms
Research development of the relationship between thymidine phosphorylase expression and colorectal carcinoma.
Colorectal Neoplasms
Review on TAS-102 development and its use for metastatic colorectal cancer.
Colorectal Neoplasms
Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
Colorectal Neoplasms
Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen.
Colorectal Neoplasms
Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma.
Colorectal Neoplasms
Specific enhanced expression of platelet-derived endothelial cell growth factor in submucosa of human colorectal cancer.
Colorectal Neoplasms
Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts.
Colorectal Neoplasms
The activities of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer depend on where the sample is taken.
Colorectal Neoplasms
The correlation of thymidine phosphorylase activity with the expression of interleukin 1 alpha, interferon alpha and interferon gamma in human colorectal carcinoma.
Colorectal Neoplasms
The dual role of thymidine phosphorylase in cancer development and chemotherapy.
Colorectal Neoplasms
The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinomas.
Colorectal Neoplasms
The relationship between clinicopathological factors and the reduction of pyrimidine nucleoside phosphorylase activity after preoperative administration of 5'-deoxy-5-fluorouridine.
Colorectal Neoplasms
The significance of thymidine phosphorylase expression in colorectal cancer.
Colorectal Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis.
Colorectal Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels in tumor and normal tissue specimens of t3 human colorectal carcinoma.
Colorectal Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.
Colorectal Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer.
Colorectal Neoplasms
Thymidine phosphorylase expressed in macrophages enhances antitumor effect of 5'-deoxy-5-fluorouridine on human colorectal carcinoma cells.
Colorectal Neoplasms
Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients.
Colorectal Neoplasms
Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5-fluorouracil-based chemotherapy: A meta-analysis.
Colorectal Neoplasms
Thymidine phosphorylase expression in human colorectal mucosa, adenoma and carcinoma: role of p53 expression.
Colorectal Neoplasms
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Colorectal Neoplasms
Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas.
Colorectal Neoplasms
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Colorectal Neoplasms
Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer.
Colorectal Neoplasms
Thymidine Phosphorylase Gene Expression in Stage III Colorectal Cancer.
Colorectal Neoplasms
Thymidine phosphorylase mRNA expression may be a predictor of response to post-operative adjuvant chemotherapy with S-1 in patients with stage III colorectal cancer.
Colorectal Neoplasms
Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.
Colorectal Neoplasms
Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?
Colorectal Neoplasms
Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis.
Colorectal Neoplasms
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
Colorectal Neoplasms
Thymidylate Synthase, Thymidine Phosphorylase, VEGF and p53 Protein Expression in Primary Colorectal Cancer for Predicting Response to 5-fluorouracil-based Chemotherapy.
Colorectal Neoplasms
Tissue concentration of platelet-derived endothelial cell growth factor in colorectal cancer.
Colorectal Neoplasms
Tumor growth pattern and thymidine phosphorylase expression are related with the risk of hematogenous metastasis in patients with Astler Coller B1/B2 colorectal carcinoma.
Colorectal Neoplasms
Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer.
Colorectal Neoplasms
Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.
Colorectal Neoplasms
[Antitumor effect of 5'-DFUR and PyNPase activity in colorectal cancer]
Colorectal Neoplasms
[Clinicopathological significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced colorectal cancer]
Colorectal Neoplasms
[Dihydropyrimidine dehydrogenase and thymidine phosphorylase as a prognostic factor of colorectal cancer patients].
Colorectal Neoplasms
[Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]
Colorectal Neoplasms
[Effect on 5'-deoxy-5-fluorouridine (5'-DFUR) of pyrimidine nucleoside phosphorylase (PyNPase), matrix metalloprotease and serum IAP values. Hokuriku Colorectal Cancer Chemotherapy Study Group]
Colorectal Neoplasms
[Enhanced anticancer effects of 5'-DFUR on colorectal cancer cell lines SW480 and LOVO by transfection with thymidine phosphorylase cDNA].
Colorectal Neoplasms
[Expression of mRNA levels of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in diffusely infiltrating colorectal cancer]
Colorectal Neoplasms
[Expression of thymidine phosphorylase in human colorectal carcinoma and its clinical significance]
Colorectal Neoplasms
[Expression of thymidine phosphorylase in primary colorectal cancer and liver metastasis-relationship between mRNA levels in cancer cells and protein levels in cancerous tissue]
Colorectal Neoplasms
[Expression of vascular growth factors in intestinal tissues in colorectal carcinoma patients with schistosomiasis japonica].
Colorectal Neoplasms
[Immunohistochemical staining of thymidine phosphorylase in primary colorectal carcinoma and metastases]
Colorectal Neoplasms
[Prognosis and efficacy of postoperative adjuvant chemotherapy in colorectal cancer correlates with nucleic acid metabolizing enzymes]
Colorectal Neoplasms
[PyNPase activity in primary and metastatic colorectal cancer]
Colorectal Neoplasms
[PyNPase expression and cancer progression in the colorectum]
Colorectal Neoplasms
[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]
Colorectal Neoplasms
[Studies on 5-FU concentration and thymidine phosphorylase activity in tissues of patients with colorectal cancer after SF-SP administration]
Colorectal Neoplasms
[Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer]
Colorectal Neoplasms
[The influence of Thymidine Phosphorylase genetic variation on clinical outcomes and safety of colorectal cancer patients received adjuvant chemotherapy after R0 resection].
Colorectal Neoplasms
[The relation between pyrimidine nucleoside phosphorylase (PyNPase) activity in colorectal cancer tissues and pathological effects]
Colorectal Neoplasms
[The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer].
Colorectal Neoplasms
[Thymidine phosphorylase expressed in monocyte-macrophages enhanced anticancer effect of 5'-deoxy-5-fluorouridine on colorectal carcinoma cells]
Colorectal Neoplasms
[Thymidine phosphorylase expression in hepatic metastasis from colorectal carcinoma]
Colorectal Neoplasms
[Transfection of thymidine phosphorylase cDNA with lentiviral vector enhances the anticancer effect of 5'-deoxy-5-fluorouridine on colorectal cancer cell lines HT29 and LS174T].
Colorectal Neoplasms
[Tumoral levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in elderly colorectal cancer patients]
COVID-19
Thymidine Phosphorylase Is Increased in COVID-19 Patients in an Acuity-Dependent Manner.
Crohn Disease
Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease.
Crohn Disease
Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease.
Cystadenocarcinoma, Serous
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in ovarian cancers.
Cystadenoma
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives.
Cystitis, Interstitial
Over expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in patients with interstitial cystitis and bladder carcinoma.
Cystitis, Interstitial
Overexpression of platelet-derived endothelial cell growth factor (PD-ECGF) factor/thymidine phosphorylase (TP) in interstitial cystitis.
Cysts
Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer.
Diabetes Mellitus
Thymidine phosphorylase participates in platelet signaling and promotes thrombosis.
Diffuse Cerebral Sclerosis of Schilder
Mitochondrial syndromes with leukoencephalopathies.
Distal Myopathies
Primary muscle diseases in Thammasat University Hospital: muscle biopsy study of 12 cases.
Dysarthria
Inherited peripheral neuropathies due to mitochondrial disorders.
Dysarthria
[Peripheral neuropathies due to mitochondrial disorders]
Endometrial Hyperplasia
Thymidine phosphorylase expression in normal and hyperplastic endometrium.
Endometrial Neoplasms
A role of thymidine phosphorylase and P53 tissue protein expression in biology of endometrial cancer.
Endometrial Neoplasms
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in endometrial cancer.
Endometrial Neoplasms
Clinical implications of expression of ETS-1 related to angiogenesis in uterine endometrial cancers.
Endometrial Neoplasms
Clinical implications of expression of interleukin-8 related to myometrial invasion with angiogenesis in uterine endometrial cancers.
Endometrial Neoplasms
Co-expression of vascular endothelial growth factor and thymidine phosphorylase in endometrial cancer.
Endometrial Neoplasms
Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase.
Endometrial Neoplasms
Effects of various steroids on platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA expression in uterine endometrial cancer cells.
Endometrial Neoplasms
Evaluation of tumor angiogenesis and thymidine phosphorylase tissue expression in patients with endometrial cancer.
Endometrial Neoplasms
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers.
Endometrial Neoplasms
Immunohistochemical expression of thymidine phosphorylase in human endometrial cancer.
Endometrial Neoplasms
Papers to Appear in Forthcoming Issues
Endometrial Neoplasms
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Endometrial Neoplasms
The cytosol activity of thymidine phosphorylase in endometrial cancer.
Endometrial Neoplasms
Thymidine phosphorylase expression in endometrial carcinomas.
Endometrial Neoplasms
Thymidine phosphorylase expression in tumor-infiltrating macrophages may be correlated with poor prognosis in uterine endometrial cancer.
Endometrial Neoplasms
Thymidine phosphorylase expression is predominantly observed in stroma of well-differentiated adenocarcinoma of endometrium and correlates with a frequency of vascular involvement.
Endometrial Neoplasms
Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer.
Endometrial Neoplasms
[Immunohistochemistry and activities of thymidine phosphorylase in the tissues of uterine cervical and endometrial carcinomas]
Endometrial Neoplasms
[The thymidine phosphorylase as the platelet-derived endothelial cell growth factor of endometrial cancer]
Endometriosis
Angiogenesis in endometriosis and angiogenic factors.
Endometriosis
Angiogenesis in ovarian clear cell carcinoma and its relation to endometriosis.
Endometriosis
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) related to angiogenesis in ovarian endometriosis.
Endometriosis
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Esophageal Neoplasms
Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas.
Esophageal Neoplasms
Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?
Esophageal Squamous Cell Carcinoma
Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas.
Esophageal Squamous Cell Carcinoma
Expression of thymidine phosphorylase and VEGF in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
High level concentration of pyrimidine nucleoside phosphorylase in esophageal squamous cell carcinoma but no correlation with clinicopathological parameters.
Esophageal Squamous Cell Carcinoma
Immunohistochemical expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in squamous cell carcinoma of the esophagus.
Esophageal Squamous Cell Carcinoma
Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
The expression of thymidine phosphorylase suppresses spontaneous apoptosis of cancer cells in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Thymidine phosphorylase and angiogenesis in early stage esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Thymidine phosphorylase in human esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Fanconi Anemia
Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes.
Fatty Liver
Fatty liver suppressed the angiogenesis in liver metastatic lesions.
Fatty Liver
Nutrition Therapy for Mitochondrial Neurogastrointestinal Encephalopathy with Homozygous Mutation of the TYMP Gene.
Fibroadenoma
[Distributions of pyrimidine nucleoside phosphorylase (PyNPase) in tissues of benign and malignant mammary diseases--immunohistochemical observations]
Gallbladder Neoplasms
Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer.
Gastritis
Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma.
Gastrointestinal Neoplasms
Comparison of the pyrimidine nucleoside phosphorylase activity in human tumors and normal tissues.
Gastrointestinal Neoplasms
Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine.
Gastrointestinal Neoplasms
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Gastrointestinal Neoplasms
Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer.
Gastrointestinal Neoplasms
Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.
Gastrointestinal Neoplasms
Increased expression of thymidine phosphorylase in tumor tissue in proportion to TP-expression in primary normal tissue.
Gastrointestinal Neoplasms
Preoperative endoscopic analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in gastrointestinal cancer.
Gastrointestinal Neoplasms
Thymidine phosphorylase gene variant, platelet counts and survival in gastrointestinal cancer patients treated by fluoropyrimidines.
Gastrointestinal Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test.
Gastrointestinal Neoplasms
[The analysis of thymidine phosphorylase examined by ELISA in bladder cancer]
Genetic Diseases, Inborn
Assessment of stability, toxicity and immunogenicity of new polymeric nanoreactors for use in enzyme replacement therapy of MNGIE.
Glaucoma, Neovascular
Expression of thymidine phosphorylase in choroidal malignant melanoma associated with neovascular glaucoma.
Glioblastoma
Angiogenic effect of thymidine phosphorylase on macrophages in glioblastoma multiforme.
Glioblastoma
Design of Novel Inhibitors of Human Thymidine Phosphorylase: Synthesis, Enzyme Inhibition, in vitro Toxicity, and Impact on Human Glioblastoma Cancer.
Glioblastoma
Evaluation of Thymidine Phosphorylase Inhibitors in Glioblastoma and Their Capacity for Temozolomide Potentiation.
Glioblastoma
Glycation of glutamate cysteine ligase by 2-deoxy-d-ribose and its potential impact on chemoresistance in glioblastoma.
Glioblastoma
Interferons upregulate thymidine phosphorylase expression via JAK-STAT-dependent transcriptional activation and mRNA stabilization in human glioblastoma cells.
Glioblastoma
Stromal angiogenesis in human glioma: a role of platelet-derived endothelial cell growth factor.
Glioblastoma
[Localization of platelet-derived endothelial cell growth factor in human glioblastoma and meningioma]
Glioma
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation.
Glioma
Interferons upregulate thymidine phosphorylase expression via JAK-STAT-dependent transcriptional activation and mRNA stabilization in human glioblastoma cells.
Glioma
Intracavitary chemotherapy with 5-fluoro-2'-deoxyuridine (FdUrd) in malignant brain tumors.
Glioma
Macrophage infiltration-associated thymidine phosphorylase expression correlates with increased microvessel density and poor prognosis in astrocytic tumors.
Glioma
Stromal angiogenesis in human glioma: a role of platelet-derived endothelial cell growth factor.
Glomerulonephritis
Upregulation of thymidine phosphorylase in chronic glomerulonephritis and its role in tubulointerstitial injury.
Head and Neck Neoplasms
Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy.
Head and Neck Neoplasms
Influence of platelet-derived endothelial cell growth factor/thymidine phosphorylase on the cell cycle in head and neck squamous cell carcinoma in vitro.
Head and Neck Neoplasms
Microvessel density, thymidine phosphorylase expression and resistance of head and neck cancer to chemo-radiotherapy.
Head and Neck Neoplasms
Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation.
Head and Neck Neoplasms
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Hearing Loss
Digestive smooth muscle mitochondrial myopathy in patients with mitochondrial-neuro-gastro-intestinal encephalomyopathy (MNGIE).
Heart Defects, Congenital
Angiogenic biomarkers in children with congenital heart disease: possible implications.
Heart Diseases
Exploring the protective effects of schizandrol A in acute myocardial ischemia mice by comprehensive metabolomics profiling integrated with molecular mechanism studies.
Hemangioma, Capillary
[The role of PD-ECGF and VEGF in proliferative and involuted mechanism of the infantile capillary hemangiomas].
Hepatitis
Platelet-derived endothelial cell growth factor (PD-ECGF) is up-regulated in human hepatocellular carcinoma (HCC) and the corresponding hepatitis liver.
Hepatitis
Thymidine phosphorylase expression in patients with chronic viral hepatitis.
Hepatitis C
Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma.
Hepatitis, Chronic
Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients.
Herpes Simplex
5-(Trifluoromethyl)-beta-l-2'-deoxyuridine, the L-enantiomer of trifluorothymidine: stereospecific synthesis and antiherpetic evaluations.
Herpes Simplex
The in vitro evaluation of nucleoside analogues as probes for use in the noninvasive diagnosis of herpes simplex encephalitis.
Histiocytoma, Malignant Fibrous
Cyclooxygenase-2 in human malignant fibrous histiocytoma: correlations with intratumoral microvessel density, expression of vascular endothelial growth factor and thymidine phosphorylase.
Hodgkin Disease
Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL).
Hodgkin Disease
Platelet-derived endothelial cell growth factor/thymidine phosphorylase immunohistochemical expression in lymphoid tissue and lymphoid malignancies.
Hodgkin Disease
Thymidine kinase and thymidine phosphorylase activities in various types of leukaemia and lymphoma.
Hyperlipidemias
Nutrition Therapy for Mitochondrial Neurogastrointestinal Encephalopathy with Homozygous Mutation of the TYMP Gene.
Hypersensitivity
Expression of platelet-derived endothelial cell growth factor and vascularity in the nasal mucosa from allergic rhinitis.
Hypersensitivity
The role of thymidine phosphorylase in the pathogenesis of allergic rhinitis.
Infections
Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma.
Infections
[Thymine- and thymidine-dependence of Yersinia pestis mutants with altered thymidylate synthetase]
Inflammatory Bowel Diseases
Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease.
Influenza, Human
The next ten stories on antiviral drug discovery (part E): Advents, Advances, and Adventures.
Intestinal Pseudo-Obstruction
Gastrointestinal dysmotility in mitochondrial neurogastrointestinal encephalomyopathy is caused by mitochondrial DNA depletion.
Kidney Neoplasms
Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story.
Kidney Neoplasms
[The correlation between thymidine phosphorylase activity of renal cancer cells and the chemosensitivity to 5-FU and 5'-DFUR]
Leiomyoma
Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma.
Leiomyoma
Expression of thymidine phosphorylase in uterine sarcoma and uterine leiomyoma: association with microvessel density and Doppler blood flow analysis.
Leiomyoma
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Leiomyoma
The activity of thymidine phosphorylase obtained from human uterine leiomyomas and studied in the presence of pyrimidine derivatives.
Leiomyoma
[Growth mechanisms and morphological structural features of large uterine leiomyoma].
Leiomyosarcoma
Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma.
Leukemia
In vitro and in vivo studies of a promising antileukemic thymidine analogue, 5-hydroxymethyl-2' deoxyuridine.
Leukemia
Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors.
Leukemia
[Activities of enzymes converting 5-fluorouracil to 5-fluorouridine-5' monophosphate and 5-fluorodeoxyuridine-5' monophosphate in subcultured cell lines and solid tumor tissues]
Leukoencephalopathies
Digestive smooth muscle mitochondrial myopathy in patients with mitochondrial-neuro-gastro-intestinal encephalomyopathy (MNGIE).
Leukoencephalopathies
Leukoencephalopathy in Mitochondrial Neurogastrointestinal Encephalomyopathy-Like Syndrome with Polymerase-Gamma Mutations.
Leukoencephalopathies
Mitochondrial neurogastrointestinal encephalomyopathy associated with progressive hearing loss.
Leukoencephalopathies
Pitfalls in diagnosing mitochondrial neurogastrointestinal encephalomyopathy.
Leukoplakia, Oral
Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma.
Lichen Sclerosus et Atrophicus
Role of angiogenesis in benign, premalignant and malignant vulvar lesions.
Liver Cirrhosis
The significance of thymidine phosphorylase activity in hepatocellular carcinoma and chronic diseased livers: a special reference to liver fibrosis and multicentric tumor occurrence.
Liver Diseases
Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients.
Liver Diseases
Significance of thymidine phosphorylase in HCC with chronic liver disease for long-term postoperative recurrence.
Liver Neoplasms
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
Liver Neoplasms
Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer.
Liver Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in hepatocellular carcinoma and metastatic liver cancer.
Liver Neoplasms
Thymidine phosphorylase promotes angiogenesis and tumour growth in intrahepatic cholangiocarcinoma.
Liver Neoplasms
[Enzymatic conversion of tegafur in human tumor tissue]
Liver Neoplasms
[The expression of platelet-derived endothelial cell growth factor in liver cancer]
Lung Neoplasms
bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer.
Lung Neoplasms
Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways.
Lung Neoplasms
Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival.
Lung Neoplasms
Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549.
Lung Neoplasms
Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neo-angiogenesis in non-small cell lung cancer.
Lung Neoplasms
Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer.
Lung Neoplasms
Inhibition of thymidine phosphorylase expression by Hsp90 inhibitor potentiates the cytotoxic effect of salinomycin in human non-small-cell lung cancer cells.
Lung Neoplasms
Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
Lung Neoplasms
Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer.
Lung Neoplasms
Metformin Induces Cytotoxicity by Down-Regulating Thymidine Phosphorylase and Excision Repair Cross-Complementation 1 Expression in Non-Small Cell Lung Cancer Cells.
Lung Neoplasms
Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer.
Lung Neoplasms
Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer.
Lung Neoplasms
Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer.
Lung Neoplasms
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Lung Neoplasms
Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients.
Lung Neoplasms
Regulation and novel action of thymidine phosphorylase in non-small cell lung cancer: crosstalk with Nrf2 and HO-1.
Lung Neoplasms
Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
Lung Neoplasms
The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Lung Neoplasms
Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer.
Lung Neoplasms
Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
Lung Neoplasms
Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.
Lung Neoplasms
Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues.
Lung Neoplasms
Thymidylate Synthase, Dihydropyrimidine Dehydrogenase, Thymidine Phosphorylase, Orotate Phosphoribosyltransferase mRNA Expression in Lung Cancer Metastatic Lymph Node Samples Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration - A Pilot Study.
Lung Neoplasms
Up-regulation of ERK1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small cell lung cancer cells.
Lung Neoplasms
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.
Lung Neoplasms
[Immunohistochemical localization of thymidine phosphorylase in primary lung cancer]
Lymphadenopathy
Thymidine kinase and thymidine phosphorylase activities in various types of leukaemia and lymphoma.
Lymphatic Metastasis
Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Lymphatic Metastasis
Clinical relevance of the concentrations of both pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer.
Lymphatic Metastasis
Clinical significance of pyrimidine nucleoside phosphorylase in colorectal carcinoma.
Lymphatic Metastasis
Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas.
Lymphatic Metastasis
Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma.
Lymphatic Metastasis
Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma.
Lymphatic Metastasis
Clinicopathological and prognostic significance of thymidine phosphorylase expression in gastric carcinoma.
Lymphatic Metastasis
Correlation between expression levels of thymidine phosphorylase (dThdPase) and clinical features in human gastric carcinoma.
Lymphatic Metastasis
Expression of angiogenic factors and tumor progression in human neuroblastoma.
Lymphatic Metastasis
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human gallbladder lesions.
Lymphatic Metastasis
Expression of pyrimidine nucleoside phosphorylase mRNA plays an important role in the prognosis of patients with oesophageal cancer.
Lymphatic Metastasis
Expression of thymidine phosphorylase in human gastric carcinoma.
Lymphatic Metastasis
High level concentration of pyrimidine nucleoside phosphorylase in esophageal squamous cell carcinoma but no correlation with clinicopathological parameters.
Lymphatic Metastasis
PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis.
Lymphatic Metastasis
Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer.
Lymphatic Metastasis
Platelet-derived endothelial cell growth factor mediates Rho-associated coiled-coil domain kinase messenger RNA expression and promotes cell motility.
Lymphatic Metastasis
Platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer.
Lymphatic Metastasis
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Lymphatic Metastasis
Reliability of platelet-derived endothelial cell growth factor as a prognostic factor for oral and oropharyngeal carcinomas.
Lymphatic Metastasis
The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus.
Lymphatic Metastasis
The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers.
Lymphatic Metastasis
Tissue concentration of platelet-derived endothelial cell growth factor in colorectal cancer.
Lymphatic Metastasis
Up-regulated pyrimidine nucleoside phosphorylase in breast carcinoma correlates with lymph node metastasis.
Lymphatic Metastasis
[Malignancy of gastric cancer analyzed by the expression of thymidine phosphorylase]
Lymphatic Metastasis
[PyNPase activity in primary and metastatic colorectal cancer]
Lymphoma
Platelet-derived endothelial cell growth factor/thymidine phosphorylase immunohistochemical expression in lymphoid tissue and lymphoid malignancies.
Lymphoma
Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors.
Lymphoma
Thymidine kinase and thymidine phosphorylase activities in various types of leukaemia and lymphoma.
Lymphoma, B-Cell
Thymidine phosphorylase expression in B-cell lymphomas and its significance: a new prognostic marker?
Lymphoma, Non-Hodgkin
Pyrimidine and purine activities in non-Hodgkin's lymphoma. Correlation with histological status and survival.
Lymphoma, Non-Hodgkin
Thymidine kinase and thymidine phosphorylase activities in various types of leukaemia and lymphoma.
Lymphoma, T-Cell
Inhibition of thymidine phosphorylase (PD-ECGF) from SD-lymphoma by phosphonomethoxyalkyl thymines.
Lymphoma, T-Cell
Structural diversity of nucleoside phosphonic acids as a key factor in the discovery of potent inhibitors of rat T-cell lymphoma thymidine phosphorylase.
Melanoma
Co-expression of thymidine phosphorylase and heme oxygenase-1 in macrophages in human malignant vertical growth melanomas.
Melanoma
Differential metabolism of thymidine in human lymphoid and melanoma cells in vitro.
Melanoma
Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors.
Melanoma
Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma.
Melanoma
Expression of thymidine phosphorylase in choroidal malignant melanoma associated with neovascular glaucoma.
Melanoma
Immunohistochemical expression of platelet growth factor and vascular endothelial growth factor in patients with melanoma with and without redness (Brenner sign).
Melanoma
Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
Meningeal Carcinomatosis
Intracavitary chemotherapy with 5-fluoro-2'-deoxyuridine (FdUrd) in malignant brain tumors.
Meningeal Carcinomatosis
Intrathecal 5-fluoro-2'-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: an in vivo study.
Meningioma
Stromal angiogenesis in human glioma: a role of platelet-derived endothelial cell growth factor.
Meningioma
[Localization of platelet-derived endothelial cell growth factor in human glioblastoma and meningioma]
Mitochondrial Diseases
Frequency of mitochondrial defects in patients with chronic intestinal pseudo-obstruction.
Mitochondrial Diseases
Gastrointestinal dysmotility in mitochondrial neurogastrointestinal encephalomyopathy is caused by mitochondrial DNA depletion.
Mitochondrial Diseases
Thymidine phosphorylase deficiency causes MNGIE: an autosomal recessive mitochondrial disorder.
Mitochondrial Diseases
Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder.
Mitochondrial Myopathies
POG01 Anti-thymidine phosphorylase antibodies in the diagnosis of mitochondrial neurogastrointestinal encephalomyopathy.
Mouth Neoplasms
Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma.
Muscle Weakness
Mitochondrial neurogastrointestinal encephalomyopathy associated with progressive hearing loss.
Muscular Diseases
Primary muscle diseases in Thammasat University Hospital: muscle biopsy study of 12 cases.
Myasthenia Gravis
Transient clinical improvement of a mitochondrial neurogastrointestinal encephalomyopathy-like syndrome after allogeneic haematopoietic stem cell transplantation.
Mycosis Fungoides
Expression of thymidine phosphorylase in lymph nodes involved with mycosis fungoides and sézary syndrome.
Myocardial Infarction
Myocardial expression of PDECGF is associated with extracellular matrix remodeling in experimental myocardial infarction in rats.
Myocardial Ischemia
Gene therapy for chronic myocardial ischemia using platelet-derived endothelial cell growth factor in dogs.
Myoma
The activity of thymidine phosphorylase in the uterine myomas and the myometrium in perimenopausal women.
Myxoma
Significance of monocyte chemotactic protein-1 and thymidine phosphorylase in angiogenesis of human cardiac myxoma.
Nasopharyngeal Carcinoma
Epstein-Barr virus latent membrane protein 1 induces the chemotherapeutic target, thymidine phosphorylase, via NF-kappaB and p38 MAPK pathways.
Nasopharyngeal Carcinoma
Heterogeneous ribonucleoprotein k and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Thymidine phosphorylase mRNA stability and protein levels are increased through ERK-mediated cytoplasmic accumulation of hnRNP K in nasopharyngeal carcinoma cells.
Neoplasm Metastasis
5-Fluorouracil-related gene expression in primary sites and hepatic metastases of colorectal carcinomas.
Neoplasm Metastasis
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Neoplasm Metastasis
Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs.
Neoplasm Metastasis
Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.
Neoplasm Metastasis
Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma.
Neoplasm Metastasis
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in cervical cancer.
Neoplasm Metastasis
Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer.
Neoplasm Metastasis
Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Neoplasm Metastasis
Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases.
Neoplasm Metastasis
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
Neoplasm Metastasis
Clinical relevance of the concentrations of both pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer.
Neoplasm Metastasis
Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma.
Neoplasm Metastasis
Clinical significance of pyrimidine nucleoside phosphorylase in colorectal carcinoma.
Neoplasm Metastasis
Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas.
Neoplasm Metastasis
Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma.
Neoplasm Metastasis
Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma.
Neoplasm Metastasis
Clinicopathological and prognostic significance of thymidine phosphorylase expression in gastric carcinoma.
Neoplasm Metastasis
Correlation between expression levels of thymidine phosphorylase (dThdPase) and clinical features in human gastric carcinoma.
Neoplasm Metastasis
Correlation between tumor angiogenesis and expression of thymidine phosphorylase, and patient outcome in uterine cervical carcinoma.
Neoplasm Metastasis
Correlation of thymidine phosphorylase staining and the Ki-67 labeling index to clinicopathologic factors and hepatic metastasis in patients with colorectal cancer.
Neoplasm Metastasis
Effects of Platelet-Derived Endothelial Cell Growth Factor and Doppler Perfusion Index in Patients with Colorectal Hepatic Metastases.
Neoplasm Metastasis
Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer.
Neoplasm Metastasis
Expression of angiogenic factors and tumor progression in human neuroblastoma.
Neoplasm Metastasis
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers.
Neoplasm Metastasis
Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.
Neoplasm Metastasis
Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma.
Neoplasm Metastasis
Expression of platelet-derived endothelial cell growth factor in bladder carcinoma.
Neoplasm Metastasis
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human gallbladder lesions.
Neoplasm Metastasis
Expression of pyrimidine nucleoside phosphorylase mRNA plays an important role in the prognosis of patients with oesophageal cancer.
Neoplasm Metastasis
Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics.
Neoplasm Metastasis
Expression of thymidine phosphorylase in human gastric carcinoma.
Neoplasm Metastasis
Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas.
Neoplasm Metastasis
Fatty liver suppressed the angiogenesis in liver metastatic lesions.
Neoplasm Metastasis
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives.
Neoplasm Metastasis
Heterogeneity and clinical role of thymidine phosphorylase activity in gastric cancer.
Neoplasm Metastasis
High level concentration of pyrimidine nucleoside phosphorylase in esophageal squamous cell carcinoma but no correlation with clinicopathological parameters.
Neoplasm Metastasis
Highly aggressive behavior and poor prognosis of small cell carcinoma in the stomach: flow cytometric and immunohistochemical analysis.
Neoplasm Metastasis
Histochemical study of angiogenesis in basaloid squamous carcinoma of the esophagus.
Neoplasm Metastasis
Immunohistochemical demonstration of angiogenic growth factors and EGF receptor in hepatic metastases and primary human gastric cancer.
Neoplasm Metastasis
Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose.
Neoplasm Metastasis
Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.
Neoplasm Metastasis
Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration.
Neoplasm Metastasis
Occurrence of hematogenous metastasis and serum levels of thymidine phosphorylase in colorectal cancer.
Neoplasm Metastasis
Papers to appear in forthcoming issues
Neoplasm Metastasis
PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis.
Neoplasm Metastasis
Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells.
Neoplasm Metastasis
Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer.
Neoplasm Metastasis
Platelet-derived endothelial cell growth factor mediates Rho-associated coiled-coil domain kinase messenger RNA expression and promotes cell motility.
Neoplasm Metastasis
Platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer.
Neoplasm Metastasis
Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy.
Neoplasm Metastasis
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Neoplasm Metastasis
Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy.
Neoplasm Metastasis
Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma.
Neoplasm Metastasis
Prognostic significance of the serum thymidine phosphorylase levels in venous blood drainage specimens in patients with colorectal cancer.
Neoplasm Metastasis
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Neoplasm Metastasis
Relative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue.
Neoplasm Metastasis
Reliability of platelet-derived endothelial cell growth factor as a prognostic factor for oral and oropharyngeal carcinomas.
Neoplasm Metastasis
Research development of the relationship between thymidine phosphorylase expression and colorectal carcinoma.
Neoplasm Metastasis
Role of angiogenesis in the development and growth of liver metastasis.
Neoplasm Metastasis
Role of lymphangiogenesis in epithelial ovarian cancer.
Neoplasm Metastasis
Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma.
Neoplasm Metastasis
Specific enhanced expression of platelet-derived endothelial cell growth factor in submucosa of human colorectal cancer.
Neoplasm Metastasis
Suppression of metastasis by thymidine phosphorylase inhibitor.
Neoplasm Metastasis
Synthesis and evaluation of multisubstrate bicyclic pyrimidine nucleoside inhibitors of human thymidine phosphorylase.
Neoplasm Metastasis
Synthesis of 6-aminouracils and pyrrolo[2,3-d]pyrimidine-2,4-diones and their inhibitory effect on thymidine phosphorylase.
Neoplasm Metastasis
Synthesis of pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors of thymidine phosphorylase.
Neoplasm Metastasis
TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma.
Neoplasm Metastasis
The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion.
Neoplasm Metastasis
The influence of pyrimidine nucleoside phosphorylase activity on metastasis of breast cancer.
Neoplasm Metastasis
The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus.
Neoplasm Metastasis
The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.
Neoplasm Metastasis
The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers.
Neoplasm Metastasis
Thymidine phosphorylase activates NF?B and stimulates the expression of angiogenic and metastatic factors in human cancer cells.
Neoplasm Metastasis
Thymidine phosphorylase expression in gastric carcinoma as a marker for metastasis.
Neoplasm Metastasis
Thymidine phosphorylase inhibitors: recent developments and potential therapeutic applications.
Neoplasm Metastasis
Thymidine phosphorylase promotes metastasis and serves as a marker of poor prognosis in hepatocellular carcinoma.
Neoplasm Metastasis
Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma.
Neoplasm Metastasis
Thymidine phosphorylase/platelet-derived endothelial cell growth factor is upregulated in advanced solid types of gastric cancer.
Neoplasm Metastasis
Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis.
Neoplasm Metastasis
Tissue concentration of platelet-derived endothelial cell growth factor in colorectal cancer.
Neoplasm Metastasis
Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum.
Neoplasm Metastasis
Tumor angiogenesis as an independent prognostic factor after extended radical esophagectomy for invasive squamous cell carcinoma of the esophagus.
Neoplasm Metastasis
Tumor growth pattern and thymidine phosphorylase expression are related with the risk of hematogenous metastasis in patients with Astler Coller B1/B2 colorectal carcinoma.
Neoplasm Metastasis
Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination.
Neoplasm Metastasis
Up-regulated pyrimidine nucleoside phosphorylase in breast carcinoma correlates with lymph node metastasis.
Neoplasm Metastasis
Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
Neoplasm Metastasis
Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors.
Neoplasm Metastasis
[Clinicopathological significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced colorectal cancer]
Neoplasm Metastasis
[Correlation between pyrimidine nucleoside phosphorylase (PyNPase) and clinicopathological factors in patients with gastric cancer]
Neoplasm Metastasis
[Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]
Neoplasm Metastasis
[Immunohistochemical staining of thymidine phosphorylase in primary colorectal carcinoma and metastases]
Neoplasm Metastasis
[Long-term outcome of preoperative chemotherapy with 5'-deoxy-5-fluorouridine (5'-DFUR) for gastric cancer]
Neoplasm Metastasis
[Malignancy of gastric cancer analyzed by the expression of thymidine phosphorylase]
Neoplasm Metastasis
[PyNPase activity in primary and metastatic colorectal cancer]
Neoplasm Metastasis
[Successful treatment of hepatic metastasis of gastric cancer with 5'-DFUR and Lentinan]
Neoplasm Metastasis
[The expression of platelet-derived endothelial cell growth factor in liver cancer]
Neoplasm Metastasis
[Thymidine phosphorylase expression in hepatic metastasis from colorectal carcinoma]
Neoplasm, Residual
Prognostic significance of ultrasound derived intratumoral peak systolic velocity in epithelial ovarian cancer.
Neoplasm, Residual
Thymidine phosphorylase in human esophageal squamous cell carcinoma.
Neoplasms
"Stromatogenesis" and tumor progression.
Neoplasms
2-Arylquinazolin-4(3H)-ones: A novel class of thymidine phosphorylase inhibitors.
Neoplasms
2-Deoxy-D-ribose, a downstream mediator of thymidine phosphorylase, regulates tumor angiogenesis and progression.
Neoplasms
4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression.
Neoplasms
5-Nitrouracil stabilizes the plasma concentration values of 5-FU in colorectal cancer patients receiving capecitabine.
Neoplasms
A case of metastatic breast cancer achieving complete response by combination therapy with 5'-deoxy-5-fluorouridine and cyclophosphamide.
Neoplasms
A case report of papilla Vater carcinoma showing positive expression of thymidine phosphorylase.
Neoplasms
A comparative study of the antitumor activities of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine (Ro09-1390) on human digestive organ cancer xenograft lines transplanted into nude mice.
Neoplasms
A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa.
Neoplasms
A kinetic, modeling and mechanistic re-analysis of thymidine phosphorylase and some related enzymes.
Neoplasms
A novel glial growth inhibitory factor, gliostatin, derived from neurofibroma.
Neoplasms
A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
Neoplasms
A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action.
Neoplasms
A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU.
Neoplasms
A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients.
Neoplasms
A prospective randomized trial comparing capecitabine-based chemoradiotherapy with 5-FU-based chemoradiotherapy in neoadjuvant setting in locally advanced carcinoma rectum.
Neoplasms
A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.
Neoplasms
A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer.
Neoplasms
A role of thymidine phosphorylase and P53 tissue protein expression in biology of endometrial cancer.
Neoplasms
A similarity model for the human angiogenic factor, thymidine phosphorylase/platelet derived-endothelial cell growth factor.
Neoplasms
Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells.
Neoplasms
Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors.
Neoplasms
Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines.
Neoplasms
Activity of thymidilate "salvage pathway" enzymes in human gastric cancer and blood serum: correlation with treatment modalities.
Neoplasms
Advanced gastric cancer with peritoneal dissemination successfully treated with paclitaxel and doxifluridine: a case report.
Neoplasms
Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs.
Neoplasms
An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed.
Neoplasms
Angiogenesis and endometrial cancer.
Neoplasms
Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast.
Neoplasms
Angiogenesis and lymphangiogenesis of gastric cancer.
Neoplasms
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in cervical cancer.
Neoplasms
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in endometrial cancer.
Neoplasms
Angiogenesis in gastric cancer: importance of the thymidine phosphorylase expression of cancer cells as an angiogenic factor.
Neoplasms
Angiogenesis in metastatic verrucous carcinoma of the uterine cervix.
Neoplasms
Angiogenesis in ovarian clear cell carcinoma and its relation to endometriosis.
Neoplasms
Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy.
Neoplasms
Angiogenesis-related factors are molecular targets for diagnosis and treatment of patients with esophageal carcinoma.
Neoplasms
Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas.
Neoplasms
Angiogenic effect of naive and 5-fluorouracil resistant colon carcinoma on endothelial cells in vitro.
Neoplasms
Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer.
Neoplasms
Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma.
Neoplasms
Angiogenic factors stimulate mast-cell migration.
Neoplasms
Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling.
Neoplasms
Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells.
Neoplasms
Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Neoplasms
Anti-tumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse and rat bladder carcinogenesis.
Neoplasms
Antiangiogenic and antitumor activity of 6-(2-aminoethyl)amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap.
Neoplasms
Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice.
Neoplasms
Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways.
Neoplasms
Antimalarial drug pyrimethamine plays a dual role in anti-tumor proliferation and metastasis through targeting DHFR and TP.
Neoplasms
Antitumor activity of 5'-deoxy-5-fluorouridine in human digestive organ cancer xenografts and pyrimidine nucleoside phosphorylase activity in normal and neoplastic tissues from human digestive organs.
Neoplasms
Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
Neoplasms
Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Neoplasms
Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Neoplasms
Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Neoplasms
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Neoplasms
Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.
Neoplasms
Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor.
Neoplasms
Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
Neoplasms
Association of thymidine phosphorylase concentration with ultrasound-derived indices of blood flow in ovarian masses.
Neoplasms
Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma.
Neoplasms
Augmentation of antitumor activity of 5'-deoxy-5-fluorouridine by thymosin fraction 5 in mouse bladder cancer cells in vitro and in vivo.
Neoplasms
Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway.
Neoplasms
Biological role of thymidine phosphorylase in human astrocytic tumors.
Neoplasms
Blockade of paclitaxel-induced thymidine phosphorylase expression can accelerate apoptosis in human prostate cancer cells.
Neoplasms
Cancer-Stromal Cell Interaction and Tumor Angiogenesis in Gastric Cancer.
Neoplasms
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Neoplasms
Capecitabine (Xeloda): from the laboratory to the patient's home.
Neoplasms
Capecitabine and radiation therapy for advanced gastrointestinal malignancies.
Neoplasms
Capecitabine bioequivalence in healthy volunteers.
Neoplasms
Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment.
Neoplasms
Capecitabine in carcinoma of the pancreas.
Neoplasms
Capecitabine induced cardiotoxicity: a case report and review of literature.
Neoplasms
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
Neoplasms
Capecitabine: a novel agent for the treatment of solid tumors.
Neoplasms
Capecitabine: preclinical pharmacology studies.
Neoplasms
Changes in thymidine phosphorylase gene expression related to treatment of rectal cancer.
Neoplasms
Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts.
Neoplasms
Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients.
Neoplasms
Clinical impact of thymidine phosphorylase expression in gastric cancer.
Neoplasms
Clinical implication of expression of platelet-derived endothelial cell growth factor (PD-ECGF) in metastatic lesions of uterine cervical cancers.
Neoplasms
Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers.
Neoplasms
Clinical implications of expression of interleukin-8 related to myometrial invasion with angiogenesis in uterine endometrial cancers.
Neoplasms
Clinical relevance of the concentrations of both pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer.
Neoplasms
Clinical significance of pyrimidine nucleoside phosphorylase in colorectal carcinoma.
Neoplasms
Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas.
Neoplasms
Clinical significance of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in transitional cell cancer.
Neoplasms
Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma.
Neoplasms
Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma.
Neoplasms
Co-expression of thymidine phosphorylase and heme oxygenase-1 in macrophages in human malignant vertical growth melanomas.
Neoplasms
Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways.
Neoplasms
Combination effect of an angiogenesis inhibitor agm-1470 with 5'-deoxy-5-fluorouridine, and with hormonal drugs in dmba-induced rat mammary-tumors.
Neoplasms
Combination of oral fluoropyrimidine and docetaxel: reappraisal of synergistic effect against gastric carcinoma xenografts.
Neoplasms
Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Neoplasms
Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma.
Neoplasms
Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
Neoplasms
Comparative analysis of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in colorectal cancer and surrounding normal tissue.
Neoplasms
Comparative antitumor activity and intestinal toxicity of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine.
Neoplasms
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Neoplasms
Comparison of the pyrimidine nucleoside phosphorylase activity in human tumors and normal tissues.
Neoplasms
Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer.
Neoplasms
Concurrent expression of angiogenic growth factors and neovascularization during tumourigenesis in colorectal carcinoma patients.
Neoplasms
Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma.
Neoplasms
Correlation between elevated intratumoral thymidine phosphorylase and prognosis of node-positive breast carcinoma undergoing adjuvant doxifluridine treatment.
Neoplasms
Correlation between expression levels of thymidine phosphorylase (dThdPase) and clinical features in human gastric carcinoma.
Neoplasms
Correlation between expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) and microvessel density in early-stage human colon carcinomas.
Neoplasms
Correlation between malignancy grade and p53 gene in relation to thymidine phosphorylase activity in colorectal cancer patients.
Neoplasms
Correlation between spontaneous apoptosis and the expression of angiogenic factors in advanced gastric adenocarcinoma.
Neoplasms
Correlation between thymidine phosphorylase expression and invasion phenotype in cervical carcinoma cells.
Neoplasms
Correlation between tumor angiogenesis and expression of thymidine phosphorylase, and patient outcome in uterine cervical carcinoma.
Neoplasms
Correlation of thymidine phosphorylase staining and the Ki-67 labeling index to clinicopathologic factors and hepatic metastasis in patients with colorectal cancer.
Neoplasms
Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Neoplasms
Crystal structure of human thymidine phosphorylase in complex with a small molecule inhibitor.
Neoplasms
Cyclooxygenase-2 in human malignant fibrous histiocytoma: correlations with intratumoral microvessel density, expression of vascular endothelial growth factor and thymidine phosphorylase.
Neoplasms
Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine.
Neoplasms
Cytotoxic response of 5-fluorouracil-resistant cells to gene- and cell-directed enzyme/prodrug treatment.
Neoplasms
Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas.
Neoplasms
Demethoxycurcumin sensitizes the response of non-small cell lung cancer to cisplatin through downregulation of TP and ERCC1-related pathways.
Neoplasms
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
Neoplasms
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Neoplasms
Design of Novel Inhibitors of Human Thymidine Phosphorylase: Synthesis, Enzyme Inhibition, in vitro Toxicity, and Impact on Human Glioblastoma Cancer.
Neoplasms
Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines.
Neoplasms
Development and characterization of 1C6-203, a new monoclonal antibody specific to human thymidine phosphorylase.
Neoplasms
Development of inhibitors of pyrimidine metabolism.
Neoplasms
Differences and relationships of thymidine phosphorylase expression in tumor-associated macrophages and cancer cells in squamous cell carcinoma of the esophagus.
Neoplasms
Different angiogenic pathways characterize superficial and invasive bladder cancer.
Neoplasms
Different angiogenic pathways in human cervical cancers.
Neoplasms
Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival.
Neoplasms
Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase.
Neoplasms
Distinct substrate specificity and physicochemical characterization of native human hepatic thymidine phosphorylase.
Neoplasms
Distribution of thymidine phosphorylase activity in gastric carcinoma and adjacent normal gastric tissue.
Neoplasms
DNA synthesis inhibitors for the treatment of gastrointestinal cancer.
Neoplasms
Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo.
Neoplasms
DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
Neoplasms
Effect of a combined administration of 5-fluorouracil and medroxyprogesterone acetate on pyrimidine nucleoside phosphorylases and thymidylate synthetase in 7,12-dimethylbenz.
Neoplasms
Effect of administration of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on the anti-tumor efficacy of 5-fluoro-2'-deoxyuridine against murine colon tumor C26-10.
Neoplasms
Effect of intratumoral OK-432 administration of thymidine phosphorylase expression in human gastric carcinoma.
Neoplasms
Effects of 5'-DFUR and lentinan on cytokines and PyNPase against AH66 ascites hepatoma in rats.
Neoplasms
Effects of 5'-DFUR and OK-432 on cytokines and thymidine phosphorylase in tumor tissue of gastric cancer patients.
Neoplasms
Effects of introduction of dThdPase cDNA on sensitivity to 5'-deoxy-5-fluorouridine and tumor angiogenesis.
Neoplasms
Effects of platelet-derived endothelial cell growth factor/thymidine phosphorylase, substrate, and products in a three-dimensional model of angiogenesis.
Neoplasms
Effects of sex steroids and growth factors on invasive activity and 5'-deoxy-5-fluorouridine sensitivity in ovarian adenocarcinoma OMC-3 cells.
Neoplasms
Effects of thymidine phosphorylase levels in cancer, background mucosa, and regional lymph nodes on survival of advanced gastric cancer patients receiving postoperative fluoropyrimidine therapy.
Neoplasms
Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma.
Neoplasms
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Neoplasms
Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer.
Neoplasms
Endogenous gamma-interferon activates thymidine phosphorylase in colorectal cancer tissue.
Neoplasms
Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma.
Neoplasms
Enhanced Anticancer Activity of 5'-DFUR-PCL-MPEG Polymeric Prodrug Micelles Encapsulating Chemotherapeutic Drugs.
Neoplasms
Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients.
Neoplasms
Enhancement of 5-fluoro-2'-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside.
Neoplasms
Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study.
Neoplasms
Enhancement of antitumor activity of 5'-deoxy-5-fluorouridine (Furtulon) by taxane in human gastric cancer xenografts.
Neoplasms
Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.
Neoplasms
Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA.
Neoplasms
Enhancement of Mitomycin C-Induced Cytotoxicity by Curcumin Results from Down-Regulation of MKK1/2-ERK1/2-Mediated Thymidine Phosphorylase Expression.
Neoplasms
Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues.
Neoplasms
Ets-1 expression in vascular endothelial cells as an angiogenic and prognostic factor in colorectal carcinoma.
Neoplasms
Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.
Neoplasms
Evaluation of tumor angiogenesis and thymidine phosphorylase tissue expression in patients with endometrial cancer.
Neoplasms
Evaluation of [(18)F]Fluorothymidine as a Biomarker for Early Therapy Response in a Mouse Model of Colorectal Cancer.
Neoplasms
Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer.
Neoplasms
Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy.
Neoplasms
Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors.
Neoplasms
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Neoplasms
Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma.
Neoplasms
Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma.
Neoplasms
Expression of angiogenic growth factors in paragangliomas.
Neoplasms
Expression of basic fibroblast growth factor is associated with a good outcome in patients with squamous cell carcinoma of the esophagus.
Neoplasms
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers.
Neoplasms
Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.
Neoplasms
Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma.
Neoplasms
Expression of platelet-derived endothelial cell growth factor in bladder carcinoma.
Neoplasms
Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease.
Neoplasms
Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: relationship to various biological factors.
Neoplasms
Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma.
Neoplasms
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in cervical intraepithelial neoplasia.
Neoplasms
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human bladder cancer.
Neoplasms
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human gallbladder lesions.
Neoplasms
Expression of pyrimidine nucleoside phosphorylase (PyNPase) in colorectal cancer.
Neoplasms
Expression of pyrimidine nucleoside phosphorylase mRNA plays an important role in the prognosis of patients with oesophageal cancer.
Neoplasms
Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations.
Neoplasms
Expression of the angiogenic factor thymidine phosphorylase in human astrocytic tumors.
Neoplasms
Expression of the angiogenic factor thymidine phosphorylase in THP-1 monocytes: induction by autocrine tumor necrosis factor-alpha and inhibition by aspirin.
Neoplasms
Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
Neoplasms
Expression of the angiogenic protein, platelet-derived endothelial cell growth factor, in coronary atherosclerotic plaques: In vivo correlation of lesional microvessel density and constrictive vascular remodeling.
Neoplasms
Expression of the thymidine phosphorylase gene in epithelial ovarian cancer.
Neoplasms
Expression of thymidine phosphorylase and angiogenesis in human ovarian tumor.
Neoplasms
Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics.
Neoplasms
Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor.
Neoplasms
Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder.
Neoplasms
Expression of thymidine phosphorylase by macrophages in colorectal cancer tissues.
Neoplasms
Expression of thymidine phosphorylase in choroidal malignant melanoma associated with neovascular glaucoma.
Neoplasms
Expression of thymidine phosphorylase in epithelial ovarian cancer: correlation with angiogenesis, apoptosis, and ultrasound-derived peak systolic velocity.
Neoplasms
Expression of thymidine phosphorylase in human cervical cancer.
Neoplasms
Expression of thymidine phosphorylase in human gastric carcinoma.
Neoplasms
Expression of thymidine phosphorylase in human superficial bladder cancer.
Neoplasms
Expression of thymidine phosphorylase in lymph nodes involved with mycosis fungoides and sézary syndrome.
Neoplasms
Expression of thymidine phosphorylase in malignant ovarian tumors: correlation with microvessel density and an ultrasound-derived index of angiogenesis.
Neoplasms
Expression of thymidine phosphorylase in uterine sarcoma and uterine leiomyoma: association with microvessel density and Doppler blood flow analysis.
Neoplasms
Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas.
Neoplasms
Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: implication for method to detect expression of these molecules in clinic.
Neoplasms
Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis.
Neoplasms
Expression of uridine and thymidine phosphorylase genes in human breast carcinoma.
Neoplasms
Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease.
Neoplasms
Expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer.
Neoplasms
Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo.
Neoplasms
Fluorescence and computational studies of thymidine phosphorylase affinity toward lipidated 5-FU derivatives.
Neoplasms
Fluorescent molecular rotors as sensors for the detection of thymidine phosphorylase.
Neoplasms
Frequent expression of thymidine phosphorylase in Epstein-Barr virus-associated gastric carcinoma of diffuse type.
Neoplasms
Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil.
Neoplasms
Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer.
Neoplasms
Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro study.
Neoplasms
H pylori status and angiogenesis factors in human gastric carcinoma.
Neoplasms
Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma.
Neoplasms
HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer.
Neoplasms
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives.
Neoplasms
Heterogeneity and clinical role of thymidine phosphorylase activity in gastric cancer.
Neoplasms
High expression of thymidine phosphorylase in basal-like breast cancers: Stromal expression in EGFR- and/or CK5/6-positive breast cancers.
Neoplasms
High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection.
Neoplasms
High level concentration of pyrimidine nucleoside phosphorylase in esophageal squamous cell carcinoma but no correlation with clinicopathological parameters.
Neoplasms
Highly aggressive behavior and poor prognosis of small cell carcinoma in the stomach: flow cytometric and immunohistochemical analysis.
Neoplasms
Histochemical study of angiogenesis in basaloid squamous carcinoma of the esophagus.
Neoplasms
Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer.
Neoplasms
Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins.
Neoplasms
Identification and comparative analysis of thymidine phosphorylase in the plasma of healthy subjects and cancer patients.
Neoplasms
Identification of 1,2,4-triazoles as new thymidine phosphorylase inhibitors: Future anti-tumor drugs.
Neoplasms
Identification of a novel class of inhibitor of human and Escherichia coli thymidine phosphorylase by in silico screening.
Neoplasms
Identification of aspartic acid-203 in human thymidine phosphorylase as an important residue for both catalysis and non-competitive inhibition by the small molecule "crystallization chaperone" 5'-O-tritylinosine (KIN59).
Neoplasms
IFN gamma-induced up-regulation of PD-ECGF/TP enhances the cytotoxicity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in bladder cancer cells.
Neoplasms
Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy.
Neoplasms
Immunohistochemical demonstration of angiogenic growth factors and EGF receptor in hepatic metastases and primary human gastric cancer.
Neoplasms
Immunohistochemical detection of platelet-derived endothelial cell growth factor/thymidine phosphorylase and angiopoietins in ameloblastic tumors.
Neoplasms
Immunohistochemical expression of thymidine phosphorylase in human endometrial cancer.
Neoplasms
Immunohistochemical localization of platelet-derived endothelial cell growth factor expression and its relation to angiogenesis in prostate.
Neoplasms
Immunohistochemical localization of thymidine phosphorylase in gastric cancer: is there a role of the differential expression in tumor cells and associated stromal cells?
Neoplasms
Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer.
Neoplasms
Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis.
Neoplasms
Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Neoplasms
Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma.
Neoplasms
Improving chemoradiotherapy in rectal cancer.
Neoplasms
In silico binding analysis and SAR elucidations of newly designed benzopyrazine analogs as potent inhibitors of thymidine phosphorylase.
Neoplasms
In vitro and in vivo evaluations of a radioiodinated thymidine phosphorylase inhibitor as a tumor diagnostic agent for angiogenic enzyme imaging.
Neoplasms
Increased expression of platelet-derived endothelial cell growth factor in human hepatocellular carcinomas correlated with high Edmondson grades and portal vein tumor thrombosis.
Neoplasms
Increased expression of thymidine phosphorylase in tumor tissue in proportion to TP-expression in primary normal tissue.
Neoplasms
Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response.
Neoplasms
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.
Neoplasms
Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.
Neoplasms
Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity.
Neoplasms
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Neoplasms
Induction of thymidine phosphorylase expression by AZT contributes to enhancement of 5'-DFUR cytotoxicity.
Neoplasms
Infiltration of thymidine phosphorylase-positive macrophages is closely associated with tumor angiogenesis and survival in intestinal type gastric cancer.
Neoplasms
Influence of platelet-derived endothelial cell growth factor/thymidine phosphorylase on the cell cycle in head and neck squamous cell carcinoma in vitro.
Neoplasms
Inhibition of 5'-deoxy-5-fluorouridine phosphorolysis by acyclothymidine in tumor cell homogenates.
Neoplasms
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda(®).
Neoplasms
Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose.
Neoplasms
Integrating oxaliplatin into the management of colorectal cancer.
Neoplasms
Interferon- ? Enhances 5'-Deoxy-5-Fluorouridine-Induced Apoptosis by ERK-Dependant Upregulation of Thymidine Phosphorylase.
Neoplasms
Interferons upregulate thymidine phosphorylase expression via JAK-STAT-dependent transcriptional activation and mRNA stabilization in human glioblastoma cells.
Neoplasms
Interrelationship of platelet-derived endothelial cell growth factor, liver macrophages, and tumor microvessel density in patients with cholangiocellular carcinoma.
Neoplasms
Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer.
Neoplasms
Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis.
Neoplasms
Lembehsterols A and B, novel sulfated sterols inhibiting thymidine phosphorylase, from the marine sponge Petrosia strongylata.
Neoplasms
Localization of thymidine phosphorylase in advanced gastric and colorectal cancer.
Neoplasms
Localization of thymidine phosphorylase in breast cancer tissue.
Neoplasms
Logistic regression model of the clinical response to 5-fluorouracil based chemotherapy for metastatic colorectal cancer patients.
Neoplasms
Long-term effect of gene therapy for chronic ischemic myocardium using platelet-derived endothelial cell growth factor in dogs.
Neoplasms
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Neoplasms
Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer.
Neoplasms
Macrophage infiltration-associated thymidine phosphorylase expression correlates with increased microvessel density and poor prognosis in astrocytic tumors.
Neoplasms
Making Capecitabine Targeted Therapy for Breast Cancer: Which is the Role of Thymidine Phosphorylase?
Neoplasms
Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration.
Neoplasms
Metformin Induces Cytotoxicity by Down-Regulating Thymidine Phosphorylase and Excision Repair Cross-Complementation 1 Expression in Non-Small Cell Lung Cancer Cells.
Neoplasms
Microdissection is essential for gene expression analysis of irradiated rectal cancer tissues.
Neoplasms
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer.
Neoplasms
Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.
Neoplasms
Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer.
Neoplasms
Molecular approach to breast cancer treatment.
Neoplasms
Molecular basis for the involvement of thymidine phosphorylase in cancer invasion.
Neoplasms
Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis.
Neoplasms
Moving forward with capecitabine: a glimpse of the future.
Neoplasms
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Neoplasms
Multicomponent Coculture System of Cancer Cells and Two Types of Stromal Cells for In Vitro Evaluation of Anticancer Drugs.
Neoplasms
Myocardial expression of PDECGF is associated with extracellular matrix remodeling in experimental myocardial infarction in rats.
Neoplasms
Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation.
Neoplasms
No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix.
Neoplasms
Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
Neoplasms
Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy.
Neoplasms
Novel (E)-5-(2-iodovinyl)-2'-deoxyuridine derivatives as potential cytostatic agents against herpes simplex virus thymidine kinase gene transfected tumors.
Neoplasms
Novel prophylactic effect of doxifluridine in superficial bladder cancer.
Neoplasms
Occurrence of hematogenous metastasis and serum levels of thymidine phosphorylase in colorectal cancer.
Neoplasms
Orotate phosphoribosyltransferase localizes to the Golgi complex and its expression levels affect the sensitivity to anti-cancer drug 5-fluorouracil.
Neoplasms
Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo.
Neoplasms
Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis.
Neoplasms
Oxidative stress and tumor progression in colorectal cancer.
Neoplasms
Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation?
Neoplasms
Papers to Appear in Forthcoming Issues
Neoplasms
Papers to appear in forthcoming issues
Neoplasms
Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy.
Neoplasms
Perillyl alcohol as a protective modulator against rat hepatocarcinogenesis via amelioration of oxidative damage and cell proliferation.
Neoplasms
Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
Neoplasms
Pharmacology and clinical status of capecitabine.
Neoplasms
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Neoplasms
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Neoplasms
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Neoplasms
Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
Neoplasms
Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma.
Neoplasms
Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis.
Neoplasms
Platelet-derived endothelial cell growth factor (PD-ECGF) is up-regulated in human hepatocellular carcinoma (HCC) and the corresponding hepatitis liver.
Neoplasms
Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer.
Neoplasms
Platelet-derived endothelial cell growth factor as a prognostic factor for radiotherapy outcome in patients with adenocarcinoma of the uterine cervix.
Neoplasms
Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix.
Neoplasms
Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer.
Neoplasms
Platelet-derived endothelial cell growth factor expression is an independent prognostic factor in colorectal cancer patients after curative surgery.
Neoplasms
Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells.
Neoplasms
Platelet-derived endothelial cell growth factor inhibits DNA synthesis in vascular smooth muscle cells.
Neoplasms
Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer.
Neoplasms
Platelet-derived endothelial cell growth factor mediates Rho-associated coiled-coil domain kinase messenger RNA expression and promotes cell motility.
Neoplasms
Platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer.
Neoplasms
Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy.
Neoplasms
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Neoplasms
Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer.
Neoplasms
Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer.
Neoplasms
Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study.
Neoplasms
Platelet-derived endothelial cell growth factor/thymidine phosphorylase immunohistochemical expression in lymphoid tissue and lymphoid malignancies.
Neoplasms
Platelet-derived endothelial cell growth factor/thymidine phosphorylase inhibitor augments radiotherapeutic efficacy in experimental colorectal cancer.
Neoplasms
Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.
Neoplasms
Possible role of thymidine phosphorylase in gynecological tumors as an individualized treatment strategy.
Neoplasms
Practical considerations in the use of oral fluoropyrimidines.
Neoplasms
Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor.
Neoplasms
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Neoplasms
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Neoplasms
Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy.
Neoplasms
Preoperative treatment with tegafur suppositories enhances apoptosis and reduces the intratumoral microvessel density of human colorectal carcinoma.
Neoplasms
Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues.
Neoplasms
Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase.
Neoplasms
Production of platelet-derived endothelial cell growth factor by normal and transformed human cells in culture.
Neoplasms
Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients.
Neoplasms
Prognostic role of angiogenesis and its correlations with thymidine phosphorylase and p53 expression in ductal adenocarcinoma of the pancreas.
Neoplasms
Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer.
Neoplasms
Prognostic significance of angiogenesis in human pancreatic cancer.
Neoplasms
Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma.
Neoplasms
Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma.
Neoplasms
Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma.
Neoplasms
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Neoplasms
Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy.
Neoplasms
Prognostic significance of ultrasound derived intratumoral peak systolic velocity in epithelial ovarian cancer.
Neoplasms
Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
Neoplasms
Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy.
Neoplasms
Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity, and oxidative stress.
Neoplasms
Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors.
Neoplasms
PyNPase expression in human colon cancer.
Neoplasms
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Neoplasms
Pyrimidine nucleoside phosphorylase activity in tumour and matched normal gastrointestinal mucosa.
Neoplasms
Pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase indicate chemosensitivity of human colon cancer specimens to doxifluridine and 5-fluorouracil, respectively.
Neoplasms
Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer.
Neoplasms
Pyrimidine nucleoside phosphorylase-activity and biological characteristics of breast-cancer.
Neoplasms
Pyrimidine nucleosides in molecular PET imaging of tumor proliferation.
Neoplasms
Pyrimidine nucleotide metabolism in human colon carcinomas: comparison of normal tissues, primary tumors and xenografts.
Neoplasms
Radiation-induced thymidine phosphorylase upregulation in rectal cancer is mediated by tumor-associated macrophages by monocyte chemoattractant protein-1 from cancer cells.
Neoplasms
Radiolabeled uracil derivative as a novel SPECT probe for thymidine phosphorylase: suppressed accumulation into tumor cells by target gene knockdown.
Neoplasms
Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil.
Neoplasms
Recent discovery of non-nucleobase thymidine phosphorylase inhibitors targeting cancer.
Neoplasms
Regulation of cancer progression by inhibition of angiogenesis and induction of apoptosis.
Neoplasms
Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells.
Neoplasms
Regulation of the expression of the angiogenic enzyme platelet-derived endothelial cell growth factor/thymidine phosphorylase in endometrial isolates by ovarian steroids and cytokines.
Neoplasms
Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer.
Neoplasms
Relationship between biodistribution of a novel thymidine phosphorylase (TP) imaging probe and TP expression levels in normal mice.
Neoplasms
Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines.
Neoplasms
Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF.
Neoplasms
Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39.
Neoplasms
Relative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue.
Neoplasms
Reliability of platelet-derived endothelial cell growth factor as a prognostic factor for oral and oropharyngeal carcinomas.
Neoplasms
Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck.
Neoplasms
Retroviral Vector-mediated Expression of Human Thyimidine Phosphorylase in Pancreatic Carcinoma Cells.
Neoplasms
Role of angiogenesis in benign, premalignant and malignant vulvar lesions.
Neoplasms
Role of angiogenesis in the development and growth of liver metastasis.
Neoplasms
Role of lymphangiogenesis in epithelial ovarian cancer.
Neoplasms
Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients.
Neoplasms
Role of thymidine phosphorylase in an in vitro model of human bladder cancer invasion.
Neoplasms
Role of thymidine phosphorylase in Fas-induced apoptosis.
Neoplasms
Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma.
Neoplasms
Role of tumor angiogenesis in gallbladder carcinoma: with special reference to thymidine phosphorylase.
Neoplasms
Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Neoplasms
Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen.
Neoplasms
Selective inhibition of spontaneous pulmonary metastasis of Lewis lung carcinoma by 5'-deoxy-5-fluorouridine.
Neoplasms
Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.
Neoplasms
Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites.
Neoplasms
Significance of expression of pyrimidine metabolizing genes in colon cancer.
Neoplasms
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.
Neoplasms
Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer.
Neoplasms
Significance of thymidine phosphorylase expression in stromal cells around invasive front of rectal cancer.
Neoplasms
Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma.
Neoplasms
Significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor in carcinoma of the papilla of Vater.
Neoplasms
Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma.
Neoplasms
Specific enhanced expression of platelet-derived endothelial cell growth factor in submucosa of human colorectal cancer.
Neoplasms
Stimulatory effects of EGF and TGF-alpha on invasive activity and 5'-deoxy-5-fluorouridine sensitivity in uterine cervical-carcinoma SKG-IIIb cells.
Neoplasms
Stromal angiogenesis in human glioma: a role of platelet-derived endothelial cell growth factor.
Neoplasms
Studies on the designing of chemotherapy for gastric cancer in man, based on the tumor tissue concentration of anticancer agents.
Neoplasms
Substrate specificity of a thymidine phosphorylase in human liver tumor.
Neoplasms
Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells.
Neoplasms
Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model.
Neoplasms
Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity.
Neoplasms
Suppression of tumor growth and downregulation of platelet-derived endothelial cell growth factor / thymidine phosphorylase in tumor cells by angiogenesis inhibitor TNP-470.
Neoplasms
Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
Neoplasms
Synthesis and enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase.
Neoplasms
Synthesis and evaluation of multisubstrate bicyclic pyrimidine nucleoside inhibitors of human thymidine phosphorylase.
Neoplasms
Synthesis of 6-aminouracils and pyrrolo[2,3-d]pyrimidine-2,4-diones and their inhibitory effect on thymidine phosphorylase.
Neoplasms
Synthesis of pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors of thymidine phosphorylase.
Neoplasms
Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers.
Neoplasms
Synthesis, evaluation of thymidine phosphorylase and angiogenic inhibitory potential of ciprofloxacin analogues: Repositioning of ciprofloxacin from antibiotic to future anticancer drugs.
Neoplasms
Synthesis, molecular docking study and thymidine phosphorylase inhibitory activity of 3-formylcoumarin derivatives.
Neoplasms
Synthesis, thymidine phosphorylase inhibition and molecular modeling studies of 1,3,4-oxadiazole-2-thione derivatives.
Neoplasms
Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
Neoplasms
Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy.
Neoplasms
Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts.
Neoplasms
Tezacitabine enhances the DNA-directed effects of fluoropyrimidines in human colon cancer cells and tumor xenografts.
Neoplasms
The activities of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer depend on where the sample is taken.
Neoplasms
The activity and expression of thymidine phosphorylase in human solid tumours.
Neoplasms
The activity of thymidine phosphorylase as a new ovarian tumor marker.
Neoplasms
The activity of thymidine phosphorylase correlates with tumor size and lymph nodes status in breast carcinoma.
Neoplasms
The activity of thymidine phosphorylase in the uterine myomas and the myometrium in perimenopausal women.
Neoplasms
The angiogenic factor thymidine phosphorylase up-regulates the cell adhesion molecule P-selectin in human vascular endothelial cells and is associated with P-selectin expression in breast cancers.
Neoplasms
The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion.
Neoplasms
The correlation of thymidine phosphorylase activity with the expression of interleukin 1 alpha, interferon alpha and interferon gamma in human colorectal carcinoma.
Neoplasms
The cytosol activity of thymidine phosphorylase in endometrial cancer.
Neoplasms
The degradation of 5'-deoxy-5-fluorouridine by pyrimidine nucleoside phosphorylase in normal and cancer tissues.
Neoplasms
The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine.
Neoplasms
The dual role of thymidine phosphorylase in cancer development and chemotherapy.
Neoplasms
The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors.
Neoplasms
The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix.
Neoplasms
The efficacy of long-term oral chemotherapy with 5'-deoxy-5-fluorouridine and cyclophosphamide for recurrent breast cancer.
Neoplasms
The evolution of fluoropyrimidine therapy: from intravenous to oral.
Neoplasms
The evolving role of capecitabine in breast cancer.
Neoplasms
The expression of platelet-derived endothelial cell growth factor in human bladder cancer.
Neoplasms
The expression of thymidine phosphorylase and its correlation with angiogenesis in gastric adenocarcinoma.
Neoplasms
The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinomas.
Neoplasms
The Expression of Thymidine Phosphorylase in Cancer-infiltrating Inflammatory Cells in Stomach Cancer.
Neoplasms
The expression of thymidine phosphorylase suppresses spontaneous apoptosis of cancer cells in esophageal squamous cell carcinoma.
Neoplasms
The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery.
Neoplasms
The influence of elevated levels of platelet-derived endothelial cell growth factor/thymidine phosphorylase on tumourigenicity, tumour growth, and oxygenation.
Neoplasms
The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo.
Neoplasms
The influence of pyrimidine nucleoside phosphorylase activity on metastasis of breast cancer.
Neoplasms
The kinetic mechanism of Human Thymidine Phosphorylase - a molecular target for cancer drug development.
Neoplasms
The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer.
Neoplasms
The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites.
Neoplasms
The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus.
Neoplasms
The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas.
Neoplasms
The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine.
Neoplasms
The rational development of capecitabine from the laboratory to the clinic.
Neoplasms
The relationship between clinicopathological factors and the reduction of pyrimidine nucleoside phosphorylase activity after preoperative administration of 5'-deoxy-5-fluorouridine.
Neoplasms
The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer.
Neoplasms
The role of peroxisome proliferator-activated receptor gamma in bladder cancer in relation to angiogenesis and progression.
Neoplasms
The role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in tumor behavior.
Neoplasms
The role of thymidine phosphorylase (TP) mRNA expression in angiogenesis of prostate cancer.
Neoplasms
The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.
Neoplasms
The role of thymidine phosphorylase expression in the invasiveness of gastric carcinoma.
Neoplasms
The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells.
Neoplasms
The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression.
Neoplasms
The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers.
Neoplasms
The significance of thymidine phosphorylase activity in hepatocellular carcinoma and chronic diseased livers: a special reference to liver fibrosis and multicentric tumor occurrence.
Neoplasms
The significance of thymidine phosphorylase expression in colorectal cancer.
Neoplasms
The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells.
Neoplasms
The Thymidine Phosphorylase Imaging Agent 123I-IIMU Predicts the Efficacy of Capecitabine.
Neoplasms
The use of capecitabine in the combined-modality therapy for rectal cancer.
Neoplasms
The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers.
Neoplasms
Three new acrylic acid derivatives from Achillea mellifolium as potential thymidine phosphorylase inhibitor: molecular docking and MD simulation studies.
Neoplasms
Thymidine Catabolism as a Metabolic Strategy for Cancer Survival.
Neoplasms
Thymidine catabolism promotes NADPH oxidase-derived reactive oxygen species (ROS) signalling in KB and yumoto cells.
Neoplasms
Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
Neoplasms
Thymidine phoshorylase as a target for antiangiogenesis treatment.
Neoplasms
Thymidine phoshorylase expression in breast cancer: the prognostic significance and its association with other angiogenesis related proteins and extracellular matrix components.
Neoplasms
Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: from biology to the bedside.
Neoplasms
Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma.
Neoplasms
Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment.
Neoplasms
Thymidine phosphorylase activates NF?B and stimulates the expression of angiogenic and metastatic factors in human cancer cells.
Neoplasms
Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer.
Neoplasms
Thymidine phosphorylase activity in plasma: a cancer marker or an artifact of ultrafiltration?
Neoplasms
Thymidine phosphorylase activity in transitional cell cancer: relation to histological parameters and chemosensitivity to fluorouracil-related drugs.
Neoplasms
Thymidine phosphorylase activity in tumor correlates with venous invasion.
Neoplasms
Thymidine phosphorylase activity required for tumor angiogenesis and growth.
Neoplasms
Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer.
Neoplasms
Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3.
Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis.
Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in hepatocellular carcinoma and metastatic liver cancer.
Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels in tumor and normal tissue specimens of t3 human colorectal carcinoma.
Neoplasms
Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story.
Neoplasms
Thymidine phosphorylase and prostrate cancer cell proliferation inhibitory activities of synthetic 4-hydroxybenzohydrazides: In vitro, kinetic, and in silico studies.
Neoplasms
Thymidine phosphorylase as a target for imaging and therapy with thymine analogs.
Neoplasms
Thymidine phosphorylase enhances reactive oxygen species generation and interleukin-8 expression in human cancer cells.
Neoplasms
Thymidine Phosphorylase Expression and Microvascular Density Correlation Analysis in Canine Mammary Tumor: Possible Prognostic Factor in Breast Cancer.
Neoplasms
Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer.
Neoplasms
Thymidine phosphorylase expression causes both the increase of intratumoral microvessels and decrease of apoptosis in human esophageal carcinomas.
Neoplasms
Thymidine phosphorylase expression correlates with tumor differentiation and Bcl-2 in invasive breast cancer.
Neoplasms
Thymidine phosphorylase expression in endometrial carcinomas.
Neoplasms
Thymidine phosphorylase expression in human colorectal mucosa, adenoma and carcinoma: role of p53 expression.
Neoplasms
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Neoplasms
Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis.
Neoplasms
Thymidine phosphorylase expression in progression of cervical cancer: correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis.
Neoplasms
Thymidine phosphorylase expression in tumor stroma of uterine cervical carcinomas: histological features and microvessel density.
Neoplasms
Thymidine phosphorylase expression in tumor-infiltrating macrophages may be correlated with poor prognosis in uterine endometrial cancer.
Neoplasms
Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
Neoplasms
Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas.
Neoplasms
Thymidine phosphorylase expression is predominantly observed in stroma of well-differentiated adenocarcinoma of endometrium and correlates with a frequency of vascular involvement.
Neoplasms
Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma.
Neoplasms
Thymidine phosphorylase expression results in a decrease in apoptosis and increase in intratumoral microvessel density in human gastric carcinomas.
Neoplasms
Thymidine phosphorylase in cancer aggressiveness and chemoresistance.
Neoplasms
Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors.
Neoplasms
Thymidine Phosphorylase in Cancer; Enemy or Friend?
Neoplasms
Thymidine phosphorylase in human esophageal squamous cell carcinoma.
Neoplasms
Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms.
Neoplasms
Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.
Neoplasms
Thymidine phosphorylase inhibitors: recent developments and potential therapeutic applications.
Neoplasms
Thymidine phosphorylase is angiogenic and promotes tumor growth.
Neoplasms
Thymidine phosphorylase is regulated by tamoxifen in T47D breast cancer cell line.
Neoplasms
Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro.
Neoplasms
Thymidine phosphorylase promotes angiogenesis and tumour growth in intrahepatic cholangiocarcinoma.
Neoplasms
Thymidine phosphorylase regulates the expression of CXCL10 in rheumatoid arthritis fibroblast-like synoviocytes.
Neoplasms
Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents.
Neoplasms
Thymidine phosphorylase suppresses Fas-induced apoptotic signal transduction independent of its enzymatic activity.
Neoplasms
Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
Neoplasms
Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.
Neoplasms
Thymidine phosphorylase/platelet-derived endothelial cell growth factor is upregulated in advanced solid types of gastric cancer.
Neoplasms
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Neoplasms
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.
Neoplasms
Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
Neoplasms
Thymidylate synthase: a critical target in cancer therapy?
Neoplasms
Tissue concentration of platelet-derived endothelial cell growth factor in colorectal cancer.
Neoplasms
Tissue levels of pyrimidine nucleoside phosphorylase activity in human and rodent bladder cancer and normal bladder tissue.
Neoplasms
Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro.
Neoplasms
Transduction of thymidine phosphorylase cDNA facilitates efficacy of cytosine deaminase/5-FC gene therapy for malignant brain tumor.
Neoplasms
Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma.
Neoplasms
Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum.
Neoplasms
Tumor angiogenesis as an independent prognostic factor after extended radical esophagectomy for invasive squamous cell carcinoma of the esophagus.
Neoplasms
Tumor growth pattern and thymidine phosphorylase expression are related with the risk of hematogenous metastasis in patients with Astler Coller B1/B2 colorectal carcinoma.
Neoplasms
Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts.
Neoplasms
Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas.
Neoplasms
Tumor specific conversion of a pyrimidine antimetabolite.
Neoplasms
Tumor vascularity predicts recurrence in differentiated thyroid carcinoma.
Neoplasms
Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination.
Neoplasms
Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality.
Neoplasms
Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer.
Neoplasms
Upregulation of thymidine phosphorylase in rectal cancer tissues by mitomycin C.
Neoplasms
Validation of real-time reverse-transcription-polymerase chain reaction for quantification of capecitabine-metabolizing enzymes.
Neoplasms
Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.
Neoplasms
Variations in the expression of platelet-derived endothelial cell growth factor in human colorectal polyps.
Neoplasms
Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer.
Neoplasms
Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer.
Neoplasms
Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer.
Neoplasms
Vascular endothelial growth factor and thymidine phosphorylase expression in salivary gland tumors with distinct metastatic behavior.
Neoplasms
Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis.
Neoplasms
Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
Neoplasms
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.
Neoplasms
Vascular endothelial growth factor.
Neoplasms
Vision of the future: capecitabine.
Neoplasms
What is the role of thymidine phosphorylase in tumor angiogenesis.
Neoplasms
X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts.
Neoplasms
Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors.
Neoplasms
Xeloda in colorectal cancer.
Neoplasms
ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.
Neoplasms
[5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues]
Neoplasms
[5-Fluorouracil level and pyrimidine nucleoside phosphorylase activity in cancer patients after oral administration of doxifluridine (5'-DFUR)]
Neoplasms
[A case of gastric carcinoma treated effectively with 5'-DFUR]
Neoplasms
[A change of tumor PyNPase level at intraperitoneal and intravenous administrations of paclitaxel]
Neoplasms
[A new anticancer drug, 5'-deoxy-5-fluorouridine (5'-DFUR)]
Neoplasms
[A study of preoperative administration of 5'-DFUR in patients with colo-rectal cancer]
Neoplasms
[Activities of enzymes converting 5-fluorouracil to 5-fluorouridine-5' monophosphate and 5-fluorodeoxyuridine-5' monophosphate in subcultured cell lines and solid tumor tissues]
Neoplasms
[Activities of pyrimidine nucleoside phosphorylase in brain tumors and antitumor effect of 5'-DFUR]
Neoplasms
[Activity of the enzymes of DNA metabolism in the blood of patients with breast cancer]
Neoplasms
[Age-dependent characteristics of metabolism of DNA precursors in healthy women, patients with mastopathy and breast cancer]
Neoplasms
[Analyses of factors influencing the chemosensitivity of human tumors xenografted into nude mice (I)]
Neoplasms
[Antitumor cytokines]
Neoplasms
[Capecitabine: an oral chemotherapeutic agent against metastatic breast and colorectal cancer]
Neoplasms
[Clinical effect of 5'-deoxy-5-fluorouridine (5'-DFUR)]
Neoplasms
[Clinical efficacy of low-dose weekly docetaxel combined with oral 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced or metastatic breast cancer: a pilot trial]
Neoplasms
[Clinical significance of pyrimidine nucleoside phosphorylase (PyNPase) in breast cancer]
Neoplasms
[Clinicopathological significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced colorectal cancer]
Neoplasms
[Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Neoplasms
[Conversion of 5'-deoxy-5-fluorouridine to 5-FU by pyrimidine nucleoside phosphorylases in normal and tumor tissues from rodents bearing tumors and cancer patients]
Neoplasms
[Correlation between pyrimidine nucleoside phosphorylase (PyNPase) and clinicopathological factors in patients with gastric cancer]
Neoplasms
[Correlation between pyrimidine nucleoside phosphorylase (PyNPase)/platelet-derived endothelial cell growth factor and histological prognostic factor, and influences of 5'-deoxy-5-fluorouridine (5'-DFUR) administration on PyNPase levels. 5'-DFUR Joint Research Group in the Osaka Area for Gastric Cancer]
Neoplasms
[Correlation between pyrimidine nucleoside phosphorylase (PyNPase)/thymidine phosphorylase/platelet-derived endothelial cell growth factor and histological prognostic factor, and influence of 5'-deoxy-5-fluorouridine (5'-DFUR) administration on PyNPase activities and serum immunosuppressive acidic protein levels. A study group of oral anti-cancer drugs in Seiban/Tajima area]
Neoplasms
[Determination of thymidine phosphorylase in adenoma and cancer of the human prostate]
Neoplasms
[Discovery and development of novel anticancer drug capecitabine]
Neoplasms
[Distributions of pyrimidine nucleoside phosphorylase (PyNPase) in tissues of benign and malignant mammary diseases--immunohistochemical observations]
Neoplasms
[Effect of 5'-deoxy-5-fluorouridine (5'-DFUR) on the activity of pyrimidine nucleoside phosphorylase (pyNPase) in normal and tumor tissues of human stomach]
Neoplasms
[Effect of preoperative oral 5'-DFUR on PyNPase level in gastrointestinal malignant tumor tissues]
Neoplasms
[Effect on 5'-deoxy-5-fluorouridine (5'-DFUR) of pyrimidine nucleoside phosphorylase (PyNPase), matrix metalloprotease and serum IAP values. Hokuriku Colorectal Cancer Chemotherapy Study Group]
Neoplasms
[Enzymatic conversion of tegafur in human tumor tissue]
Neoplasms
[Evaluation by multiple regression analysis of factors influencing the chemosensitivity of human tumors xenografted into nude mice]
Neoplasms
[Expression of thymidine phosphorylase in cancer]
Neoplasms
[Expression of thymidine phosphorylase in primary colorectal cancer and liver metastasis-relationship between mRNA levels in cancer cells and protein levels in cancerous tissue]
Neoplasms
[Expression rates of three angiogenic factors in hepatocellular carcinoma and their relation with microvessel density and portal vein tumor thrombosis]
Neoplasms
[Immunohistochemical staining of thymidine phosphorylase in primary colorectal carcinoma and metastases]
Neoplasms
[Immunohistochemical study of thymidine phosphorylase in uterine cervical intraepithelial neoplasia]
Neoplasms
[In vivo study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) in meningeal dissemination of malignant tumor]
Neoplasms
[Influence of intratumor administration of OK-432 on the tumor selectivity of 5'-DFUR]
Neoplasms
[Influence of the selected pyrimidine compounds on the activity of thymidine phosphorylase from normal and tumor endometrial cells]
Neoplasms
[Influence of the thymidine phosphorylase (platelet-derived endothelial cell growth factor) on tumor angiogenesis. Catalytic activity of enzyme inhibitors]
Neoplasms
[Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts]
Neoplasms
[Influences of 5'-deoxy-5-fluorouridine (5'-DFUR) on cell cycle in patients with breast cancer]
Neoplasms
[Ki-67 expression, thymidine phosphorylase and PTEN in intraepithelial cervical carcinoma].
Neoplasms
[Lactate dehydrogenase, adenosine deaminase and thymidine phosphorylase activity of blood and tissues in breast tumor patients]
Neoplasms
[Localization of platelet-derived endothelial cell growth factor in human glioblastoma and meningioma]
Neoplasms
[Malignancy of gastric cancer analyzed by the expression of thymidine phosphorylase]
Neoplasms
[Measurement of 5'-deoxy-5-fluorouridine (5'-DFUR) by high-performance liquid chromatography and studies on pharmacokinetics of 5'-DFUR and 5-fluorouracil by oral and intravenous administration]
Neoplasms
[Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine]
Neoplasms
[Mode of action of fluoropyrimidines, in relation to their clinical application]
Neoplasms
[Molecular markers as basis for chemotherapy?]
Neoplasms
[New molecular target of cancer therapy--angiogenesis regulator VEGF]
Neoplasms
[Phase I clinical trial evaluation of capecitabine in concurrent combination of radiotherapy in nasopharyngeal carcinoma]
Neoplasms
[Prognostic effect of PyNPase (pyrimidine nucleoside phosphorylase) activity in breast cancer]
Neoplasms
[PyNPase activity in primary and metastatic colorectal cancer]
Neoplasms
[PyNPase and DPD expression potentially predict response to 5'-DFUR treatment for node-positive breast cancer patients]
Neoplasms
[PyNPase expression and cancer progression in the colorectum]
Neoplasms
[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]
Neoplasms
[Significance of 5'-deoxy-5-fluorouridine (5'-DFUR) administration before surgery for advanced gastric and colonic cancers--activity of pyrimidine nucleoside phosphorylase (PyNPase) and serum immunosuppressive acidic protein (IAP)]
Neoplasms
[Significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced gastric cancers]
Neoplasms
[Significance of pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase levels to predict postoperative recurrence in primary breast cancer]
Neoplasms
[Significance of tissue PyNPase, TS, and DPD activities in breast cancer]
Neoplasms
[Studies on 5-FU concentration and thymidine phosphorylase activity in tissues of patients with colorectal cancer after SF-SP administration]
Neoplasms
[Study of PyNPase activity in patients with gastric cancer--the association with preoperative IAP values]
Neoplasms
[Study on pyrimidine nucleoside phosphorylase (PyNPase) activity in resected tissues of patients with gastric cancer]
Neoplasms
[Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer]
Neoplasms
[Successful treatment of hepatic metastasis of gastric cancer with 5'-DFUR and Lentinan]
Neoplasms
[The alteration of PyNPase activity in breast cancers due to preoperative oral administration of 5'-DFUR]
Neoplasms
[The analysis of thymidine phosphorylase examined by ELISA in bladder cancer]
Neoplasms
[The efficacy of combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR), cyclophosphamide (CPA) and medroxyprogesterone acetate (MPA) for bone metastasis in breast cancer patients]
Neoplasms
[The enzymatic activity of DNA metabolism of the blood in patients operated on in stomach cancer]
Neoplasms
[The importance of tumor angiogenesis as a prognostic indicator in primary breast cancer]
Neoplasms
[The mRNA expression of platelet-derived endothelial cell growth factor of bladder transitional cell carcinoma and its relation to invasiveness]
Neoplasms
[The relation between pyrimidine nucleoside phosphorylase (PyNPase) activity in colorectal cancer tissues and pathological effects]
Neoplasms
[The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer].
Neoplasms
[The significance of platelet-derived endothelial cell growth factor mRNA expression in superficial bladder cancer]
Neoplasms
[The thymidine phosphorylase as the platelet-derived endothelial cell growth factor of endometrial cancer]
Neoplasms
[Thymidine phosphorylase activity and neo-angiogenesis in ovarian cancer]
Neoplasms
[Thymidine phosphorylase as a prognostic factors of breast cancers]
Neoplasms
[Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential]
Neoplasms
[Use of enzyme test in chemotherapy of patients with cancer of the breast]
Neoplasms, Squamous Cell
Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma.
Neoplasms, Squamous Cell
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Nephrosis
Experimentally induced puromycine aminonucleoside nephrosis (PAN) in rats: evaluation of angiogenic protein platelet-derived endothelial cell growth factor (PD-ECGF) expression in glomeruli.
Neuroblastoma
Correlations of dihydropyrimidine dehydrogenase, thymidine phosphorylase and thymidine kinase activities in strongly and weakly malignant cultured murine neuroblastoma cells.
Neuroblastoma
[Antitumor cytokines]
Neurodegenerative Diseases
Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B.
Neurofibroma
A novel glial growth inhibitory factor, gliostatin, derived from neurofibroma.
Neurologic Manifestations
Pregnancy in MNGIE: a clinical and metabolic honeymoon.
Odontogenic Tumors
Immunohistochemical detection of platelet-derived endothelial cell growth factor/thymidine phosphorylase and angiopoietins in ameloblastic tumors.
Ophthalmoplegia
Digestive smooth muscle mitochondrial myopathy in patients with mitochondrial-neuro-gastro-intestinal encephalomyopathy (MNGIE).
Ophthalmoplegia
Inherited peripheral neuropathies due to mitochondrial disorders.
Ophthalmoplegia
Leukoencephalopathy in Mitochondrial Neurogastrointestinal Encephalomyopathy-Like Syndrome with Polymerase-Gamma Mutations.
Ophthalmoplegia
Mitochondrial neurogastrointestinal encephalomyopathy associated with progressive hearing loss.
Ophthalmoplegia
Pitfalls in diagnosing mitochondrial neurogastrointestinal encephalomyopathy.
Ophthalmoplegia
Transient clinical improvement of a mitochondrial neurogastrointestinal encephalomyopathy-like syndrome after allogeneic haematopoietic stem cell transplantation.
Ophthalmoplegia
[Peripheral neuropathies due to mitochondrial disorders]
Oropharyngeal Neoplasms
A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients.
Oropharyngeal Neoplasms
Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer.
Ovarian Neoplasms
4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression.
Ovarian Neoplasms
Could serologic and ultrasonographic indexes be useful for therapeutic decisions in patients with ovarian cancer?
Ovarian Neoplasms
Effects of platelet-derived endothelial cell growth factor/thymidine phosphorylase, substrate, and products in a three-dimensional model of angiogenesis.
Ovarian Neoplasms
Expression of angiogenesis factors in monolayer culture, multicellular spheroid and in vivo transplanted tumor by human ovarian cancer cell lines.
Ovarian Neoplasms
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in ovarian cancers.
Ovarian Neoplasms
Expression of thymidine phosphorylase in malignant ovarian tumors: correlation with microvessel density and an ultrasound-derived index of angiogenesis.
Ovarian Neoplasms
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Ovarian Neoplasms
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Ovarian Neoplasms
Role of lymphangiogenesis in epithelial ovarian cancer.
Ovarian Neoplasms
The activity of thymidine phosphorylase as a new ovarian tumor marker.
Ovarian Neoplasms
Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer.
Ovarian Neoplasms
Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo.
Ovarian Neoplasms
[Investigation of 5-fluorouracil (5-FU) levels and pyrimidine nucleoside phosphorylase activities in the tissues from patients with uterine cervical and ovarian cancers after oral administration of 5'-DFUR]
Ovarian Neoplasms
[Significance of tissue thymidine phosphorylase and dihydropyrimidine dehydrogenase activities in ovarian cancer]
Ovarian Neoplasms
[Thymidine phosphorylase activity and neo-angiogenesis in ovarian cancer]
Paget's Disease, Mammary
The role of vascular endothelial growth factor-A (VEGF-A) and platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in Paget's disease of the vulva and breast.
Pancreatic Neoplasms
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Pancreatic Neoplasms
Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis.
Pancreatic Neoplasms
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Pancreatic Neoplasms
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Pancreatic Neoplasms
Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
Pancreatic Neoplasms
Prognosis Relevance of Serum Cytokines in Pancreatic Cancer.
Pancreatic Neoplasms
Prognostic significance of angiogenesis in human pancreatic cancer.
Pancreatic Neoplasms
Prognostic value of thymidine phosphorylase expression for pancreatic cancer.
Pancreatic Neoplasms
Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.
Pancreatic Neoplasms
[The thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio in pancreatic cancer]
Pancreatitis, Chronic
Mitochondrial DNA A3243G mutation involved in familial diabetes, chronic intestinal pseudo-obstruction and recurrent pancreatitis.
Paraganglioma
Expression of angiogenic growth factors in paragangliomas.
Peripheral Arterial Disease
Platelet-derived endothelial cell growth factor gene therapy for limb ischemia.
Peripheral Nervous System Diseases
Late-onset MNGIE without peripheral neuropathy due to incomplete loss of thymidine phosphorylase activity.
Peripheral Nervous System Diseases
Leukoencephalopathy in Mitochondrial Neurogastrointestinal Encephalomyopathy-Like Syndrome with Polymerase-Gamma Mutations.
Peripheral Nervous System Diseases
Mitochondrial neurogastrointestinal encephalomyopathy associated with progressive hearing loss.
Peripheral Nervous System Diseases
POG01 Anti-thymidine phosphorylase antibodies in the diagnosis of mitochondrial neurogastrointestinal encephalomyopathy.
Peripheral Vascular Diseases
Platelet-derived endothelial cell growth factor gene therapy for limb ischemia.
Phenylketonurias
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.
Phyllodes Tumor
[Distributions of pyrimidine nucleoside phosphorylase (PyNPase) in tissues of benign and malignant mammary diseases--immunohistochemical observations]
Plague
[Thymidine phosphorylase activity and its relationship to trimethoprim in initial strains and thymidine-, thymine-dependent and trimethoprim-resistant mutants of plague microbe]
Polyneuropathies
Digestive smooth muscle mitochondrial myopathy in patients with mitochondrial-neuro-gastro-intestinal encephalomyopathy (MNGIE).
Poroma
Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Purine and pyrimidine activities in acute and chronic lymphocytic leukaemia: relation to cellular proliferative status.
Prostatic Neoplasms
Blockade of paclitaxel-induced thymidine phosphorylase expression can accelerate apoptosis in human prostate cancer cells.
Prostatic Neoplasms
Expression of thymidine phosphorylase correlates with microvessel density in prostate cancer.
Prostatic Neoplasms
Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer.
Prostatic Neoplasms
Immunohistochemical localization of platelet-derived endothelial cell growth factor expression and its relation to angiogenesis in prostate.
Prostatic Neoplasms
The role of thymidine phosphorylase (TP) mRNA expression in angiogenesis of prostate cancer.
Prostatic Neoplasms
[Determination of thymidine phosphorylase in adenoma and cancer of the human prostate]
Pseudolymphoma
Pyrimidine and purine activities in non-Hodgkin's lymphoma. Correlation with histological status and survival.
Psoriasis
2-Arylquinazolin-4(3H)-ones: A novel class of thymidine phosphorylase inhibitors.
Psoriasis
Synthesis, molecular docking study and thymidine phosphorylase inhibitory activity of 3-formylcoumarin derivatives.
Pyloric Stenosis, Hypertrophic
Study of insulin-like growth factor-1 (IGF-1) and platelet-derived endothelial cell growth factor (PDEGF) expression in children with infantile hypertrophic pyloric stenosis.
Rectal Neoplasms
Changes in thymidine phosphorylase gene expression related to treatment of rectal cancer.
Rectal Neoplasms
Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy.
Rectal Neoplasms
Immunohistochemical Markers as Predictors of Histopathologic Response and Prognosis in Rectal Cancer Treated with Preoperative Adjuvant Therapy: State of the Art.
Rectal Neoplasms
Importance of thymidine phosphorylase expression at the invasive front of T3 rectal cancer as a prognostic factor.
Rectal Neoplasms
Importance of thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase expression at the invasive front of T3 rectal cancer as prognostic factors.
Rectal Neoplasms
Preoperative Chemoradiation for Rectal Cancer Using Capecitabine and Celecoxib Correlated with Posttreatment Assessment of Thymidylate Synthase and Thymidine Phosphorylase Expression.
Rectal Neoplasms
Pretreatment Expression of 13 Molecular Markers as a Predictor of Tumor Responses After Neoadjuvant Chemoradiation in Rectal Cancer.
Rectal Neoplasms
Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
Rectal Neoplasms
Radiation-induced thymidine phosphorylase upregulation in rectal cancer is mediated by tumor-associated macrophages by monocyte chemoattractant protein-1 from cancer cells.
Rectal Neoplasms
Significance of thymidine phosphorylase expression in stromal cells around invasive front of rectal cancer.
Rectal Neoplasms
The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery.
Rectal Neoplasms
Thymidine phosphorylase and hypoxia-inducible factor 1-? expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis.
Rectal Neoplasms
Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
Rectal Neoplasms
Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
Rectal Neoplasms
Upregulation of thymidine phosphorylase in rectal cancer tissues by mitomycin C.
Rhinitis, Allergic
Expression of platelet-derived endothelial cell growth factor and vascularity in the nasal mucosa from allergic rhinitis.
Rhinitis, Allergic
The role of thymidine phosphorylase in the pathogenesis of allergic rhinitis.
Sarcoma
Expression of thymidine phosphorylase in uterine sarcoma and uterine leiomyoma: association with microvessel density and Doppler blood flow analysis.
Sarcoma
[Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential]
Sarcoma 180
[Activities of pyrimidine nucleoside phosphorylase in brain tumors and antitumor effect of 5'-DFUR]
Sarcoma, Kaposi
Morphological and cytogenetic studies of angiosarcoma in Stewart-Treves syndrome.
Sarcoma, Kaposi
Thymidine phosphorylase expression in Kaposi sarcoma.
Schistosomiasis
[Expression of vascular growth factors in intestinal tissues in colorectal carcinoma patients with schistosomiasis japonica].
Small Cell Lung Carcinoma
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Squamous Cell Carcinoma of Head and Neck
Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Effects of smoking and alcohol consumption on 5-fluorouracil-related metabolic enzymes in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics.
Squamous Cell Carcinoma of Head and Neck
Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Influence of platelet-derived endothelial cell growth factor/thymidine phosphorylase on the cell cycle in head and neck squamous cell carcinoma in vitro.
Squamous Cell Carcinoma of Head and Neck
The effect of neoadjuvant therapy on the 5-fluorouracil metabolic and relative enzymes of oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Thymidine phosphorylase expression in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
[The expressions of TP, MK and CD105 in laryngeal squamous cell carcinoma and their clinical significance]
Stomach Neoplasms
Alpha-fetoprotein-producing gastric cancer: histochemical analysis of cell proliferation, apoptosis, and angiogenesis.
Stomach Neoplasms
Angiogenesis and lymphangiogenesis of gastric cancer.
Stomach Neoplasms
Angiogenesis in gastric cancer: importance of the thymidine phosphorylase expression of cancer cells as an angiogenic factor.
Stomach Neoplasms
Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer.
Stomach Neoplasms
Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma.
Stomach Neoplasms
Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer.
Stomach Neoplasms
Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes.
Stomach Neoplasms
Cancer-Stromal Cell Interaction and Tumor Angiogenesis in Gastric Cancer.
Stomach Neoplasms
Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts.
Stomach Neoplasms
Choice of Capecitabine or S1 in Combination with Oxaliplatin based on Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase Expression Status in Patients with Advanced Gastric Cancer.
Stomach Neoplasms
Clinical impact of thymidine phosphorylase expression in gastric cancer.
Stomach Neoplasms
Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients.
Stomach Neoplasms
Correlation between expression levels of thymidine phosphorylase (dThdPase) and clinical features in human gastric carcinoma.
Stomach Neoplasms
Correlation between spontaneous apoptosis and the expression of angiogenic factors in advanced gastric adenocarcinoma.
Stomach Neoplasms
Effects of 5'-DFUR and OK-432 on cytokines and thymidine phosphorylase in tumor tissue of gastric cancer patients.
Stomach Neoplasms
Effects of thymidine phosphorylase levels in cancer, background mucosa, and regional lymph nodes on survival of advanced gastric cancer patients receiving postoperative fluoropyrimidine therapy.
Stomach Neoplasms
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Stomach Neoplasms
Expression of thymidylate synthase and thymidine phosphorylase in recurrence and survival rates of advanced gastric cancer.
Stomach Neoplasms
Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
Stomach Neoplasms
Expressions of Thymidylate Synthase,Thymidine Phosphorylase, Class III ?-tubulin, and Excision Repair Cross-complementing Group 1predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or Cisplatin.
Stomach Neoplasms
Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil.
Stomach Neoplasms
H pylori status and angiogenesis factors in human gastric carcinoma.
Stomach Neoplasms
Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma.
Stomach Neoplasms
Heterogeneity and clinical role of thymidine phosphorylase activity in gastric cancer.
Stomach Neoplasms
Immunohistochemical demonstration of angiogenic growth factors and EGF receptor in hepatic metastases and primary human gastric cancer.
Stomach Neoplasms
Immunohistochemical localization of thymidine phosphorylase in gastric cancer: is there a role of the differential expression in tumor cells and associated stromal cells?
Stomach Neoplasms
Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
Stomach Neoplasms
Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Stomach Neoplasms
Measurement of serum thymidine phosphorylase levels by highly sensitive enzyme-linked immunosorbent assay in gastric cancer.
Stomach Neoplasms
Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).
Stomach Neoplasms
p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer.
Stomach Neoplasms
Partial purification of a thymidine phosphorylase from human gastric cancer.
Stomach Neoplasms
Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway.
Stomach Neoplasms
Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor.
Stomach Neoplasms
Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Stomach Neoplasms
Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers.
Stomach Neoplasms
Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients.
Stomach Neoplasms
Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer.
Stomach Neoplasms
Systemic immune-inflammation index, thymidine phosphorylase and survival of localized gastric cancer patients after curative resection.
Stomach Neoplasms
The expression of thymidine phosphorylase and its correlation with angiogenesis in gastric adenocarcinoma.
Stomach Neoplasms
The Expression of Thymidine Phosphorylase in Cancer-infiltrating Inflammatory Cells in Stomach Cancer.
Stomach Neoplasms
The inhibition of thymidine phosphorylase can reverse acquire 5FU resistance in gastric cancer cells.
Stomach Neoplasms
The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine.
Stomach Neoplasms
Thymidine phosphorylase activity and angiogenesis in gastric cancer.
Stomach Neoplasms
Thymidine phosphorylase activity in tumor correlates with venous invasion.
Stomach Neoplasms
Thymidine phosphorylase expression correlates with malignant potential and anti-tumor effect of doxifluridine on gastric cancer: multivariate analysis for adjuvant chemotherapy doxifluridine vs. 5-fluorouracil.
Stomach Neoplasms
Thymidine phosphorylase expression in gastric cancer in association with proliferative activity and angiogenesis.
Stomach Neoplasms
Thymidine phosphorylase expression is useful in selecting adjuvant chemotherapy for stage III gastric cancer.
Stomach Neoplasms
Thymidine Phosphorylase/?-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Stomach Neoplasms
Thymidine phosphorylase/platelet-derived endothelial cell growth factor is upregulated in advanced solid types of gastric cancer.
Stomach Neoplasms
Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer.
Stomach Neoplasms
[Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Stomach Neoplasms
[Correlation between pyrimidine nucleoside phosphorylase (PyNPase) and clinicopathological factors in patients with gastric cancer]
Stomach Neoplasms
[Correlation between pyrimidine nucleoside phosphorylase (PyNPase)/platelet-derived endothelial cell growth factor and histological prognostic factor, and influences of 5'-deoxy-5-fluorouridine (5'-DFUR) administration on PyNPase levels. 5'-DFUR Joint Research Group in the Osaka Area for Gastric Cancer]
Stomach Neoplasms
[Correlation between pyrimidine nucleoside phosphorylase (PyNPase)/thymidine phosphorylase/platelet-derived endothelial cell growth factor and histological prognostic factor, and influence of 5'-deoxy-5-fluorouridine (5'-DFUR) administration on PyNPase activities and serum immunosuppressive acidic protein levels. A study group of oral anti-cancer drugs in Seiban/Tajima area]
Stomach Neoplasms
[Effect of 5'-deoxy-5-fluorouridine (5'-DFUR) on the activity of pyrimidine nucleoside phosphorylase (pyNPase) in normal and tumor tissues of human stomach]
Stomach Neoplasms
[Malignancy of gastric cancer analyzed by the expression of thymidine phosphorylase]
Stomach Neoplasms
[Significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced gastric cancers]
Stomach Neoplasms
[Study of PyNPase activity in patients with gastric cancer--the association with preoperative IAP values]
Stomach Neoplasms
[Study on pyrimidine nucleoside phosphorylase (PyNPase) activity in resected tissues of patients with gastric cancer]
Stomach Neoplasms
[The dynamics of the enzymatic activity of DNA metabolism during the treatment of stomach cancer patients]
Stomach Neoplasms
[The expression of thymidylate synthase and thymidine phosphorylase in the early-stage of gastric cancer]
Stomach Ulcer
Expression of the angiogenic factor thymidine phosphorylase in THP-1 monocytes: induction by autocrine tumor necrosis factor-alpha and inhibition by aspirin.
Synovitis
Synovial inflammation and hyperplasia induced by gliostatin/platelet-derived endothelial cell growth factor in rabbit knees.
Syringoma
Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors.
Thrombocytosis
Poor Prognosis Associated with High Levels of Thymidine Phosphorylase and Thrombocytosis in Patients with Renal Cell Carcinoma.
Thrombocytosis
Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma.
Thrombocytosis
Thymidine phosphorylase gene variant, platelet counts and survival in gastrointestinal cancer patients treated by fluoropyrimidines.
Thrombosis
Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.
Thrombosis
Increased expression of platelet-derived endothelial cell growth factor in human hepatocellular carcinomas correlated with high Edmondson grades and portal vein tumor thrombosis.
Thrombosis
Targeting Thymidine Phosphorylase With Tipiracil Hydrochloride Attenuates Thrombosis Without Increasing Risk of Bleeding in Mice.
Thrombosis
Thymidine Phosphorylase Is Increased in COVID-19 Patients in an Acuity-Dependent Manner.
Thrombosis
Thymidine phosphorylase participates in platelet signaling and promotes thrombosis.
Thrombosis
Thymidine phosphorylase: A potential new target for treating cardiovascular disease.
Thrombosis
[Expression rates of three angiogenic factors in hepatocellular carcinoma and their relation with microvessel density and portal vein tumor thrombosis]
thymidine phosphorylase deficiency
Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy.
thymidine phosphorylase deficiency
Assessment of stability, toxicity and immunogenicity of new polymeric nanoreactors for use in enzyme replacement therapy of MNGIE.
thymidine phosphorylase deficiency
Biochemical abnormalities in a patient with thymidine phosphorylase deficiency with fatal outcome.
thymidine phosphorylase deficiency
Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy.
thymidine phosphorylase deficiency
Deoxyuridine accumulation in urine in thymidine phosphorylase deficiency (MNGIE).
thymidine phosphorylase deficiency
Elevated plasma deoxyuridine in patients with thymidine phosphorylase deficiency.
thymidine phosphorylase deficiency
Genetic study of mutants of Escherichia coli K-12 with a thymidine phosphorylase deficiency.
thymidine phosphorylase deficiency
HPLC-UV analysis of thymidine and deoxyuridine in plasma of patients with thymidine phosphorylase deficiency.
thymidine phosphorylase deficiency
Increased blood-brain barrier permeability with thymidine phosphorylase deficiency.
thymidine phosphorylase deficiency
Mitochondrial neurogastrointestinal encephalomyopathy treated with peritoneal dialysis and bone marrow transplantation.
thymidine phosphorylase deficiency
Mitochondrial neurogastrointestinal encephalomyopathy: case report.
thymidine phosphorylase deficiency
Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B.
thymidine phosphorylase deficiency
Mitochondrial syndromes with leukoencephalopathies.
thymidine phosphorylase deficiency
Proceedings: Investigation of the nucleoside metabolism in Rhizobium lupini: obligatory thymidine phosphorylase deficiency.
thymidine phosphorylase deficiency
Regulation by degradation, a cellular defense against deoxyribonucleotide pool imbalances.
thymidine phosphorylase deficiency
Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency.
thymidine phosphorylase deficiency
Spontaneous abdominal esophageal perforation in a patient with mitochondrial neurogastrointestinal encephalomyopathy.
thymidine phosphorylase deficiency
Thymidine kinase 2 enzyme kinetics elucidate the mechanism of thymidine-induced mitochondrial DNA depletion.
thymidine phosphorylase deficiency
Thymidine phosphorylase deficiency causes MNGIE: an autosomal recessive mitochondrial disorder.
thymidine phosphorylase deficiency
[Fatal cachexia caused by mitochondrial neuro-gastro-intestinal encephalomyopathy].
Thyroid Cancer, Papillary
Increased expression of mRNA specific for thymidine kinase, deoxycytidine kinase or thymidine phosphorylase in human papillary thyroid carcinoma.
Thyroid Neoplasms
Platelet-derived endothelial cell growth factor.
Thyroid Neoplasms
Production of platelet-derived endothelial cell growth factor by normal and transformed human cells in culture.
Thyroid Neoplasms
Tumor vascularity predicts recurrence in differentiated thyroid carcinoma.
Urinary Bladder Neoplasms
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human bladder cancer.
Urinary Bladder Neoplasms
Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers.
Urinary Bladder Neoplasms
Expression of the fluoropyrimidine-metabolizing enzymes in bladder cancers as measured by the Danenberg tumor profile.
Urinary Bladder Neoplasms
Expression of thymidine phosphorylase in human superficial bladder cancer.
Urinary Bladder Neoplasms
Expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer.
Urinary Bladder Neoplasms
IFN gamma-induced up-regulation of PD-ECGF/TP enhances the cytotoxicity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in bladder cancer cells.
Urinary Bladder Neoplasms
Molecular basis for the involvement of thymidine phosphorylase in cancer invasion.
Urinary Bladder Neoplasms
Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy.
Urinary Bladder Neoplasms
Novel prophylactic effect of doxifluridine in superficial bladder cancer.
Urinary Bladder Neoplasms
Prognostic significance of platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in stage pT1 G3 bladder cancer.
Urinary Bladder Neoplasms
Prognostic Significance of Thymidine Phosphorylase in Superficial Bladder Carcinoma.
Urinary Bladder Neoplasms
Radiosensitization by thymidine phosphorylase inhibitor in thymidine phosphorylase negative and overexpressing bladder cancer cell lines.
Urinary Bladder Neoplasms
Role of thymidine phosphorylase in an in vitro model of human bladder cancer invasion.
Urinary Bladder Neoplasms
The expression of platelet-derived endothelial cell growth factor in human bladder cancer.
Urinary Bladder Neoplasms
The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer.
Urinary Bladder Neoplasms
The role of peroxisome proliferator-activated receptor gamma in bladder cancer in relation to angiogenesis and progression.
Urinary Bladder Neoplasms
Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer.
Urinary Bladder Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer.
Urinary Bladder Neoplasms
Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer.
Urinary Bladder Neoplasms
Tissue levels of pyrimidine nucleoside phosphorylase activity in human and rodent bladder cancer and normal bladder tissue.
Urinary Bladder Neoplasms
[Enhancement effect of interferon gamma on the sensitivity of RT4 bladder cancer cells to 5'-deoxy-5-fluorouridine,and 5-fluorouracil through up-regulation of PD-ECGF/TP]
Urinary Bladder Neoplasms
[The analysis of thymidine phosphorylase examined by ELISA in bladder cancer]
Urinary Bladder Neoplasms
[The significance of platelet-derived endothelial cell growth factor mRNA expression in superficial bladder cancer]
Urologic Diseases
Expression of platelet-derived endothelial cell growth factor and its potential role in up-regulation of angiogenesis in scarred kidneys secondary to urinary tract diseases.
Uterine Cervical Neoplasms
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in cervical cancer.
Uterine Cervical Neoplasms
Clinical implication of expression of platelet-derived endothelial cell growth factor (PD-ECGF) in metastatic lesions of uterine cervical cancers.
Uterine Cervical Neoplasms
Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers.
Uterine Cervical Neoplasms
Different angiogenic pathways in human cervical cancers.
Uterine Cervical Neoplasms
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers.
Uterine Cervical Neoplasms
Expression of thymidine phosphorylase in human cervical cancer.
Uterine Cervical Neoplasms
Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix.
Uterine Cervical Neoplasms
Platelet-derived endothelial cell growth factor in keratinizing-type squamous cell uterine cervical cancer.
Uterine Cervical Neoplasms
Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer.
Uterine Cervical Neoplasms
Plausible linkage of hypoxia inducible factor-1alpha in uterine cervical cancer.
Uterine Cervical Neoplasms
Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy.
Uterine Cervical Neoplasms
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Uterine Cervical Neoplasms
The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix.
Uterine Cervical Neoplasms
The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers.
Uterine Cervical Neoplasms
Thymidine phosphorylase expression in progression of cervical cancer: correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis.
Uterine Cervical Neoplasms
Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis.
Uterine Neoplasms
Thymidine phosphorylase expression in tumor stroma of uterine cervical carcinomas: histological features and microvessel density.
Virus Diseases
The next ten stories on antiviral drug discovery (part E): Advents, Advances, and Adventures.
Vulvar Diseases
Angiogenesis in benign, pre-malignant and malignant vulvar lesions.
Vulvar Neoplasms
Role of angiogenesis in benign, premalignant and malignant vulvar lesions.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Zimmerman, M.; Seidenberg, J.
Deoxyribosyl transfer. I. Thymidine phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissues
J. Biol. Chem.
239
2618-2621
1964
Cavia porcellus, Homo sapiens, Mesocricetus auratus, Rattus norvegicus
brenda
Sugata, S.; Kono, A.; Hara, Y.; Karube, Y.; Matsushima, Y.
Partial purification of a thymidine phosphorylase from human gastric cancer
Chem. Pharm. Bull.
34
1219-1222
1986
Homo sapiens
brenda
Zimmerman, M.
Deoxyribosyl transfer. II. Nucleoside:pyrimidine deoxyribosyltransferase activity of three partially purified thymidine phosphorylases
J. Biol. Chem.
239
2622-2627
1964
Escherichia coli, Escherichia coli B / ATCC 11303, Homo sapiens, Rattus norvegicus
brenda
Desgranges, C.; Razaka, G.; Rabaud, M.; Bricaud, H.
Catabolism of thymidine in human blood platelets: purification and properties of thymidine phosphorylase
Biochim. Biophys. Acta
654
211-218
1981
Homo sapiens
brenda
Kubilus, J.; Lee, L.D.; Baden, H.P.
Purification of thymidine phosphorylase from human amniochorion
Biochim. Biophys. Acta
527
221-228
1978
Homo sapiens
brenda
el Kouni, M.H.; el Kouni, M.M.; Naguib, F.N.
Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines
Cancer Res.
53
3687-3693
1993
Homo sapiens, Mus musculus
brenda
Pizzorno, G.; Cao, D.; Leffert, J.J.; Russell, R.L.; Zhang, D.; Handschumacher, R.E.
Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update
Biochim. Biophys. Acta
1587
133-144
2002
Homo sapiens
brenda
de Bruin, M.; Smid, K.; Laan, A.C.; Noordhuis, P.; Fukushima, M.; Hoekman, K.; Pinedo, H.M.; Peters, G.J.
Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells
Biochem. Biophys. Res. Commun.
301
675-679
2003
Homo sapiens
brenda
Finnis, C.; Dodsworth, N.; Pollitt, C.E.; Carr, G.; Sleep, D.
Thymidine phosphorylase activity of platelet-derived endothelial cell growth factor is responsible for endothelial cell mitogenicity
Eur. J. Biochem.
212
201-210
1993
Escherichia coli, Homo sapiens
brenda
Liu, M.; Cao, D.; Russell, R.; Handschumacher, R.E.; Pizzorno, G.
Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors
Cancer Res.
58
5418-5424
1998
Homo sapiens
brenda
Miszczak-Zaborska, E.; Wozniak, K.
The activity of thymidine phosphorylase obtained from human uterine leiomyomas and studied in the presence of pyrimidine derivatives
Z. Naturforsch. c
52
670-675
1997
Homo sapiens
brenda
Miyadera, K.; Dohmae, N.; Takio, K.; Sumizawa, T.; Haraguchi, M.; Furukawa, T.; Yamada, Y.; Akiyama, S.
Structural characterization of thymidine phosphorylase purified from human placenta
Biochem. Biophys. Res. Commun.
212
1040-1045
1995
Homo sapiens
brenda
Miyadera, K.; Sumizawa, T.; Haraguchi, M.; Yoshida, H.; Konstanty, W.; Yamada, Y.; Akiyama, S.
Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase
Cancer Res.
55
1687-1690
1995
Homo sapiens
brenda
Sumizawa, T.; Furukawa, T.; Haraguchi, M.; Yoshimura, A.; Takeyasu, A.; Ishizawa, M.; Yamada, Y.; Akiyama, S.
Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor
J. Biochem.
114
9-14
1993
Homo sapiens
brenda
Klein, R.S.; Lenzi, M.; Lim, T.H.; Hotchkiss, K.A.; Wilson, P.; Schwartz, E.L.
Novel 6-substituted uracil analogs as inhibitors of the angiogenic actions of thymidine phosphorylase
Biochem. Pharmacol.
62
1257-1263
2001
Homo sapiens
brenda
Focher, F.; Spadari, S.
Thymidine phosphorylase: a two-face janus in anticancer chemotherapy
Curr. Cancer Drug Targets
1
141-153
2001
Escherichia coli, Homo sapiens
brenda
Yang, Q.; Yoshimura, G.; Mori, I.; Sakurai, T.; Kakudo, K.
Thymidine phosphorylase and breast carcinoma
Anticancer Res.
22
2355-2360
2002
Homo sapiens
brenda
McNally, V.A.; Gbaj, A.; Douglas, K.T.; Stratford, I.J.; Jaffar, M.; Freeman, S.; Bryce, R.A.
Identification of a novel class of inhibitor of human and Escherichia coli thymidine phosphorylase by in silico screening
Bioorg. Med. Chem. Lett.
13
3705-3709
2003
Escherichia coli, Homo sapiens
brenda
Akiyama, S.; Furukawa, T.; Sumizawa, T.; Takebayashi, Y.; Nakajima, Y.; Shimaoka, S.; Haraguchi, M.
The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression
Cancer Sci.
95
851-857
2004
Homo sapiens
brenda
De Bruin, M.; Van Capel, T.; Smid, K.; Fukushima, M.; Hoekman, K.; Pinedo, H.M.; Peters, G.J.
The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase
Eur. J. Pharmacol.
491
93-99
2004
Homo sapiens
brenda
Miszczak-Zaborska, E.; Wojcik-Krowiranda, K.; Kubiak, R.; Bienkiewicz, A.; Bartkowiak, J.
The activity of thymidine phosphorylase as a new ovarian tumor marker
Gynecol. Oncol.
94
86-92
2004
Homo sapiens
brenda
Liekens, S.; Hernandez, A.I.; Ribatti, D.; De Clercq, E.; Camarasa, M.J.; Perez-Perez, M.J.; Balzarini, J.
The nucleoside derivative 5'-O-trityl-inosine (KIN59)suppresses thymidine phosphorylase-triggered angiogenesis via a noncompetitive mechanism of action
J. Biol. Chem.
279
29598-29605
2004
Escherichia coli, Homo sapiens
brenda
Reigan, P.; Edwards, P.N.; Gbaj, A.; Cole, C.; Barry, S.T.; Page, K.M.; Ashton, S.E.; Luke, R.W.; Douglas, K.T.; Stratford, I.J.; Jaffar, M.; Bryce, R.A.; Freeman, S.
Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs
J. Med. Chem.
48
392-402
2005
Escherichia coli, Homo sapiens (P19971), Homo sapiens
brenda
Kobayashi, M.; Okamoto, K.; Akimori, T.; Tochika, N.; Yoshimoto, T.; Okabayashi, T.; Sugimoto, T.; Araki, K.
Localization of thymidine phosphorylase in advanced gastric and colorectal cancer
J. Mol. Histol.
35
69-74
2004
Homo sapiens
brenda
Norman, R.A.; Barry, S.T.; Bate, M.; Breed, J.; Colls, J.G.; Ernill, R.J.; Luke, R.W.; Minshull, C.A.; McAlister, M.S.; McCall, E.J.; McMiken, H.H.; Paterson, D.S.; Timms, D.; Tucker, J.A.; Pauptit, R.A.
Crystal structure of human thymidine phosphorylase in complex with a small molecule inhibitor
Structure
12
75-84
2004
Homo sapiens (P19971), Homo sapiens
brenda
Ma, T.; Zhu, Z.G.; Ji, Y.B.; Zhang, Y.; Yu, Y.Y.; Liu, B.Y.; Yin, H.R.; Lin, Y.Z.
Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine
World J. Gastroenterol.
10
172-176
2004
Homo sapiens
brenda
Zhang, J.M.; Mizoi, T.; Shiiba, K.; Sasaki, I.; Matsuno, S.
Expression of thymidine phosphorylase by macrophages in colorectal cancer tissues
World J. Gastroenterol.
10
545-549
2004
Homo sapiens
brenda
Liakakos, T.; Troupis, T.; Ghiconti, I.; Triantafyllidis, S.; Macheras, A.; Karatzas, G.; Pavlakis, K.
Immunohistochemical localization of thymidine phosphorylase in gastric cancer: is there a role of the differential expression in tumor cells and associated stromal cells?
Anticancer Res.
26
3899-3904
2006
Homo sapiens (P19971), Homo sapiens
brenda
El Omari, K.; Bronckaers, A.; Liekens, S.; Perez-Perez, M.J.; Balzarini, J.; Stammers, D.K.
Structural basis for non-competitive product inhibition in human thymidine phosphorylase: implications for drug design
Biochem. J.
399
199-204
2006
Homo sapiens (P19971), Homo sapiens
brenda
Jeung, H.C.; Che, X.F.; Haraguchi, M.; Zhao, H.Y.; Furukawa, T.; Gotanda, T.; Zheng, C.L.; Tsuneyoshi, K.; Sumizawa, T.; Roh, J.K.; Akiyama, S.
Protection against DNA damage-induced apoptosis by the angiogenic factor thymidine phosphorylase
FEBS Lett.
580
1294-1302
2006
Homo sapiens (P19971)
brenda
Hirano, M.; Lagier-Tourenne, C.; Valentino, M.L.; Marti, R.; Nishigaki, Y.
Thymidine phosphorylase mutations cause instability of mitochondrial DNA
Gene
354
152-156
2005
Homo sapiens (P19971), Homo sapiens
brenda
Passantino, L.; Patruno, R.; Valerio, P.; Penna, A.; Mazzone, F.; Zito, A.F.; Catalano, V.; Pellecchia, A.; Jirillo, E.; Ranieri, G.
Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages
Immunopharmacol. Immunotoxicol.
27
95-107
2005
Homo sapiens
brenda
Temmink, O.H.; de Bruin, M.; Laan, A.C.; Turksma, A.W.; Cricca, S.; Masterson, A.J.; Noordhuis, P.; Peters, G.J.
The role of thymidine phosphorylase and uridine phosphorylase in (fluoro)pyrimidine metabolism in peripheral blood mononuclear cells
Int. J. Biochem. Cell Biol.
38
1759-1765
2006
Homo sapiens (P19971)
brenda
Temmink, O.H.; de Bruin, M.; Turksma, A.W.; Cricca, S.; Laan, A.C.; Peters, G.J.
Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines
Int. J. Biochem. Cell Biol.
39
565-575
2007
Homo sapiens
brenda
Ezaki, T.; Ikegami, T.; Maeda, T.; Yamada, T.; Ishida, T.; Hashizume, M.; Maehara, Y.
Prognostic value of thymidine phosphorylase activity in liver tissue adjacent to hepatocellular carcinoma
Int. J. Clin. Oncol.
10
171-176
2005
Homo sapiens
brenda
van Kuilenburg, A.B.; Zoetekouw, L.
Determination of thymidine phosphorylase activity by a non-radiochemical assay using reversed-phase high-performance liquid chromatography
J. Chromatogr. B
820
271-275
2005
Homo sapiens
brenda
Meropol, N.J.; Gold, P.J.; Diasio, R.B.; Andria, M.; Dhami, M.; Godfrey, T.; Kovatich, A.J.; Lund, K.A.; Mitchell, E.; Schwarting, R.
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer
J. Clin. Oncol.
24
4069-4077
2006
Homo sapiens (P19971), Homo sapiens
brenda
Edwards, P.N.
A kinetic, modeling and mechanistic re-analysis of thymidine phosphorylase and some related enzymes
J. Enzyme Inhib. Med. Chem.
21
483-499
2006
Homo sapiens (P19971), Homo sapiens
brenda
Allan, A.L.; Gladstone, P.L.; Price, M.L.; Hopkins, S.A.; Juarez, J.C.; Donate, F.; Ternansky, R.J.; Shaw, D.E.; Ganem, B.; Li, Y.; Wang, W.; Ealick, S.
Synthesis and evaluation of multisubstrate bicyclic pyrimidine nucleoside inhibitors of human thymidine phosphorylase
J. Med. Chem.
49
7807-7815
2006
Homo sapiens (P19971), Homo sapiens
brenda
McNally, V.A.; Rajabi, M.; Gbaj, A.; Stratford, I.J.; Edwards, P.N.; Douglas, K.T.; Bryce, R.A.; Jaffar, M.; Freeman, S.
Design, synthesis and enzymatic evaluation of 6-bridged imidazolyluracil derivatives as inhibitors of human thymidine phosphorylase
J. Pharm. Pharmacol.
59
537-547
2007
Homo sapiens, Homo sapiens (P19971)
brenda
Liekens, S.; Balzarini, J.; Hernandez, A.I.; De Clercq, E.; Priego, E.M.; Camarasa, M.J.; Perez-Perez, M.J.
Thymidine phosphorylase is noncompetitively inhibited by 5-O-trityl-inosine (KIN59) and related compounds
Nucleosides Nucleotides Nucleic Acids
25
975-980
2006
Escherichia coli, Homo sapiens (P19971), Homo sapiens
brenda
Chujo, M.; Miura, T.; Kawano, Y.; Miyawaki, M.; Imakiire, T.; Hayashita, Y.; Kawahara, K.
Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues
Oncol. Rep.
16
777-780
2006
Homo sapiens (P19971), Homo sapiens
brenda
Oberemm, A.; Meckert, C.; Brandenburger, L.; Herzig, A.; Lindner, Y.; Kalenberg, K.; Krause, E.; Ittrich, C.; Kopp-Schneider, A.; Stahlmann, R.; Richter-Reichhelm, H.; Gundert-Remy, U.
Differential signatures of protein expression in marmoset liver and thymus induced by single-dose TCDD treatment
Toxicology
206
33-48
2005
Homo sapiens (P19971)
brenda
Ogiuchi, Y.; Maruoka, Y.; Ando, T.; Kobayashi, M.; Ogiuchi, H.
Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma
Acta Histochem. Cytochem.
41
39-46
2008
Homo sapiens
brenda
Jensen, S.A.; Vainer, B.; Witton, C.J.; Jorgensen, J.T.; Sorensen, J.B.
Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer
Acta Oncol.
47
1054-1061
2008
Homo sapiens
brenda
Ijuin, T.; Nibu, K.; Doi, K.; Inoue, H.; Saitoh, M.; Ohtsuki, N.; Makino, K.; Amatsu, M.
Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer
Acta Otolaryngol.
127
305-311
2007
Homo sapiens
brenda
Puglisi, F.; Cardellino, G.G.; Crivellari, D.; Di Loreto, C.; Magri, M.D.; Minisini, A.M.; Mansutti, M.; Andreetta, C.; Russo, S.; Lombardi, D.; Perin, T.; Damante, G.; Veronesi, A.
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer
Ann. Oncol.
19
1541-1546
2008
Homo sapiens
brenda
Soong, R.; Shah, N.; Salto-Tellez, M.; Tai, B.C.; Soo, R.A.; Han, H.C.; Ng, S.S.; Tan, W.L.; Zeps, N.; Joseph, D.; Diasio, R.B.; Iacopetta, B.
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy
Ann. Oncol.
19
915-919
2008
Homo sapiens
brenda
Andreetta, C.; Puppin, C.; Minisini, A.; Valent, F.; Pegolo, E.; Damante, G.; Di Loreto, C.; Pizzolitto, S.; Pandolfi, M.; Fasola, G.; Piga, A.; Puglisi, F.
Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer
Ann. Oncol.
20
265-271
2008
Homo sapiens
brenda
Puglisi, F.; Andreetta, C.; Valent, F.; Minisini, A.M.; Rijavec, E.; Russo, S.; Mansutti, M.; Cardellino, G.; Pizzolitto, S.; Di Loreto, C.
Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells
Anticancer Drugs
18
883-888
2007
Homo sapiens (P19971), Homo sapiens
brenda
Koizumi, W.; Okayasu, I.; Hyodo, I.; Sakamoto, J.; Kojima, H.; Kojima, H.
Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase
Anticancer Drugs
19
819-824
2008
Homo sapiens
brenda
Ogata, Y.; Sasatomi, T.; Mori, S.; Matono, K.; Ishibashi, N.; Akagi, Y.; Fukushima, T.; Murakami, H.; Ushijima, M.; Shirouzu, K.
Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma
Anticancer Res.
27
2605-2611
2007
Homo sapiens
brenda
Sakurai, Y.; Yoshida, I.; Kamoshida, S.; Inaba, K.; Isogaki, J.; Komori, Y.; Uyama, I.; Tsutsumi, Y.
Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts
Anticancer Res.
28
1593-1602
2008
Homo sapiens, Mus musculus (Q99N42), Mus musculus
brenda
Ikeda, R.; Tajitsu, Y.; Iwashita, K.; Che, X.F.; Yoshida, K.; Ushiyama, M.; Furukawa, T.; Komatsu, M.; Yamaguchi, T.; Shibayama, Y.; Yamamoto, M.; Zhao, H.Y.; Arima, J.; Takeda, Y.; Akiyama, S.; Yamada, K.
Thymidine phosphorylase inhibits the expression of proapoptotic protein BNIP3
Biochem. Biophys. Res. Commun.
370
220-224
2008
Homo sapiens
brenda
Liekens, S.; Bronckaers, A.; Perez-Perez, M.J.; Balzarini, J.
Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy
Biochem. Pharmacol.
74
1555-1567
2007
Homo sapiens
brenda
Pomeisl, K.; Holy, A.; Votruba, I.; Pohl, R.
Syntheses of N3-substituted thymine acyclic nucleoside phosphonates and a comparison of their inhibitory effect towards thymidine phosphorylase
Bioorg. Med. Chem. Lett.
18
1364-1367
2008
Escherichia coli, Homo sapiens
brenda
Bartsch, R.; Steger, G.G.; Forstner, B.; Wenzel, C.; Pluschnig, U.; Rizovski, B.; Altorjai, G.; Zielinski, C.C.; Mader, R.M.
Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel
BMC Clin. Pharmacol.
7
7-7
2007
Homo sapiens
brenda
Graham-Cole, C.L.; Thomas, H.D.; Taylor, G.A.; Newell, D.R.; Melton, R.G.; Hesp, R.; Boddy, A.V.
An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed
Cancer Chemother. Pharmacol.
59
197-206
2007
Homo sapiens
brenda
Guarcello, V.; Blanquicett, C.; Naguib, F.N.; El Kouni, M.H.
Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity
Cancer Chemother. Pharmacol.
62
85-96
2008
Homo sapiens
brenda
Saif, M.W.; Black, G.; Roy, S.; Bell, D.; Russo, S.; Eloubeidi, M.A.; Steg, A.; Johnson, M.R.; Zelterman, D.; Diasio, R.B.
Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase
Cancer J.
13
247-256
2007
Homo sapiens
brenda
Layman, R.M.; Thomas, D.G.; Griffith, K.A.; Smerage, J.B.; Helvie, M.A.; Roubidoux, M.A.; Diehl, K.M.; Newman, L.A.; Sabel, M.S.; Hayman, J.A.; Pierce, L.J.; Hayes, D.F.; Schott, A.F.
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer
Clin. Cancer Res.
13
4092-4097
2007
Homo sapiens
brenda
Chen, L.C.; Hsueh, C.; Tsang, N.M.; Liang, Y.; Chang, K.P.; Hao, S.P.; Yu, J.S.; Chang, Y.S.
Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma
Clin. Cancer Res.
14
3807-3813
2008
Homo sapiens
brenda
Reigan, P.; Gbaj, A.; Stratford, I.J.; Bryce, R.A.; Freeman, S.
Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors
Eur. J. Med. Chem.
43
1248-1260
2008
Escherichia coli, Homo sapiens (P19971), Homo sapiens
brenda
Stoebner, P.E.; Le Gallic, L.; Berthe, M.L.; Boulle, N.; Lallemant, B.; Marque, M.; Gaspard, C.; Delfour, C.; Lavabre-Bertrand, T.; Martinez, J.; Meunier, L.
Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas
Exp. Dermatol.
17
908-915
2008
Homo sapiens
brenda
Jinfeng, M.; Kimura, W.; Sakurai, F.; Moriya, T.; Mizutani, M.; Hirai, I.
Prognostic role of angiogenesis and its correlations with thymidine phosphorylase and p53 expression in ductal adenocarcinoma of the pancreas
Hepatogastroenterology
54
1635-1640
2007
Homo sapiens
brenda
Hayashi, T.; Kawahara, H.; Kobayashi, S.; Kashiwagi, H.; Hirai, K.; Yanaga, K.
Importance of thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase expression at the invasive front of T3 rectal cancer as prognostic factors
Hepatogastroenterology
55
403-406
2008
Homo sapiens
brenda
Haraguchi, M.; Komuta, K.; Ueda, T.; Akashi, A.; Minami, S.; Furui, J.; Kanematsu, T.
Prognostic significance of the serum thymidine phosphorylase levels in venous blood drainage specimens in patients with colorectal cancer
Hepatogastroenterology
55
418-421
2008
Homo sapiens
brenda
Kobayashi, Y.; Wada, Y.; Ohara, T.; Okuda, Y.; Suzuki, N.; Hasegawa, K.; Kiguchi, K.; Ishizuka, B.
Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues
Hum. Cell
20
107-110
2007
Homo sapiens
brenda
Miyake, K.; Imura, S.; Yoshizumi, T.; Ikemoto, T.; Morine, Y.; Shimada, M.
Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer
Int. J. Clin. Oncol.
12
111-119
2007
Homo sapiens
brenda
Ranieri, G.; Grammatica, L.; Patruno, R.; Zito, A.F.; Valerio, P.; Iacobellis, S.; Gadaleta, C.; Gasparini, G.; Ribatti, D.
A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients
J. Cell. Mol. Med.
11
362-368
2007
Homo sapiens
brenda
Jang, J.S.; Lee, W.S.; Lee, J.S.; Kim, H.W.; Ko, G.H.; Ha, W.S.
The expression of thymidine phosphorylase in cancer-infiltrating inflammatory cells in stomach cancer
J. Korean Med. Sci.
22
S109-S114
2007
Homo sapiens
brenda
Nencka, R.; Votruba, I.; Hrebabecky, H.; Jansa, P.; Tloustova, E.; Horska, K.; Masojidkova, M.; Holy, A.
Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase
J. Med. Chem.
50
6016-6023
2007
Homo sapiens
brenda
Honda, J.; Sasa, M.; Moriya, T.; Bando, Y.; Hirose, T.; Takahashi, M.; Nagao, T.; Tangoku, A.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results
J. Med. Invest.
55
54-60
2008
Homo sapiens
brenda
Gunningham, S.P.; Currie, M.J.; Morrin, H.R.; Tan, E.Y.; Turley, H.; Dachs, G.U.; Watson, A.I.; Frampton, C.; Robinson, B.A.; Fox, S.B.
The angiogenic factor thymidine phosphorylase up-regulates the cell adhesion molecule P-selectin in human vascular endothelial cells and is associated with P-selectin expression in breast cancers
J. Pathol.
212
335-344
2007
Homo sapiens
brenda
Kocakova, I.; Svoboda, M.; Kubosova, K.; Chrenko, V.; Roubalova, E.; Krejci, E.; Sefr, R.; Slampa, P.; Frgala, T.; Zaloudik, J.
Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma
Neoplasma
54
447-453
2007
Homo sapiens
brenda
Mazurek, A.; Kuc, P.; Mazurek-Wadolkowska, E.; Laudanski, T.
A role of thymidine phosphorylase and P53 tissue protein expression in biology of endometrial cancer
Neoplasma
55
261-265
2008
Homo sapiens
brenda
Grierson, J.R.; Brockenbrough, J.S.; Rasey, J.S.; Wiens, L.W.; Schwartz, J.L.; Jordan, R.; Vesselle, H.
Evaluation of 5-deoxy-5-[F-18]fluorothymidine as a tracer of intracellular thymidine phosphorylase activity
Nucl. Med. Biol.
34
471-478
2007
Homo sapiens
brenda
Pomeisl, K.; Holy, A.; Votruba, I.
Pyrimidine acyclic nucleoside phosphonates and phosphorylated analogs. Part 2. Syntheses and investigation of their inhibitory effects towards human thymidine phosphorylase
Nucleic Acids Symp. Ser.
52
657-658
2008
Homo sapiens
brenda
Panova, N.; Kosiova, I.; Petrova, M.; Vanek, V.; Liboska, R.; Kovackova, S.; Kocalka, P.; Kralikova, S.; Tocik, Z.; Pav, O.; Paces, O.; Rejman, D.; Rosenberg, I.
Nucleoside phosphonic acids in thymidine phosphorylase inhibition: structure-activity relationship
Nucleic Acids Symp. Ser.
52
665-666
2008
Homo sapiens
brenda
Pomeisl, K.; Votruba, I.; Holy, A.; Pohl, R.
Syntheses of pyrimidine acyclic nucleoside phosphonates as potent inhibitors of thymidine phosphorylase (PD-ECGF) from SD-lymphoma
Nucleosides Nucleotides Nucleic Acids
26
1025-1028
2007
Escherichia coli, Homo sapiens
brenda
Bijnsdorp, I.V.; de Bruin, M.; Laan, A.C.; Fukushima, M.; Peters, G.J.
The role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in tumor behavior
Nucleosides Nucleotides Nucleic Acids
27
681-691
2008
Homo sapiens
brenda
Han, H.S.; Hwang, T.S.
Angiogenesis in gastric cancer: importance of the thymidine phosphorylase expression of cancer cells as an angiogenic factor
Oncol. Rep.
17
61-65
2007
Homo sapiens
brenda
Tanikawa, T.; Waguri-Nagaya, Y.; Kusabe, T.; Aoyama, M.; Asai, K.; Otsuka, T.
Gliostatin/thymidine phosphorylase-regulated vascular endothelial growth-factor production in human fibroblast-like synoviocytes
Rheumatol. Int.
27
553-559
2007
Homo sapiens
brenda
Saif, M.W.; Juneja, V.; Black, G.; Thronton, J.; Johnson, M.R.; Diasio, R.B.
Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation?
Support. Cancer Ther.
4
211-218
2007
Homo sapiens
brenda
Hua, D.; Huang, Z.H.; Mao, Y.; Deng, J.Z.
Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer
World J. Gastroenterol.
13
5030-5034
2007
Homo sapiens
brenda
Fujimoto, K.; Matsumura, Y.; Tani, Y.; Ozono, S.; Hirao, Y.; Okajima, E.
Tissue levels of pyrimidine nucleoside phosphorylase activity in human and rodent bladder cancer and normal bladder tissue
Int. J. Urol.
14
754-759
2007
Homo sapiens (P19971), Homo sapiens
brenda
Nakajima, Y.; Madhyastha, R.; Maruyama, M.
2-Deoxy-D-ribose, a downstream mediator of thymidine phosphorylase, regulates tumor angiogenesis and progression
Anticancer Agents Med. Chem.
9
239-245
2009
Homo sapiens
brenda
Loo, W.T.; Chow, L.W.; Suzuki, T.; Ono, K.; Ishida, T.; Hirakawa, H.; Ohuchi, N.; Sasano, H.
Expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in human breast carcinoma cells and tissues
Anticancer Res.
29
2525-2530
2009
Homo sapiens
brenda
Mitsiki, E.; Papageorgiou, A.C.; Iyer, S.; Thiyagarajan, N.; Prior, S.H.; Sleep, D.; Finnis, C.; Acharya, K.R.
Structures of native human thymidine phosphorylase and in complex with 5-iodouracil
Biochem. Biophys. Res. Commun.
386
666-670
2009
Homo sapiens (P19971), Homo sapiens
brenda
Bronckaers, A.; Aguado, L.; Negri, A.; Camarasa, M.J.; Balzarini, J.; Perez-Perez, M.J.; Gago, F.; Liekens, S.
Identification of aspartic acid-203 in human thymidine phosphorylase as an important residue for both catalysis and non-competitive inhibition by the small molecule crystallization chaperone 5'-O-tritylinosine (KIN59)
Biochem. Pharmacol.
78
231-240
2009
Homo sapiens (P19971), Homo sapiens
brenda
Jain, H.V.; Rasheed, R.; Kalman, T.I.
The role of phosphate in the action of thymidine phosphorylase inhibitors: implications for the catalytic mechanism
Bioorg. Med. Chem. Lett.
20
1648-1651
2010
Escherichia coli, Homo sapiens (P19971)
brenda
Pula, G.; Mayr, U.; Evans, C.; Prokopi, M.; Vara, D.S.; Yin, X.; Astroulakis, Z.; Xiao, Q.; Hill, J.; Xu, Q.; Mayr, M.
Proteomics identifies thymidine phosphorylase as a key regulator of the angiogenic potential of colony-forming units and endothelial progenitor cell cultures
Circ. Res.
104
32-40
2009
Homo sapiens
brenda
Birck, M.; Clinch, K.; Gainsford, G.; Schramm, V.; Tyler, P.
Syntheses of 5-chlorouracils/thymines with 1-[phosphono(methyl/difluoromethyl)]-1,2-unsaturated-moiety-substituted methyl groups at N(1) and human thymidine phosphorylase inhibitory activity
Helv. Chim. Acta
92
823-838
2009
Homo sapiens
-
brenda
Miszczak-Zaborska, E.; Kubiak, R.; Bienkiewicz, A.; Bartkowiak, J.
The cytosol activity of thymidine phosphorylase in endometrial cancer
J. Exp. Clin. Cancer Res.
27
64
2008
Homo sapiens
brenda
Brockenbrough, J.S.; Morihara, J.K.; Hawes, S.E.; Stern, J.E.; Rasey, J.S.; Wiens, L.W.; Feng, Q.; Vesselle, H.
Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation
J. Histochem. Cytochem.
57
1087-1097
2009
Homo sapiens
brenda
Bakker, J.A.; Schlesser, P.; Smeets, H.J.; Francois, B.; Bierau, J.
Biochemical abnormalities in a patient with thymidine phosphorylase deficiency with fatal outcome
J. Inherit. Metab. Dis.
33
S139-143
2010
Homo sapiens
brenda
Bronckaers, A.; Gago, F.; Balzarini, J.; Liekens, S.
The dual role of thymidine phosphorylase in cancer development and chemotherapy
Med. Res. Rev.
29
903-953
2009
Geobacillus stearothermophilus, Escherichia coli, Homo sapiens, Mus musculus, Rattus norvegicus, Salmonella enterica subsp. enterica serovar Typhimurium
brenda
Chen, L.C.; Liu, H.P.; Li, H.P.; Hsueh, C.; Yu, J.S.; Liang, C.L.; Chang, Y.S.
Thymidine phosphorylase mRNA stability and protein levels are increased through ERK-mediated cytoplasmic accumulation of hnRNP K in nasopharyngeal carcinoma cells
Oncogene
28
1904-1915
2009
Homo sapiens
brenda
Yue, H.; Tanaka, K.; Furukawa, T.; Karnik, S.S.; Li, W.
Thymidine phosphorylase inhibits vascular smooth muscle cell proliferation via upregulation of STAT3
Biochim. Biophys. Acta
1823
1316-1323
2012
Homo sapiens
brenda
Marak, D.; Otmar, M.; Votruba, I.; Dracinsky, M.; Krecmerova, M.
8-Aza-7,9-dideazaxanthine acyclic nucleoside phosphonate inhibitors of thymidine phosphorylase
Bioorg. Med. Chem. Lett.
21
652-654
2011
Escherichia coli, Homo sapiens
brenda
Marti, R.; Lopez, L.C.; Hirano, M.
Assessment of thymidine phosphorylase function: measurement of plasma thymidine (and deoxyuridine) and thymidine phosphorylase activity
Methods Mol. Biol.
837
121-133
2012
Homo sapiens
brenda
Thanasai, J.; Limpaiboon, T.; Jearanaikoon, P.; Sripa, B.; Pairojkul, C.; Tantimavanich, S.; Miwa, M.
Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma
World J. Gastroenterol.
16
1631-1638
2010
Homo sapiens
brenda
Ko, J.C.; Chiu, H.C.; Syu, J.J.; Jian, Y.J.; Chen, C.Y.; Jian, Y.T.; Huang, Y.J.; Wo, T.Y.; Lin, Y.W.
Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells
Biochem. Pharmacol.
88
119-127
2014
Homo sapiens
brenda
Bera, H.; Dolzhenko, A.V.; Sun, L.; Dutta Gupta, S.; Chui, W.K.
Synthesis and in vitro evaluation of 1,2,4-triazolo[1,5-a][1,3,5]triazine derivatives as thymidine phosphorylase inhibitors
Chem. Biol. Drug Des.
82
351-360
2013
Homo sapiens
brenda
Deves, C.; Rostirolla, D.C.; Martinelli, L.K.; Bizarro, C.V.; Santos, D.S.; Basso, L.A.
The kinetic mechanism of human thymidine phosphorylase - a molecular target for cancer drug development
Mol. Biosyst.
10
592-604
2014
Homo sapiens (P19971), Homo sapiens
brenda
Tozer, T.; Heale, K.; Manto Chagas, C.; de Barros, A.L.B.; Alisaraie, L.
Interdomain twists of human thymidine phosphorylase and its active-inactive conformations binding of 5-FU and its analogues to human thymidine phosphorylase versus dihydropyrimidine dehydrogenase
Chem. Biol. Drug Des.
94
1956-1972
2019
Homo sapiens (P19971), Homo sapiens
brenda
Bajaj, S.; Roy, P.P.; Singh, J.
Synthesis, thymidine phosphorylase inhibitory and computational study of novel 1,3,4-oxadiazole-2-thione derivatives as potential anticancer agents
Comput. Biol. Chem.
76
151-160
2018
Homo sapiens (P19971)
brenda
Bera, H.; Chigurupati, S.
Recent discovery of non-nucleobase thymidine phosphorylase inhibitors targeting cancer
Eur. J. Med. Chem.
124
992-1003
2016
Escherichia coli (P0C037), Homo sapiens (P19971)
brenda
Zhao, S.; Li, K.; Jin, Y.; Lin, J.
Synthesis and biological evaluation of novel 1-(aryl-aldehyde-oxime)uracil derivatives as a new class of thymidine phosphorylase inhibitors
Eur. J. Med. Chem.
144
41-51
2018
Homo sapiens (P19971)
brenda
Tampellini, M.; Bironzo, P.; Di Maio, M.; Scagliotti, G.V.
Thymidine phosphorylase the unforeseen driver in colorectal cancer treatment?
Future Oncol.
14
1223-1231
2018
Homo sapiens (P19971)
brenda
Oh, T.; El Kouni, M.H.
Kinetics mechanism and regulation of native human hepatic thymidine phosphorylase
Int. J. Biochem. Cell Biol.
110
122-129
2019
Homo sapiens (P19971), Homo sapiens, Mus musculus (Q99N42)
brenda
de Moura Sperotto, N.D.; Deves Roth, C.; Rodrigues-Junior, V.S.; Ev Neves, C.; Reisdorfer Paula, F.; da Silva Dadda, A.; Bergo, P.; Freitas de Freitas, T.; Souza Macchi, F.; Moura, S.; Duarte de Souza, A.P.; Campos, M.M.; Valim Bizarro, C.; Santos, D.S.; Basso, L.A.; Machado, P.
Design of novel inhibitors of human thymidine phosphorylase synthesis, enzyme inhibition, in vitro toxicity, and impact on human glioblastoma cancer
J. Med. Chem.
62
1231-1245
2019
Homo sapiens (P19971), Homo sapiens
brenda
Oh, T.; El Kouni, M.H.
Distinct substrate specificity and physicochemical characterization of native human hepatic thymidine phosphorylase
PLoS ONE
13
e0202826
2018
Homo sapiens (P19971), Homo sapiens
brenda
Zaman, K.; Rahim, F.; Taha, M.; Wadood, A.; Shah, S.A.A.; Ahmed, Q.U.; Zakaria, Z.A.
Synthesis of new isoquinoline-base-oxadiazole derivatives as potent inhibitors of thymidine phosphorylase and molecular docking study
Sci. Rep.
9
16015
2019
Homo sapiens (P19971)
brenda
2.4.2.4 thymidine phosphorylase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
